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Effective control of parasitic sea lice (including Lepeophtheirus salmonis and Caligus 
elongatus), is a major challenge currently facing sea cage salmon aquaculture.  Emamectin 
benzoate (EMB; SLICE®), a macrocyclic lactone (ML), has been the drug of choice for sea lice 
treatment over the past decade due to its ease of administration, as well as efficacy, on all 
parasitic stages of the salmon parasite.  This over-reliance led to increased tolerance to the drug 
and a consequent decline in its use.  Macrocyclic lactone resistance has been linked to ATP-
binding cassette (ABC) transporters such as P-glycoprotein (P-gp) in arthropods and nematodes.  
The present study investigated the role of P-gp in sea lice resistance to EMB.  Analysis of 
bioassay results indicated a 4 to 26 fold higher EMB EC50 for L. salmonis samples collected from 
salmon farms in the Bay of Fundy, New Brunswick (NB), in 2011 compared with a similar study 
carried out between 2002 and 2004, suggesting loss of EMB efficacy in sea lice in this region.  
An assay for ATPase activity (utilizing SB-MDR1-Sf9 membranes over-expressing P-gp), as 
well as a competitive inhibition test, showed that EMB interacts with this transporter.  
Emamectin benzoate caused a significant concentration-dependent increase in P-gp mRNA 
expression in L. salmonis.  Also, results indicated a temporal increase in P-gp mRNA levels in 
archived L. salmonis collected from 2002 to 2011.  These findings suggest that EMB is a 
substrate for P-gp, will induce higher expression of the transporter, and that the latter is likely 
involved in loss of EMB efficacy in L. salmonis.  Contrary to initial prediction that prior host 
immunostimulation would enhance EMB efficacy in the parasite, sea lice attached to salmon 
with a history of immunostimulation exhibited greater survival and significantly higher P-gp 
mRNA expression compared with control groups (P < 0.05).  Prior host immunostimulation 
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likely caused increased expression of P-gp which could have consequently caused decreased 
EMB efficacy.   
The present study also investigated (using bioassays and RT-qPCR) reports of differences 
in sea lice EMB sensitivity in salmon farming regions in the Bay of Fundy.  Lepeophtheirus 
salmonis collected from Grand Manan [Bay Management Area (BMA) 2b] recorded >2 fold 
lower EMB EC50 values compared with BMAs 1 and 2a populations, confirming the presence of 
relatively EMB-sensitive sea lice in BMA 2b.  Laboratory-reared sea lice maintained their EMB 
sensitivity status for up to three filial generations.  Caligus elongatus, collected from BMA 2a, 
also showed >2 fold lower EMB EC50 values compared with L. salmonis collected from the same 
site, indicating species differences in sensitivity to the parasiticide.  Attempts to localize sea lice 
P-gp protein and mRNA in situ using immunohistochemistry and in situ hybridization 
techniques, respectively, were not successful.  Similarly, the quantification of P-gp in L. 
salmonis using ELISA and Western blot techniques was unsuccessful.  This could be due to low 
P-gp expression at mRNA and protein levels and/or poor antigenic specificity of the antibodies 
used.   
Results in this study strongly support the hypothesis that the efflux transporter, P-gp, is 
involved in reduced sensitivity of L. salmonis to EMB, and that this occurs over time due to drug 
selection of resistant strains of the parasite.  However, there is a need to develop sensitive tools, 
e.g. probes and antibodies, which will localize and quantify L. salmonis P-gp mRNA and protein 
production.  This will allow for a greater understanding of the role of P-gp in sea lice resistance 
to EMB as well as a greater ability to monitor resistance development to the parsiticide.  
Changes in the expression of resistance-associated genes, such as those for P-gp, can be 
monitored and used in the diagnosis of resistance development to parasiticides.  Knowledge of 
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the timing for resistance development will inform necessary changes to treatment options to 
prevent treatment failure.  Further comparisons between EMB-sensitive and -resistant strains of 
L. salmonis may be necessary to verify the degree to which P-gp is involved in the loss of 
parasite sensitivity to the drug.  More investigations on the nature of the species differences in 
EMB sensitivity in sea lice, as well as the heredity of EMB resistance mechanisms, is necessary 
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1.1.  Salmon Aquaculture 
Aquaculture, which has seen tremendous growth and diversification over the years (FAO 
2012), was first documented by the Chinese in 475 BC (Liao & Chao 2009).  The increase seen 
in fish farming is partly due to the realization that fish and other aquatic species are cost-
effective and healthier sources of animal protein compared with land-based livestock.  Atlantic 
salmon, Salmo salar, is one of the most intensively farmed marine fish (Naylor & Burke 2005) 
and its commercial production is currently dominated by the aquaculture industries of Norway, 
Chile, Scotland, Ireland, and Canada (Boxaspen 2006, Lees et al. 2008).   
The demand for salmon has been rising over the years and, as with any such enterprise, as 
demand increases, there is pressure to produce more as well.  As with other sectors of 
aquaculture, the steady growth in commercial salmon production comes with increasing 
challenge to the industry (Olesen, Myhr & Rosendal 2011).  Challenges to aquaculture (such as 
salmon farming) include, but are not limited to infections, animal welfare, environmental 
perturbation, and ecological impacts (Buschmann et al. 2009, Burt et al. 2012).  Of these 
challenges, the most significant are viral, bacterial, fungal and parasitic infections, which can 
manifest as outbreaks on salmon farms (Asche et al. 2009).  In addition to direct costs incurred 
by salmon farmers for disease treatments, secondary challenges of disease management and 
control include negative consequences such as antibacterial resistance in humans (Midtlyng, 
Grave & Horsberg 2011) and toxicity to benthic non-target species of economic and ecological 
significance (e.g. lobster) (Burridge et al. 2010).   
Of the numerous infections that may affect salmon, sea lice have become one of the most 
prominent.  This is mainly due to current difficulty in controlling the parasite on salmon farms.  
However, the greatest financial losses due to sea lice are attributed to reduced growth rate and 
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poor feed conversion ratio (Mustafa, Rankaduwa & Campbell 2001).  An estimate of sea lice 
costs to the world salmonid farming industry was generated by Costello (2009), using data from 
countries where sea lice have been reported to be a problem.  The analysis assumed that sea lice 
control costs increased in proportion to production.  Multiplying the sea lice costs by the Food 
and Agriculture, Fisheries and Aquaculture Information and Statistics Service salmonid 
production figures for 2006, indicated a total cost of CAD $496 million.  As profit margins get 
narrower because of increased competitiveness, increased fish-feed costs, and pressure on farms 
to control sea lice to prevent spread to wild fish and other farms; sea lice control remains a 
significant challenge to commercial salmon production.  
Salmon aquaculture not only suffers from the direct cost associated with sea lice 
treatments and reduced market value of affected salmon, but also negative public image, 
particularly during major sea lice outbreaks (Hansen & Onozaka 2011).  Although sea lice 
infection on wild salmon have been documented for several decades (White 1940, Berland & 
Margolis 1983, Margolis & Berland 1984), declines in wild salmon populations have been 
blamed on the presence of high numbers of sea lice in commercial sea cage salmon farms 
(Anderson, Whoriskey & Goode 2000, Krkošek et al. 2011, 2013).  However, factors affecting 
sea lice epizootics in the ocean, both for the farmed and wild salmonids, are numerous and can 
be very complex (Frazer 2009). 
1.2.  Sea lice 
Sea lice are ectoparasites known to cause mortalities in wild and farmed salmonids 
(White 1940, Bakke & Harris 1998, Todd et al. 2000).  Lepeophtheirus salmonis and Caligus 
elongatus are the major species of sea lice that infect Atlantic salmon, S. salar, in Atlantic 
Canada and Northern Europe, L. salmonis and C. clemensi in Pacific Canada, while C. 
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rogercresseyi is a significant pest in Chile (Burka, Fast & Revie 2012).  Lepeophtheirus salmonis 
and C. clemensi are the sea lice species infecting salmonids on the Pacific coast of Canada.  
Recent studies have suggested that Pacific L. salmonis differ from Atlantic L. salmonis in terms 
of genetic make-up (Todd et al. 2004, Yazawa et al. 2008), host pathogenicity (Saksida et al. 
2007a) and infection of alternate hosts such as three spine stickleback (Jones & Prosperi-Porta 
2011).   
Sea lice have a direct life cycle (Fig. 1.1) with attached juveniles and mobile preadult and 
adult stages on the host (Schram 1993).  Lepeophtheirus salmonis and C. elongatus undergo 10 
and 8 developmental stages, respectively, during their life cycle, each separated by a molt.  The 
first 2 stages are planktonic; the third, the copepodid, is the first infective stage that locates and 
attaches to the host and is frequently found on skin, gills and other external surfaces on the host; 
the 4 chalimus stages attach to the salmon host by a frontal filament, while the last 3 stages (2 
preadults and an adult in L. salmonis; no preadult stages in C. elongatus), often referred to as 
‘mobiles’, can move freely on the surface of the host and are the stages that are most pathogenic 
to the host (White 1942, Johnson & Albright 1991).  The mobile stages can transfer from one 
host to another and may be critical where single year class smolt stocking is not practiced 



















































Figure 1.1.  Developmental stages of Lepeophtheirus salmonis [diagram (not to scale) modified 
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1.2.1.  Factors affecting sea lice survival and dispersal 
According to Bron et al. (1991), L. salmonis copepodids prefer to attach to the fins and 
mostly locate the host salmon through chemoattractants (Ingvarsdóttir et al. 2002) and taste cues 
originating from the host (Pert et al. 2009).  Local water current (Bron et al. 1991), temperature, 
salinity (Heuch, Nordhagen & Schram 2000, Bricknell et al. 2006) and light intensity (Genna, 
Mordue & Pike 2005) have all been shown to affect survival and settlement of sea lice 
copepodids.  For instance, poor settlement was recorded at ~7°C compared with 12°C; and at 24 
ppt salinity compared with 34 ppt (Tucker, Sommerville & Wootten 2000).  Also, at low water 
temperature (7.1°C), sea lice egg production, hatchability and development are reduced 
compared with 12.2°C (Heuch, Nordhagen & Schram 2000), suggesting that temperature may be 
an important factor in the biology of early stages of the parasite.  Earlier work by Johnson and 
Albright (1991) showed that as water temperature decreased from 15 to 5 °C, development time 
of eggs increased and, that at salinity of 10 and 15 ppt, there were neither egg nor nauplii 
development, respectively. Copepodids in this latter work were obtained only at 30 ppt. 
Sea lice infections on wild salmonids were reported several decades ago (White 1940).  
Although there is literature stating that salmon farms may contribute to sea lice epizootics in 
wild salmon populations (Krkošek et al. 2013), how the contribution relates to declines in wild 
salmonids (Parrish et al. 1998, Levin & Schiewe 2001) is not well understood.  It is most likely 
that cross-infection of sea lice occurs between farmed and wild hosts.  In Pacific Canada, refuge 
for sea lice includes farmed and wild salmon (Saksida et al. 2007b, Marty, Saksida & Quinn 
2010), opportunistic hosts or alternate nearshore environments where they overwinter and are 
then available to directly infect new hosts or to release larvae in late winter (Brooks 2009).  
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Contrary to the situation in Pacific Canada, in Atlantic Canada, knowledge of sea lice refuge 
and/or where the parasites overwinter are largely lacking.    
The first outbreaks of sea lice infection occurred on Atlantic salmon farms during the 
1960s and late 1980s in Norway and North America, respectively, soon after the introduction of 
sea cage salmon aquaculture (Pike & Wadsworth 1999).  Confinement of large numbers of 
salmon in sea cages creates an ideal environment for sea lice to easily locate a host and multiply 
rapidly (Bakke & Harris 1998).  The entire age and development range is frequently present 
within the salmon cage, although the stage population depends on the type and effectiveness of 
control measures in place (Pike & Wadsworth 1999).  
1.2.2.  Pathology and host responses to sea lice infections  
Host response to sea lice infection depends on several factors including species of host as 
well as species and stage of the parasite.  Lepeophtheirus salmonis is larger, more aggressive and 
more pathogenic than Caligus spp.  Host responses to an infection of sea lice range from 
depressed appetite to death (Boxaspen 2006).  Newly attached copepodids of L. salmonis cause a 
local cellular response on the skin which can be seen as an inflamed dark spot visible to the 
naked eye.  Low-level L. salmonis infection (8-11 sea lice per fish) caused several changes in the 
expression of the following immune genes in the Atlantic salmon: major histocompatibility 
(MH) class I, MH class II and interleukin (IL) 1 (Fast et al. 2006), but did not cause remarkable 
stress responses (Tully & Nolan 2002, Fast et al. 2006).  However, some studies reported 
increased stress in Atlantic salmon in response to a higher (~100 per fish) sea lice burden 
(Bowers et al. 2000, Mustafa et al. 2000) and was attributed to development through to late 
chalimus, and preadult stages.  Contrariwise, 10 sea lice per fish for up to 10 days caused 
increased Na+/K+-ATPase and chloride ion concentrations compared with 3 and 6 sea lice/fish 
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groups (Nolan, Reilly & Wendelaar Bonga 1999) indicating stress to the fish.  This indicates that 
as the number of sea lice on a fish and infection period increase, the level of stress on the fish 
increases.   
Other problems associated with sea lice infection include edema, sloughing of the scales 
and epidermal pathology, such as necrosis of skin pavement cells, apoptosis of inner epidermal 
cell layers and increased mucus discharge (Nolan, Reilly & Wendelaar Bonga 1999).  Abrasion 
of the skin predisposes the host to secondary bacterial and viral infections (Jónsdóttir et al. 1992, 
Barker et al. 2009) as well as osmoregulatory problems (Wagner et al. 2003).  Parasite-induced 
increase in irritability may also lead to changes in behaviour including poor swimming 
performance (Wagner et al. 2003) and flashing.  
1.2.3.  Control of sea lice 
Several strategies have been used or are being developed for the control of sea lice in 
salmon farms [(Rae 2002) Table 1.1] and include biological predators (Bjordal 1990, Deady, 
Varian & Fives 1995), vaccines (Raynard et al. 1994, Grayson et al. 1995, Raynard et al. 2002, 
Ross et al. 2006, Frost, Nilsen & Hamre 2007, Carpio et al. 2011), immunostimulants (Covello et 
al. 2011, Purcell et al. 2012, Poley et al. 2013), drugs and chemicals (Burka et al. 1997, Burka, 
Fast & Revie 2012), as well as good management practices such as disinfectants (Pietrak & 
Opitz 2004), fallowing, single year class, and removal of sick or dead salmon (Bron et al. 1993).  
Freshwater bath treatment was not successful in controlling the parasite (Stone et al. 2002).  
Differences in susceptibility to sea lice infection within Atlantic salmon families (Glover, Nilsen 
& Skaala 2004, Glover et al. 2005, Gjerde & Saltkjelvik 2009) can also be exploited to combat 
sea lice epizootics through selective breeding for resistant strains of the host salmon (Jones et al. 
2002, Gjerde, Odegard & Thorland 2011).  However, selective breeding for sea lice resistant 
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strains of salmon can be challenging (Glover, Nilsen & Skaala 2004) because factors affecting 
susceptibility of salmon to sea lice infection in the wild, farm and laboratory conditions are not 
completely understood (Glover et al. 2004, Hamre & Nilsen 2011).  These factors can vary with 
strain of host and parasite, ecological circumstances, country/region, and farm management 
practices.  
1.2.3.1.  Host immunostimulation as a treatment strategy for sea lice infections 
Innate immunity is the major means of protection against pathogen invasion in fish (Magnadóttir 
2006, Whyte 2007) and its manipulation is being explored as a sea lice control strategy.  Three 
main hallmarks of effective innate responses to sea lice are inflammation, cellular infiltration and 
hyperplasia.  While chinook (Oncorhynchus tshawytscha) and coho (O. kisutch) salmon mount 
inflammation and hyperplastic responses at the sites of sea lice attachment and are able to reject 
the parasite shortly after infection (Johnson & Albright 1992, Braden et al. 2012); Atlantic 
salmon lacks such effective responses (Fast et al. 2003) despite induction of innate immune 
response genes (Skugor et al. 2008, Tadiso et al. 2011).  This could explain the higher sea lice 
susceptibility of Atlantic salmon compared with coho, chinook and pink salmon (O. gorbuscha)
(Johnson & Albright 1992, Jones, Kim & Bennett 2008, Wagner 2008), hence generating interest 
in inducing innate immune responses of Atlantic salmon as a control strategy against sea lice 
infection. 
In the laboratory study by Sutherland et al. (2011), juvenile pink salmon weighing 0.3, 
0.7 and 2.4 g were examined for transcriptional profiles 6 days post infection with L. salmonis. 
Results of the transcriptional analyses revealed susceptible, intermediate and resistant responses 




Table 1.1.  Summary of different strategies employed for the control of sea lice 
Strategy Scientific basis Advantages Disadvantages References 
Biological control Natural predation on sea lice 
using cleaner fish such as 
wrasse 
Cost effective, less 
environmental impact 
Predator fish may transmit disease to salmon; 
also it may be invasive to the local fauna and 
flora; wrasse have also been shown to be more 
interested in eating the salmon feed rather than 
sea lice; and some species of wrasse do not 
over-winter well 
(Deady, Varian & Fives 
1995, Treasurer 2002, 





Maintenance of optimal 
environment for salmon health  
Cost effective, less 
environmental impact  
Has to be conducted in combination with other 
control strategies to maximize effectiveness  
(Bron et al. 1993) 
Selective breeding Selection of sea lice resistant 
breeds of salmon 
Low environmental 
impact 
Takes a very long time to develop; may lead to 
unwanted traits such as poor food conversion 
ratio 
(Jones et al. 2002, Gjerde, 
Odegard & Thorland 2011)  




Despite promising results (50% parasite 
reduction), no large scale field observation has 
been made so far  
(Covello et al. 2011, 2012, 
Purcell et al. 2012, Poley et 
al. 2013) 
Vaccines Induction of acquired immunity 




Not very effective; poor antibody response in 
Atlantic salmon probably due to lack of 
isolation of potent antigens within the sea louse 
(Raynard et al. 1994, 
Grayson et al. 1995, 
Raynard et al. 2002, Ross et 
al. 2006, Frost, Nilsen & 




Selectively kill sea lice usually 
through neurotoxicity or 
disruption of molting cycle 
Very effective especially 
shortly after introduction 
Development of resistance to the agents over 
time leading to ineffective treatments; toxicity 
to non-target organisms and handlers; stressful 
to fish; expensive; may require withdrawal 
periods 
(Burka et al. 1997, Burka, 





The higher susceptibility of the 0.3 g fish was linked to increased expression of matrix 
metalloproteinase (mmp)-9 and 13, together with cell proliferation inhibition-related genes 
(sesn1, tob1 and btg1) culminating in cellular stress and possibly poor availability of nutrients to 
the fish at this stage of rapid development as a result parasite induced nutrient diversion.  These 
changes were absent in the larger fish except for the 0.7 g fish which showed increased 
expression of mmp-9 and mmp-13, but not cell proliferation inhibition-related genes.  Matrix 
metalloproteinase 9 plays a major role in inflammatory response to infection in fish (Chadzinska 
et al. 2008) and its up-regulation without simultaneous cell proliferation could have caused 
increased stress-induced susceptibility in the host.  Several cell proliferation genes including 
protein phosphatase 1L, and Cdc37 [cell division cycle 37; chaperone involved in cell growth 
(Hunter & Poon 1997)] were up-regulated in the 2.4 g fish.  Also, genes such as nucleolysin 
(tia1), involved in neutrophil activity and apoptosis of cytolytic lymphocytes (Tian et al. 1991), 
were up-regulated in the 0.7 and 2.4 g fish.  Confirming the assertion by Johnson & Albright 
(1992) that neutrophils play a role in teleost defense against sea lice.  Taken together, these 
findings indicate that manipulating the immune system of Atlantic salmon could result in 
reduced host susceptibility to sea lice infections.  However, investigation into boosting Atlantic 
salmon innate immunity to sea lice yielded mixed results, depending on the type of 
immunostimulant used (Covello et al. 2012).  Immunostimulants which have been used included 
-glucans, occurring as polysaccharides in fungi, plants and bacteria (Tsoni & Brown 2008); 
cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN), unmethylated motifs found 
within bacterial and viral DNA (Carrington & Secombes 2006); and yeast extracts (Andrews et 
al. 2009).  Covello et al. (2012) showed that whereas fish treated with -glucan had higher sea 
lice numbers (24%) compared with untreated controls, CpG ODN and yeast extracts (AllBrew 
12 

NuPro) recorded 31-46% and 11-31% decrease in sea lice burden respectively.  Cytosine-
phosphate-guanine oligodeoxynucleotide, which resulted in the maximum percent reduction in 
sea lice infection, also caused mild to moderate inflammation and epidermal hyperplasia in the 
host, but not to the level seen in coho, pink and chinook salmon. The 3 immunostimulants used 
in the study by Covello et al. (2012) are highly conserved pathogen-associated molecular 
patterns (PAMPs) found in lower organisms, but absent in Metazoa (Tsoni & Brown 2008).  
Pathogen-associated molecular patterns are sensed by pattern recognition receptors (PRRs) such 
as Toll-like (TLR) (Bricknell & Dalmo 2005, Cuesta, Esteban & Meseguer 2008, Palti et al. 
2010) and C-lectin (CLR) receptors (Tsoni & Brown 2008) in the host.  On recognition of 
PAMPs, PRRs activate signaling pathways leading to transcription of genes involved in immune 
responses, including inflammation, antiviral responses and dendritic cell maturation (reviewed 
by Whyte 2007).  Another study that investigated the effect of prior immunostimulation, using 
CpG and crude yeast extracts, on the efficacy of emamectin benzoate (EMB), revealed that 
Atlantic salmon that were treated with immunostimulants had lower numbers of sea lice 
compared with the control (Poley et al. 2013).  Also, inclusion of CpG in the diet of Atlantic 
salmon re-infected with L. salmonis, resulted in lower sea lice numbers compared with first-time 
sea lice infections and the no treatment controls (Purcell et al. 2012).  This observation, together 
with up-regulation of the inflammatory markers- mmp-9, IL-1, IL-12 and down-regulation of 
TLR-9, suggest inflammatory and enhanced acquired immune responses in salmon against the 
sea lice for the CpG-treated fish.  More studies on the exploitation of innate immune responses 
of Atlantic salmon as a treatment strategy against sea lice parasitosis are needed.   
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1.2.3.2.  Use of drugs and chemicals in the control of sea lice 
So far, the most effective and common means of sea lice control has been through the 
administration of chemicals or antiparasitic drugs either topically as bath treatments or orally in 
the feed.  It is important to monitor sea lice abundance routinely (Heuch & Mo 2000, Treasurer 
& Pope 2000, Penston, Millar & Davies 2008) to determine timing for sea lice treatment, based 
on sea lice trigger levels (Heuch, Gettinby & Revie 2011), in order to delay development of drug 
resistance in the parasite population.  This will be discussed further below.  Also, the use of 
chemotherapeutants for sea lice control warrants monitoring for environmental impacts 
following treatment episodes (Davies et al. 2001, Willis & Ling 2003, Willis et al. 2005, 
Burridge et al. 2010).  The major classes of drugs used for sea lice treatment (Table 1.2) are 
organophosphates (Bruno, Munro & McHenery 1990), pyrethroids (Hart et al. 1997), and 
macrocyclic lactones [MLs (Johnson & Margolis 1993, Stone et al. 2000b)].  Others include 
chitin synthesis inhibitors (Branson, Ronsberg & Ritchie 2000) and hydrogen peroxide (Johnson, 
Constible & Richard 1993, Bruno & Raynard 1994, Treasurer & Grant 1997, Bravo et al. 2010).  
1.2.3.2.1.  Advantages and disadvantages of different drug/chemical treatments 
The advantages and disadvantages of the different types of sea lice treatment may vary 
depending on the type of chemical, dosage, and the mode of administration (Table 1.2).   
1.2.3.2.1.1.  Bath treatments 
Bath treatment is the administration of drugs dissolved in water through complete 
immersion for a pre-determined period.  One major advantage of bath treatments, especially 
when administered using well boats, is that all the parasites are exposed to the same 
concentration of the drug.  This decreases the rate at which sub-therapeutic based drug 
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resistance/selection develops in sea lice compared with in-feed treatments.  Until the mid-1990s, 
most bath treatments for sea lice control were performed with the organophosphates, metrifonate, 
dichlorvos and azamethiphos (O'Halloran & Hogans 1996).  Later on, the pyrethroids 
(deltamethrin and cypermethrin) were introduced in several countries but not Canada; 
cypermethrin in 1996 and deltamethrin in 1998.  Although pyrethrum was tested for sea lice 
control in Canada, its use and that of pyrethroids were not adopted for treating sea lice in 
Canadian salmon aquaculture (Roth 2000).  However, recently, due to resistance development to 
EMB (the most widely used sea lice medicine) in Canada, deltamethrin (AlphaMax™) (Giffin et 
al. 2010) and azamethiphos were approved for use in New Brunswick.   
Some of the bath treatment drugs had to be applied twice at 2 to 3 week intervals to 
achieve optimal efficacy as protection waned within a short time due to rapid reduction in 
therapeutic concentration of the drug within and around the sea-cage (Corner et al. 2011).   
To achieve therapeutic concentrations during bath treatments, skirt enclosures, tarpaulins 
or well boats are used and extra supplies of oxygen provided.  Food is also withheld.  Procedures 
for bath treatments may be stressful for the fish, may cause minor injuries as fish are crowded 
and handled during treatment, and may reduce appetite post-treatment.  When using H2O2, there 
is potential for high levels of re-infection due to resistance development (Treasurer, Wadsworth 
& Grant 2000).  Therefore, farmers can potentially incur direct financial losses associated with 
the treatment, as well as with the potential for reduced growth of fish due to these secondary 
factors.  Bath treatments are labor-intensive, and when using organophosphorous drugs, some 
salmon farmers may fail to follow recommendations to repeat the treatment, consequently 
encouraging the development of drug resistance by the parasite (Grave et al. 2004).  If there are 
mobile stages of sea lice on the fish before or during the treatment, the farmer has to repeat the 
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treatment frequently (Mustafa, Rankaduwa & Campbell 2001).  Apart from cypermethrin, bath 
treatments are only effective against preadult and adult stages of sea lice, allowing chalimus 
stages to survive and continue the cycle of infection.  Treatments are, therefore, indicated only 
when populations reach preadult and adult stages and, thus, must be repeated frequently for 
effective control (Stone et al. 1999).  Also the continual need for monitoring the efficacy of sea 
lice treatment results in further increases to production costs.   
1.2.3.2.1.2.  Pros and cons of in-feed treatments 
In-feed treatments are administered to the fish with the drug directly milled into the diet.  
They are more advantageous compared with bath treatments because the former are less stressful 
to the fish, and relatively nonhazardous to the farmer (Ramstad et al. 2002).  In-feed treatments 
allow medication during adverse weather conditions and permit simultaneous medication of all 
cages on a site and all sites in a loch, fjord, or single bay system, thus reducing cross-infection 
that commonly occur during the several days necessary to apply bath treatments to all cages on a 
site (Stone et al. 1999).  
From 1996 to 2001, chitin-synthesis inhibitors were used as in-feed treatments, but their 
use was discontinued due to their lack of effect on the adult parasite following the final moult 
(Branson, Ronsberg & Ritchie 2000, Ritchie et al. 2002).  For maximum efficacy and optimal 
sea lice control with chitin-synthesis inhibitors, treatments have to target developing stages of the 
parasite before the appearance of significant levels of the adult stage.  Clearly, a treatment option 
that is efficacious against all parasitic stages of sea lice and which could be administered in feed, 
to avoid the disadvantages associated with bath applications and chitin-synthesis inhibitors, 
became highly desirable.  The glutamate-gated chloride channels (GluCl) activators, avermectins 
(Smith & Clarke 1988, Stone et al. 1999), held such promise.  However, due to the variability in 
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appetite among fish, and the natural hierarchies that exist within a cage, in-feed treatment has a 
greater probability of sub-therapeutic dosing of salmon than bath treatments.  Also, potential 
variations in pharmacokinetics of individual fish will affect drug exposure to the attaching sea 
lice.  Sick fish are likely to consume less feed/drug, leading to sub-optimal exposure of the 
parasite to the drug, consequently favouring development of resistance. 
1.3.  Avermectins 
Avermectins are hydrophobic semi-synthetic MLs derived from a Streptomyces 
avermitilis culture discovered collaboratively by Merck & Co Inc, USA and the Kitasato 
Institute, Japan (Campbell 2012).  Ivermectin (IVM) was the initial ML to be used in sea lice 
control (Smith & Clarke 1988, Johnson & Margolis 1993), but the high toxicity in the salmon 
host (Johnson & Margolis 1993, Davies & Rodger 2000) discouraged its continued use as a sea 
lice therapeutant.  However, ivermectin was recently re-introduced as a sea lice medicine in New 
Brunswick.  Another avermectin, doramectin, has been used for treatment of carp infected with 
the copepod anchor worm, Lernaea cyprinacea (Hemaprasanth et al. 2008), but not for sea lice.  
Ivermectin was shown to affect benthic organisms (Collier & Pinn 1998, Grant & Briggs 1998), 
hence the development of another ML, emamectin benzoate (EMB), which had a better 
therapeutic index (Roy et al. 2000) and is very effective for the control of sea lice parasitosis 
(Stone et al. 1999, Armstrong et al. 2000).  Emamectin benzoate was initially developed and 
used as a pesticide against plant pests including lepidopterous insects (Leibee et al. 1995).  The 
drug is marketed as a sea lice medicine under the brand name SLICE® and is administered in 
salmon feed at a dose of 50 g kg-1 fish biomass for 7 days (Ramstad et al. 2002).   
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Table 1.2.  Summary of different drugs and chemotherapeutants used in sea lice control 











Dichlorvos Organophosphate Nuvan®, 
Aquagard® 
1 mg L-1 per 
h 
 






Trichlorfon Organophosphate Neguvon® 300 mg L-1 
per h 
 




Azamethiphos Organophosphate Alfacron®/ 
Salmosan® 
0.01 mg L-1 
per h 
 






Roth et al. 1996) 
 
Carbaryl Organophosphate Sevin® 0.3-0.5 mg 
L-1 per h 
 




Pyrethrum Pyrethrum Py-Sal 10 µg L-1 - 













Cypermethrin  Pyrethroid Excis®/ 
Betamax® 











(Hart et al. 
1997) 




> 10 µg L-
1
 





Oxidizer Paramove® 1.5 mg L-1 
per 20 min  
 







Teflubenzuron Growth inhibitor Calicide® 10 mg kg-1 











Diflubenzuron Growth inhibitor Lepsidon® ? Chitin synthesis 
inhibition 
 




Ivermectin Avermectin Ivomec® 0.2 mg kg-1 
1x; 










0.4 mg kg-1, 
1x;  
0.05 mg kg-1 






(Palmer et al. 
1987, Johnson 
& Margolis 
1993, Smith et 
al. 1993)  
Emamectin 
benzoate 
Avermectin SLICE® 50 µg kg-1 per 











(Roy et al. 2000) 
AChE = acetycholinesterase; ? = unknown; NA = not applicable; mobile stages = preadults and adults 
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However, currently, double and triple doses are used in some salmon farms in Atlantic Canada 
(M. Beattie, Department of Agriculture, Aquaculture and Fisheries of New Brunswick, 
http://www.dfo-mpo.gc.ca/science/enviro/aquaculture/rd2011/rdsealice-pou-eng.html) as 
the manufacturer’s recommended dose is no longer clinically effective.  Emamectin benzoate, 
similar to other avermectins, is believed to act by blocking nerve transmission in arthropods 
resulting in starvation, paralysis and, consequently, death of the parasite (Arena et al. 1995, 
Stone et al. 1999).  Unlike bath treatments, which are more labor intensive and can be stressful to 
the fish, EMB as an in-feed therapeutant is safely and effectively administered, and whole 
sites/bay systems can be medicated in a coordinated manner (Lees et al. 2008).   
In a laboratory study to determine therapeutic dose and duration of administration for 
EMB in-feed treatment in Atlantic salmon experimentally infected with L. salmonis, the 
parasiticide had high efficacy against all parasitic stages of the parasite especially for the 50 g 
kg-1 fish biomass for 7 days treatment group (Stone et al. 1999).  The 50 g kg-1 fish biomass 
treatment group recorded up to 95% parasite reduction which was higher than the 25 g kg-1 fish 
biomass treatment group, but similar to the 100 g kg-1 fish biomass treatment group.  The multi-
stage lethality of EMB disrupts the parasite life cycle at multiple points, thereby hampering 
propagation.  In a field trial, in-feed treatment with EMB was shown to prevent development of 
copepodids for several weeks post-treatment compared with untreated control fish (Stone et al. 
2000b).  The efficacy of EMB was greater than 90% for at least 55 days from the start of 
treatment clearly showing that the parasiticide is not only highly effective in reducing existing 
sea lice burdens, but also prevents recruitment of new sea lice for several weeks from the 
initiation of treatment.   
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Sea lice collected during warmer temperatures appear to be more susceptible to EMB 
compared with those collected during the winter (Westcott et al. 2008) and environmental 
temperature has been described as a potential factor for EMB toxicity in L. salmonis (Lees et al. 
2008).  Results from experimental field trials with EMB-treated salmon revealed that treatment 
at higher temperatures (autumn) was more efficacious (63.3 - 99.3% efficacy) than during low 
temperatures (winter; 25.4 - 89.7% efficacy) (Stone et al. 2000b).  However, the mechanisms of 
temperature effect on EMB efficacy require further investigation. Results to date suggest that 
seasonal/temperature-associated variation in EMB efficacy should be exploited in the timing of 
EMB treatment by administering the drug when efficacy has been shown to be optimal.  
1.4.  Pharmacology of emamectin benzoate as an ectoparasiticide for Atlantic salmon 
1.4.1.  Physicochemical properties of emamectin benzoate  
The scientific name for EMB is (4''R)-5-O-demethyl-4''deoxy-4''(methylamino) 
avermectin A1a and (4''R)-5-O-demethyl-25-de (1-methylpropyl)-4''-deoxy-4''(methylamino)-25-
(1-methylethyl) avermectin A1a (9:1) (Schering Plough Animal Health 1998).  The benzoate salt 
of emamectin occurs as a white powder consisting of two components: 4'-epimethyamino-4'-
deoxyavermectin B1a benzoate (B1a) and 4'-epimethyamino-4'-deoxyavermectin B1b benzoate 
(B1b).  B1a, the active component, makes up ~90 % of the drug; the molecular formula is 
C49H75NO13C7H6O2 with molecular weight of 1008.26 g/mol.  The molecular formula of the B1b 
homologue is C48H73NO13C7H6O2 with a molecular weight of 994.24 g/mol.  The two 
components differ from each other at the C26 position of the compound (Fig.1.2.).  While B1a has 
a methylene group on the isobutyl side chain, B1b has a methyl group at that position.  Ivermectin 
homologues differ at the C25 position (Shoop & Soll 2002); B1a and B1b possess a secondary 
butyl group and isopropyl moiety at this position, respectively.  Similar to EMB, the B1a 
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homologue of IVM makes up ~90 % of the drug.  The solubility of EMB ranges from 24 (pH 
7.04) to 320 (pH 5.03) mg L-1 in fresh water and 5.5 mg L-1 in salt water (Bright & Dionne 
2005).  Emamectin benzoate has an octanol-water coefficient (Log Kow) of 5.0.  The half-life of 
the drug is as follows: hydrolysis- ~136 days (pH 9, 25°C); photolysis- 1.4 to 22.4 days in 
solution; soil- 193.4, 427 and 174 days for aerobic, anaerobic, and at aerobic followed by 
anaerobic, respectively; and for marine sediment 164 to 175 days (Bright & Dionne 2005).   
1.4.2.  Pharmacokinetics of emamectin benzoate  
The high lipid solubility of MLs plays a major role in their absorption in both host and 
parasites. Macrocyclic lactones accumulate in lipid tissue (Escribano et al. 2012) and are slowly 
released in vivo, hence causing sustained therapeutic concentration within the host (reviewed by 
McKellar & Gokbulut 2012, Geary & Moreno 2012).  Lipophilicity of EMB is important in sea 
lice treatment because the drug persists in the fish at a therapeutic concentration for up to 9 
weeks (at 13 - 15°C) following termination of administration (Sevatdal et al. 2005a), offering 
protection against sea lice for prolonged periods (Stone et al. 2000a).   
When EMB is fed to fish, it is absorbed from the gut and redistributed throughout the fish 
with concentrations several folds higher in the skin compared with the muscle (Sevatdal et al. 
2005a, Whyte et al. 2011).  This is desirable for drug availability to sea lice through the mucus 
(Sevatdal et al. 2005a).  Sea lice become exposed to the parasiticide primarily through ingestion 
of mucus of treated salmon, although cuticular absorption cannot be ruled out.  This is because 
the attaching sea louse is submerged in salmon mucus while feeding on the host.  By 63 days 
post-treatment, EMB concentration in the muscle returns close to insignificant levels (Skilbrei et 
al. 2008), an important consideration for determining the withdrawal period of the drug.  A study 
by Sevatdal et al. (2005a) on the content of EMB in blood, mucus and muscle following field 
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administration of the recommended dose revealed that EMB concentrations reached maximum 
levels of 128, 105 and 68 ng/g (ppb) for blood, mucus and muscle respectively, on day 7, the last 
day of administration.  From day 7 the concentration in the blood declined until it was less than 
the limit of detection on day 77.  The concentration was higher in mucus compared with plasma, 
except on days 7 and 21.  The concentration of EMB decreased gradually from the end of 
treatment (day 7) to day 70 with half-lives of 9.2, 10.0 and 11.3 days in muscle, plasma and 
mucus, respectively.  The highest concentration of EMB in plasma was detected on the last day 
of treatment (day 7).  For all other time points, the highest concentration of EMB was found in 
the mucus.  Autoradiography revealed substantially higher EMB radioactivity in the intestinal 
mucosa than in other tissues for several days following administration.  This could be linked to 
enterohepatic cycling of the drug as was shown for rainbow trout (O. mykiss) (Roy et al. 2006), 
and a consequence of very minimal metabolism of the parasiticide within the host (Kim-Kang et 
al. 2004).  The parasiticide crossed the blood-brain-barrier (BBB), although quantities in the 
brain were lower than in muscle and blood for the first 4 days, but then exceeded those for the 
rest of the sampling period.  How the kinetics of EMB and IVM differs at the BBB is discussed 
further below.  The therapeutic effect of EMB may last less than six weeks in total, but with 
great inter-individual variation in protection, which may be a consequence of differences in 
appetite (Skilbrei et al. 2008) and the natural hierarchies that exist within a cage of Atlantic 


























Temperature also plays a role in the pharmacokinetics of EMB in salmonids; as 
temperature increases, muscle half-life of the parasiticide decreases (Kim-Kang et al. 2004, Roy 
et al. 2006).  This is an important consideration for the timing of EMB treatments between cold 
and warm seasons.  For example, the mean water temperature in the Bay of Fundy in March and 
July of 2011 were 2.6 and 11.2°C, respectively (pers. comm. Dr. S.K. Whyte, Centre for Aquatic 
Health Sciences), and variations in seasonal temperature have been associated with seasonal 
differences in EMB efficacy in sea lice (Lees et al. 2008, Westcott et al. 2008).  
1.4.3.  Pharmacodynamics of emamectin benzoate  
A great deal of what is known regarding the site and mechanism of action of EMB is 
extrapolated from studies on other MLs, particularly IVM, and mainly in nematodes.  Hence, this 
section is based mainly on studies done in nematodes as well as the arthropod, Drosophila 
melanogaster.  Most parasiticides exert their action through disruption of parasite neuromuscular 
systems (Geary et al. 1992, McVeigh et al. 2012).  Macrocyclic lactones, including EMB, were 
initially presumed to act on -aminobutyric acid (GABA) receptors (Campbell et al. 1983), but 
the existence of glutamate-gated chloride channels (GluCls) in parasites was not known at the 
time (Geary & Moreno 2012).  About a decade later, two GluCl subunits,  and , were cloned 
from Caenorhabditis elegans, a nonparasitic nematode, and expressed in Xenopus oocytes (Cully 
et al. 1994).  These subunits were capable of forming homomeric or heteromeric channels 
sensitive to glutamate, ibotenate, IVM and other avermectins.  Glutamate-gated chloride 
channels are members of ligand-gated ion channels (LGICs) together with nicotinic 
acetylcholine, GABAA, glycine (GlyR), serotonin 5-HT3, cation channel selective N-methyl-D-
aspartic acid (NMDA) and non-NMDA receptors (Cully et al. 1996).  Ligand-gated ion channels 
are pentamers with subunits characterized by long N-terminal extracellular domain and four 
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membrane spanning domains with the second membrane-spanning domains forming the pore 
(Yates, Portillo & Wolstenholme 2003).  Genes that encode LGICs are highly conserved in most 
nematodes, explaining why these channels are targets of many neurotoxic parasiticides 
(Williamson, Walsh & Wolstenholme 2007).  Ligand-gated ion channel gene was also cloned 
from the mollusk, Aplysia californica (Kehoe et al. 2009).  The GluCl subunit from 
Haemonchus contortus, a parasitic nematode, expressed in Xenopus oocytes, is activated by IVM 
and moxidectin in a slow but irreversible manner (Forrester et al. 2003).  However, it is generally 
believed that avermectins act on both GABA and GluCl receptors (Yates, Portillo & 
Wolstenholme 2003), although GluCl seem to be the more widely accepted target site 
(Wolstenholme & Rogers 2005).  Studies have shown that avermectins and milbemycins bind 
and activate C. elegans GluCl (Arena et al. 1995), suggesting that GluCl is the major target site 
of avermectin in nematodes (Yates, Portillo & Wolstenholme 2003).  The high affinity binding 
of IVM at H. contortus GluCl (HcGluCl) is further proof that this receptor is an IVM target 
site in nematodes (Cheeseman et al. 2001).  Other avermectins compete with IVM for the 
binding site on GluCl but their affinities are lower.  Picrotoxin, fipronil, glutamate and GABA 
did not compete with IVM at this site, suggesting that they bind to different sites on GluCl 
channels (Yates, Portillo & Wolstenholme 2003).  Ivermectin irreversibly activates C. elegans 
heteromeric GluCl  and  channels as well as GluCl homomeric channels in D. melanogaster 
(Cully et al. 1996), but studies in H. contortus and C. elegans showed that IVM does not bind to 
GluCl subunit (Cheeseman et al. 2001), indicating selectivity for nematode GluCl subunit by 
the drug.  Binding of IVM to the membranes derived from C. elegans was described as a two-
step process (Schaeffer & Haines 1989) - an initial rapidly reversible binding characterized by a 
higher rate of dissociation followed by a slowly reversible binding which increases over time.  
25 

Binding affinity of the drug to C. elegans membranes was 100-fold higher compared with 
membranes from rat brain containing GABA receptors and was not affected by GABA, 
picrotoxin or bicuculline.  Glutamate-gated chloride channel  and Rdl (resistance to dieldrin) 
subunits of GABA co-assemble as a heteromeric receptor for IVM in D. melanogaster head 
membranes (Ludmerer et al. 2002).  Using anti-HcGluCl and anti-GABA antibodies, HcGluCl 
 and  subunits were localized in GABAnergic motor neurons of H. contortus (Portillo, 
Jagannathan & Wolstenholme 2003), further evidence that the two subunits form the receptor.  
Haemonchus contortus GluCl3A were localized with specific antibodies on amphidial 
structures, the major chemosensory organs in nematodes.  The above-discussed studies, 
especially in nematodes, provide strong evidence that GluCl is the major target site for MLs.  
Effects of IVM in C. elegans include inhibition of pharynx movement, motility and 
development of the larvae (Ardelli et al. 2009).  Ivermectin and moxidectin caused reduced 
motility, paralysis and decreased fecundity in the filarioid parasite, Brugia malayia (Tompkins, 
Stitt & Ardelli 2010).  Male B. malayi were more sensitive to the drugs compared with the 
females probably due to size differences; males are typically smaller in size than the females.  
This is contrary to observations made in sea lice, where female L. salmonis in laboratory 
bioassays were found to be more sensitive to EMB than the males (Westscott et al. 2008) and 
may be linked to intrinsically higher expression of P-glycoprotein (P-gp) mRNA in the male L. 
salmonis compared with the female L. salmonis (Chapter 2).  Bioavailability of MLs in dogs and 
rats has been shown to be higher in females than males and was suggested to be due to 
differences in P-gp (protein) and/or other multidrug resistance (MDR) transporter activity or 
expression levels (reviewed by Lespine et al. 2009).  The pharynx of the free-living nematode, C. 
elegans, was shown to be more sensitive to IVM than to moxidectin.  Unlike in C. elegans, 
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electrophysiological recordings revealed that pharyngeal muscle of the chick luminal nematode, 
Ascaridia galli, is insensitive to IVM (Holden-Dye & Walker 2006), emphasizing the possible 
error associated with extrapolation of data from one species to another.  Also, based on 
measurements of ingested 3H-inulin, it seems that IVM has no effect on the feeding activity (i.e. 
no effect on the pharynx) of H. contortus (Sheriff et al. 2005), but on the contrary, IVM reduced 
the uptake of inulin in the parasitic nematode Trichostrongylus colubriformis (Sheriff et al. 
2002), suggesting that the effects of this parasiticide may differ among different species of 
nematodes.  An earlier study concluded that the major effect of IVM is paralysis of the pharynx 
in H. contortus (Geary et al. 1993).  On the contrary, Sheriff et al. (2005) hypothesized that 
decreased motility rather than pharyngeal paralysis was the major effect of IVM in H. contortus.  
Since GluCl is expressed in the pharynx and somatic muscles of nematodes, these two effects 
may actually be occurring concurrently within these organisms following exposure to IVM 
(Wolstenholme & Rogers 2005).  GluCl3B of H. contortus was shown to be more sensitive to 
glutamate and IVM compared with the corresponding subunit in C. elegans or the parasitic 
nematode Dirofilaria immitis (McCavera et al. 2009).  Mutation at D. melanogaster GluCl 
caused decreased sensitivity to IVM, giving further evidence that the compound acts on this 
receptor (Kane et al. 2000).  Higher concentration of IVM was needed to activate C. elegans 
GluCl receptors expressed in Xenopus oocytes compared with the concentration that paralyzes 
the pharynx and decreases worm motility of the free-living nematode in vitro (Yates, Portillo & 
Wolstenholme 2003).  This was speculated to be due to differences in subunit composition 
between both systems or as a result of allosteric relationship that exists between the glutamate 
and IVM binding sites in vivo (Wolstenholme & Rogers 2005).  Similar to its action on 
nematode GluCl channels, IVM acted as an agonist and irreversible activator of cloned human 
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GlyRs at low and high concentrations, respectively (Shan, Haddrill & Lynch 2001).  It has also 
been suggested that IVM also acts through enhancing immune responses leading to rejection of 
microfilariae (Brugia malayi) in humans probably by inhibiting parasite secretions necessary for 
survival in the host (Moreno et al. 2010). 
1.4.4.  Toxic and side effects of emamectin benzoate in the host 
The difference in therapeutic index between EMB and IVM in salmon has been linked to 
differences in P-gp substrate activity in the fish BBB (Horsberg 2012) and will be discussed 
further below.  Although the two avermectins were shown to cross the salmon BBB (Høy, 
Horsberg & Nafstad 1990, Sevatdal et al. 2005a), IVM accumulated in salmon brain at toxic 
levels (Høy, Horsberg & Nafstad 1990), whereas EMB is likely pumped directly out on crossing 
the BBB explaining its relatively lower concentration in the teleost brain (Sevatdal et al. 2005a).  
Concentration of IVM was higher in the brain compared with the muscle at 2 days post-
administration and all through the sampling period (28 days), except at 12 and 24 h post-
administration (Høy, Horsberg & Nafstad 1990).  However, EMB attained higher concentrations 
in the brain compared with the muscle at 28 days post-administration (Sevatdal et al. 2005a).  
Also, while EMB caused toxicity (lethargy, dark colouration, depressed appetite and poor 
coordination) there was no mortality in salmon at ~7x the recommended dose (356 µg kg-1 fish 
biomass day-1 for 7 days) (Roy et al. 2000), whereas oral administration of 400 µg kg-1 fish 
biomass IVM as a single dose to Atlantic salmon resulted in higher mortality compared with 200 
µg kg-1 fish biomass treatment (Palmer et al. 1987).  These studies suggest differences between 
the affinity of EMB and IVM to P-gp at the salmon BBB.  The presence of P-gp in vertebrate 
(mice) BBB causes the efflux of IVM away from the brain (central nervous system) (Schinkel et 
al. 1994) limiting access of the drug to GABA receptors located in the brain (Kiki-Mvouaka et 
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al. 2010).  Using wild-type and mdr1ab (−/−) knockout mice Kiki-Mvouaka et al. (2010) 
showed that the transporter affected absorption of IVM and eprinomectin and also caused 
increased elimination of eprinomectin, but had insignificant effects on the kinetics of moxidectin.  
These findings suggest that the effect of P-gp on toxicity of MLs may vary.  There are also 
species differences in the role of P-gp in the toxicity of MLs.  Mutation in the mdr1 gene (which 
codes for P-gp) that gives rise to a sudden stop to P-gp mRNA translation was linked to 
increased IVM sensitivity in collies (Mealey et al. 2001).  The mutation was shown to be either a 
4-bp GATA or ATAG deletion (Roulet et al. 2003).  Disruption of this gene caused increased 
IVM toxicity in mice (Schinkel et al. 1994), most likely due to compromised BBB confirming 
the role of P-gp in IVM distribution (Mealey 2008).   
In a laboratory study to determine the margin of safety of EMB in Atlantic salmon, S. 
salar and rainbow trout, O. mykiss, the parasiticide was well tolerated by both salmonids for up 
to 3-4 times the recommended dose (50 g kg-1 fish biomass for 7 days) (Olsvik et al. 2008).  
However, analyses of hepatic genes in Atlantic salmon following 50 g kg-1 EMB treatment 
revealed moderate (mostly < 2-fold) effects.  These included genes encoding proteins involved in 
modification processes (such as acetylation, methylation or phosphorylation), inflammatory 
responses, and protein binding and nucleotide cleavage (Olsvik et al. 2008).  This shows that 
although EMB is administered to kill sea lice, the effect of the drug on host salmon may be 
present at the molecular level, especially on the stress and inflammatory processes, possibly 
interfering with the host-parasite relationship.  This should be considered particularly in salmon 
farms locations, for example in the Bay of Fundy, New Brunswick, Canada, where currently 2-
3x the recommended dosage are administered to the fish due to lack of clinical effectiveness of 
the manufacturer recommended dose within some areas in the Bay (M. Beattie, Department of 
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Agriculture, Aquaculture and Fisheries of New Brunswick, http://www.dfo-
mpo.gc.ca/science/enviro/aquaculture/rd2011/rdsealice-pou-eng.html).  
1.4.5. Fate and effects of emamectin benzoate on the environment 
Similar to most parasiticides, drugs and chemicals used for sea lice control, including 
EMB, are potentially toxic to non-target and benthic organisms (Burridge et al. 2010) especially 
crustaceans (Willis & Ling 2003, Waddy et al. 2007).  This is because the action of these 
parasiticides on sea lice is non-specific.  Hence the drug/chemical will affect most other 
organisms that are phylogenetically close to sea lice and/or possess the target sites for the 
parasiticide.  Accumulation of EMB in sediments around sea cages arises from uneaten 
medicated feed as well as from fish faecal matter containing the parent compound and its 
desmethylamino metabolite.  Emamectin benzoate undergoes very minimal metabolism within 
the host (Kim-Kang et al. 2004); hence the fish faeces will contain more of the parent drug than 
its metabolite.  Grave et al. (2004) showed that the rate of sea lice treatments, including EMB, in 
Norway, increased over time (from 1988 to 2002) due to reduced efficacy and/or increase in fish 
biomass.  This implies that higher concentrations of sea lice medicine are introduced into the 
environment over time.  Since EMB has low water solubility and high Log Kow, there exists the 
potential for the drug to persist in the marine environment tightly bound to sediments for 
prolonged periods (Bright & Dionne 2005, Burridge et al. 2010).  An investigation into the 
environmental effects of EMB in a commercial salmon farm (Telfer et al. 2006) concluded that 
the maximum concentration of the drug in the sediments (2.73 g kg-1 wet weight) had no toxic 
effects on free-living organisms such as crabs, polychaetes and whelks within 10 m of the sea 
cages.  Similar to EMB, IVM has the potential to accumulate in the sediment, and may cause 
mortality among polychaetes over time (Black et al. 1997, Collier & Pinn 1998).  Although, an 
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earlier study reported that in-feed IVM treatment at 50 g kg-1 twice per week for 3 months did 
not affect polychaetes resident in sediment under the treated sea cages (Costelloe et al. 1998).  
Emamectin benzoate was shown to cause premature molting in American lobsters (Homarus 
americanus) (Waddy et al. 2007), but that this occurs if a 500-g lobster consumes a minimum of 
110 µg of EMB (22 g of medicated feed) which is highly unlikely.  The effect of EMB on 
benthic organisms varies widely.  A 48 h acute toxicity test (carried out in the laboratory with 
filtered sea water) using marine copepods (Acartia clausi, Pseudocalanus elongatus, Temora 
longicornis and Oithona similis) revealed 5 to 2000-fold higher EMB EC50 for O. similis 
compared with the other copepods (Willis & Ling 2003).  Also, the blue mussels (Mytilus edulis) 
can bioaccumulate IVM (up to 5.2 mg kg-1 mussel tissue) when exposed to very high 
concentration 6.9 µg L-1 of the parasiticide in the laboratory for 6 days and it has a depuration 
half-life of 22 days (Davies, McHenery & Rae 1997).  Although degradation of IVM in the 
environment is slow and the half-life may be more than 100 days (Davies et al. 1998), such high 
concentrations of IVM (6.9 µg L-1) are not normally obtained in the environment (Davies, 
McHenery & Rae 1997).  However, prolonged use of higher concentrations of avermectin sea 
lice medicines such as EMB (as reported in some salmon farms in Atlantic Canada), for example 
due to resistance development, may lead to accumulation and persistence of high levels of the 
drugs in the sediments.  There is the need to exercise caution in using higher concentrations of 
EMB or frequent repeat treatments for sea lice control, as the drug has the potential to persist in 
the sediment and affect non-target benthos within the exposed site. 
1.5.  Parasiticide resistance 
Resistance is the heritable loss of sensitivity to a drug by target organisms (Sangster 
2001, He et al. 2009) and usually manifests when most individuals within the population survive 
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doses of the drug that kill a ‘normal’ population of the same species (Prichard et al. 1980).  Loss 
of drug efficacy is described as cross-resistance when the affected drugs possess different modes 
of action (Prichard et al. 1980).  Multiple-resistance occurs when a parasite population becomes 
insensitive to several drugs with different mechanisms of action (Wrigley et al. 2006).   
The effectiveness of EMB and its advantages over other chemotherapeutants quickly 
made it the drug of choice with almost exclusive use for sea lice control in salmon farms in the 
Bay of Fundy, NB (Westcott, Hammell & Burka 2004) and elsewhere.  However, the use of 
EMB has sharply declined in recent years due to resistance development (discussed below).  
Widespread drug resistance to available sea lice therapeutants, especially to EMB, has 
exacerbated the challenge of sea lice control.  
1.5.1.  Sea lice resistance to emamectin benzoate 
Resistance has developed to various parasiticides used to control salmon lice (Denholm et 
al. 2002, Grave et al. 2004), numerous parasites of land-based animal husbandry around the 
world (Le Jambre 1993, Swan et al. 1994, West et al. 1994, Vermunt, West & Pomroy 1996, 
Jackson et al. 2006, Waghorn et al. 2006, Slocombe, de Gannes & Lake 2007, Howell et al. 
2008, Sutherland et al. 2008, Condi, Soutello & Amarante 2009, Demeler et al. 2009, Gasbarre et 
al. 2009, Edmonds, Johnson & Edmonds 2010, Perez-Cogollo et al. 2010), as well as the 
parasitic nematode Onchocerca volvulus in human filariasis (Osei-Atweneboana et al. 2007).  
Hence, reliance on drugs and chemicals can only serve as short-term solutions for the control and 
management of most parasitic organisms (Prichard et al. 1980).   
The limited range of treatment options and control strategies for several years has 
contributed to resistance development in sea lice (Denholm et al. 2002).  Although the need for 
chemical diversity and the avoidance of over-dependence on a single chemotherapeutant cannot 
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be over-emphasized (Sangster 2003, Wolstenholme et al. 2004), the tendency to rely on single 
products for salmon lice control still exists.  This may be traced to the difficulty in developing 
and licensing new drugs (Denholm et al. 2002) and the reliance of farmers on available therapies 
that maintain their efficacy.  In Canada, regulatory bottlenecks are some of the major challenges 
towards developing or approving new drugs for sea lice control.  Emamectin benzoate was 
initially approved for use in Canadian salmon aquaculture in 1999 by Health Canada Veterinary 
Drugs Directorate under the Emergency Drug Release programme, but it did not receive full 
drug approval until 2009.   
For several years, EMB resistance development was a major concern for L. salmonis 
control due to over-reliance on the parasiticide by salmon farmers (Westcott, Hammell & Burka 
2004).  Consequently resistance development to the drug by L. salmonis has been reported in 
Atlantic Canada and Europe (Hjelmervik et al. 2010, Westcott et al. 2010) and by Caligus 
rogercresseyi in Chile (Bravo, Sevatdal & Horsberg 2008, Horsberg 2012).  This emphasizes the 
need for early detection of changes in EMB sensitivity as part of resistance management 
strategies (Westcott et al. 2008).  A study to determine temporal changes in EMB efficacy in 
different sea lice life stages using data collected from salmon farms in New Brunswick between 
2004 and 2008 revealed a decrease in EMB treatment efficacy (Jones et al. 2013).  The study 
also showed that EMB sensitivity varied among different farm locations and decreased at a faster 
rate in NB compared with analysis of data collected from salmon farms in Scotland between 
2002 and 2006 (Lees et al. 2008).  
In a study by Bravo et al. (2008), loss of sensitivity in C. rogercresseyi to EMB was 
attributed to the exclusive use of EMB to control sea lice in Chile for more than seven years, 
coupled with the previous employment of IVM, used for approximately ten years during the 
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1990s.  This favoured selection for resistance towards this class of parasiticides.  The sensitivity 
studies using bioassays were performed between 2006 and 2007 when clinical failures of EMB 
treatments were already evident, making it difficult to determine EMB sensitivity in naïve 
parasites for comparison purposes; although the authors suggest a loss of sensitivity in 
comparison with L. mugiloidis control (Bravo, Sevatdal & Horsberg 2008).  Since EMB has been 
used extensively in doses higher than the recommended dose and for extended treatment periods 
without yielding tangible clinical effectiveness, it is probable that EMB eliminated susceptible 
parasites leading to the propagation of EMB resistant strains of sea lice (Bravo, Sevatdal & 
Horsberg 2008).  In contrast to the study by Bravo, Sevatdal & Horsberg (2008), EMB bioassay 
studies carried out with L. salmonis collected from the Bay of Fundy, NB from 2002 to 2005 
prior to resistance development (Westcott et al. 2008) showed that the parasite were relatively 
more EMB sensitive in the latter study.  In addition to the prior use of IVM in Chilean salmon 
aquaculture, the differences in EMB sensitivity between the studies by Bravo et al. (2008) and 
Westcott et al. (2008) may be linked to duration of use of the parasiticide.  While EMB was 
approved as the only sea lice medicine in Chilean salmon aquaculture in 2000, the drug gained 
full approval for use in Canada only in 2009.   
The high efficacy and broad spectrum of activity of MLs led to over-dependence on this 
class of drugs for parasite control in plants, animals and man, globally.  The over-dependence 
has consequently led to emergence of resistant strains of the target parasites to the different MLs 
over time.  H. contortus, a common trichostrongylid parasite of ruminants, developed resistance 
to MLs, including IVM (Blackhall et al. 1998a).  Ivermectin, the only available drug for mass 
treatment of onchocerciasis (caused by O. volvulus) and lymphatic filariasis in West Africa and 
the Americas, selected for resistant parasites over time, due to therapeutic pressure (drug 
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selection of resistant strains of the parasite), leading to treatment failure (Eng et al. 2006).  
Hence, there is widespread resistance development to different MLs as well as the other major 
classes of parasiticides, and an urgent need for the development of new classes of parasiticides as 
well alternative control strategies. 
Work to understand development of drug resistance in L. salmonis is of practical 
importance (Denholm et al. 2002) because such knowledge is necessary for implementing 
effective drug rotations.  It is widely believed and commonly observed that drugs in the same 
class with similar mechanism of action select for the same resistance mechanism, especially for 
resistance development involving target site mutation or increased/decreased metabolism.  
1.5.2.  Resistance mechanisms 
Understanding drug resistance mechanisms, especially at the molecular and/or receptor 
level, is necessary for tracking resistance development (Blackhall et al. 1998a, Sangster & Gill 
1999, Prichard et al. 2007) and for responsible use of different classes of parasiticides (Geary, 
Sangster & Thompson 1999).  Two important concepts usually considered in drug resistance are: 
1) drug binding at the target site and 2) therapeutic concentration of the drug at the target site.  
These two concepts, usually associated with the different resistance mechanisms, are discussed 
below. 
1.5.2.1.  Target site 
Resistance at the target site is generally due to mutations that affect the ability of the drug 
to bind to its target, as shown for the organophosphate binding site on acetylcholinesterase 
(AChE) in sea lice (Jones, Sommerville & Wootten 1992, Denholm et al. 2002, Fallang et al. 
2004).  Also, drug resistance can occur due to down-regulation of gene expression leading to a 
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reduction in the expression of the corresponding target protein as has been shown for 
avermectins in H. contortus (Blackhall et al. 1998b, Wolstenholme et al. 2004).  Mutation at the 
D6 subunit of nicotinic acetylcholine receptor (nAChR) was linked to specific and high-level 
spinosyn (a tetracyclic-macrolide) resistance in D. melanogaster (Watson et al. 2010), but no 
cross-resistance was observed to avermectins, pyrethroids, oxadiazines, neonicotinoids and 
nicotinics.  Silencing of the D6 nAChR subunit gene conferred high-level spinosyn resistance 
in D. melanogaster (Perry, McKenzie & Batterham 2007). 
Pyrethroid resistance, an example of knockdown resistance (kdr), which arises from point 
mutations in the target site, the para-type sodium channel of nerve membranes (Fallang et al. 
2005) has been reported for deltamethrin in sea lice (Sevatdal & Horsberg 2003, Fallang et al. 
2005).  The two pyrethroids with approval for salmon lice control (deltamethrin and 
cypermethrin) are structurally similar and are expected to be cross-resisted through target-site 
mutation (Denholm et al. 2002).   
Macrocyclic lactone resistance has been linked to changes in the target site and an 
increase in drug efflux (reviewed by Wolstenholme, Kaplan 2012).  Most of the investigations 
into the involvement of target site changes in ML resistance utilized nematodes.  Mutations in 
GluCls have been implicated in resistance to IVM in both parasitic and free-living nematodes 
(Dent et al. 2000, Njue et al. 2004, McCavera et al. 2009) and may be polygenic, requiring 
mutation in different GluCl genes before high level resistance occurs.  Simultaneous mutation of 
the GluCl genes, avr-14, avr-15, and glc-1, conferred over 4000-fold resistance to IVM in C. 
elegans (Dent et al. 2000).  Ivermectin and moxidectin selected one allele of GluCl subunit, but 
none at the  subunit, suggesting that resistance to the avermectins is due to target site mutation 
at the  subunit (Blackhall et al. 1998a).  Such target site mutations can also be useful in tracking 
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resistance development to this family of parasiticides.  Mutation in GluCl3 and GluCl subunits 
located at the N-terminal extracellular domain caused an approximate 2.5-fold decrease in IVM 
and moxidectin sensitivities in the parasitic nematode Cooperia oncophora (Njue et al. 2004).  
Differences in allele frequency of GluCl3 were reported between IVM - resistant and - sensitive 
C. oncophora, whereby alleles E and H were higher in the resistant strain than in the sensitive 
strain, while allele A was higher in the sensitive strain than in the resistant strain (Njue & 
Prichard 2004).  Also, some studies have linked ML resistance to mutation at GABA receptors, 
suggesting these receptors are targets for ML activity.  Ivermectin and moxidectin selected for 
resistant alleles for genes encoding H. contortus GABA receptors (Blackhall, Prichard & Beech 
2003).  Ivermectin susceptible and resistance subunits of GABA-A receptor /, HG1A and 
HG1E, respectively, were cloned from H. contortus (Feng et al. 2002).  However, results from 
binding studies using membranes from IVM-sensitive and -resistant H. contortus L3 larva 
suggest that target site change is not involved in IVM resistance (Rohrer et al. 1994).  Also, 
comparison of cDNA sequences of IVM-sensitive and -resistant H. contortus revealed no coding 
differences, suggesting that either IVM does not select for an existing target site mutation in the 
parasite or that the putative mutation occurs in the non-coding region of the GluCl gene 
(Cheeseman et al. 2001).  Ivermectin resistance was linked to GluCl mutation in D. 
melanogaster (Kane et al. 2000).  Also, selection for abamectin resistance in the two-spotted 
spider mite, Tetranychus urticae, was reported to cause resistance to milbemectin (Sato et al. 
2005).  This is an important consideration for sea lice control using avermectins.  For example in 
the Bay of Fundy, although most salmon cage sites are already reporting reduced EMB efficacy, 
IVM has been re-introduced for the control of sea lice. 
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In addition to the issue of resistance among MLs, cases of cross-resistance have been 
described for this class of drugs whereby the use of a particular ML selected for resistance to 
another drug belonging to an entirely different class.  A classical example of this phenomenon is 
the study where selection for avermectin-resistant strains of H. contortus using IVM and 
moxidectin treatment alone also selected for benzimidazole resistance (de Lourdes Mottier, 
Prichard 2008).  Avermectin-induced benzimidazole resistance was linked to selection for single 
nucleotide polymorphisms (SNPs) from TTC (Phe) to TAC (Tyr) at codon 200 and 167 in the -
tubulin isotype-1, but not isotype-2 or -tubulin.  However, benzimidazole resistance did not 
confer IVM resistance in nematodes (Eng et al. 2006).  Restriction fragment length 
polymorphism and single strand conformational polymorphism analyses of several genes in O. 
volvulus isolated from humans treated or not treated with IVM revealed genetic polymorphism in 
-tubulin (Bourguinat et al. 2007, Lustigman & McCarter 2007), ATP-binding cassette (ABC) 
transporter homologue OvABC-3 (Ardelli & Prichard 2007) and P-gp genes (Eng & Prichard 
2005) (to be discussed below).  Ivermectin and moxidectin selected for different alleles of H. 
contortus P-gp gene compared with untreated parasites (Blackhall et al. 1998b).   
A change in amphidial structure has also been linked to IVM resistance in H. contortus 
(Freeman et al. 2003), as noted earlier.  The study by Freeman et al. (2003) showed that dendritic 
processes of IVM-resistant strains of H. contortus were further away from amphidial pore 
openings compared with the same structures in sensitive strains of the parasite.   
1.5.2.2.  Decreased drug uptake 
P-glycoprotein, a member of ABC transporters that belong to integral plasma membrane 
proteins, causes the efflux of a diverse range of molecules from within cells to the exterior (Fojo 
et al. 1985, Raviv et al. 1990).  Although genetic changes in GluCl channels have been 
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associated with ML resistance (Njue et al. 2004), increased expression of P-gp is widely believed 
to be the primary mechanism responsible for loss of parasite sensitivity to MLs (reviewed by 
Prichard & Roulet, 2007).  P-glycoprotein appears to play a major role in the protection of 
aquatic invertebrates from xenobiotics (Smital & Kurelec 1998, Fulton et al. 1999, Lyons-
Alcantara et al. 2002).   
Macrocylic lactones are substrates for P-gp and have high binding affinity for the 
transporter (Lespine et al. 2007).  Increased expression of P-gp was linked to ML resistance in C. 
elegans and H. contortus (Blackhall et al. 1998b, Xu et al. 1998, Sangster et al. 1999, James & 
Davey 2009).  Using in situ hybridization, P-gp mRNA was localized in the digestive tract and 
pharynx of H. contortus (Smith & Prichard 2002).  However, the level of expression in the 
pharynx did not differ between IVM and moxidectin resistant and sensitive strains of the 
parasite.  Some studies have shown that acute and chronic inflammatory responses can increase 
or decrease P-gp expression, respectively (Dumoulin et al. 1997, Ho & Piquette-Miller 2006).  
Therefore, although inflammation plays a positive role in the rejection of sea lice in salmonids 
(Johnson & Albright 1992, Jones, Kim & Bennett 2008, Wagner 2008), concurrent 
administration of EMB and immunostimulants to Atlantic salmon may, in fact, favour resistance 
development to the drug (Chapter 3). 
Macrocyclic lactone resistance can be reversed using modulators of the pump, such as 
verapamil (Molento & Prichard 2001), confirming the role of ABC transporters in IVM 
resistance.  Reversal of ABC transporters is a potential means of enhancing ML efficacy (Bartley 
et al. 2009), but differences in the kinetics of different MLs and existing reversal agents and 
potential toxicity of the latter may hamper realistic use of this strategy (Lespine et al. 2008).  
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Apart from being substrates of P-gp, MLs have also been shown to reverse P-gp-associated 
multidrug resistance in mammalian cells (Pouliot et al. 1997, Griffin et al. 2005).   
Based on several studies associating P-gp with resistance to IVM in parasitic and free-
living invertebrates, it was logical to investigate the involvement of this transporter in EMB 
resistance in sea lice.  It is hypothesized that up-regulation or over-expression of the P-gp gene in 
the gastrointestinal epithelium would serve to limit the absorption of various compounds, 
including EMB, ingested by the salmon louse (Tribble, Burka & Kibenge 2007).  A putative L. 
salmonis P-gp was cloned based on sequences of the transporter in the GenBank database at the 
time (Tribble et al. 2008).  However, with the cloning and addition of more P-gp sequences to 
the GenBank database, the putative ABC transporter reported by Tribble et al. (2008) was 
discovered to be a mitochondria half-transporter (Heumann et al. 2012).  A novel L. salmonis P-
gp SL-PGY1 (GenBank accession number HQ684737) was cloned by Heumann et al. (2012).  
Nematodes have numerous P-gp genes compared with mammals with C. elegans possessing up 
to 15 (Prichard & Roulet 2007); the number of P-gp genes in sea lice is unknown.  A component 
of the current study investigating the relative expression of the P-gp gene in L. salmonis is based 
on the SL-PGY1 sequence reported by Heumann et al. (2012). 
1.5.2.3.  Reduced metabolism 
Resistance can also result from enhancement of detoxification systems, for example 
through amplified esterases (Denholm et al. 2002) such as cytochrome P450 monooxygenase in 
pyrethroid-resistant sea lice (Sevatdal et al. 2005b).  It is not known whether EMB undergoes 
any significant enzymatic breakdown within the salmon louse.  Emamectin benzoate undergoes 
limited metabolism in Atlantic salmon (Kim-Kang et al. 2004) and, if this can be extrapolated to 
the parasite, would suggest that changes in metabolism would not significantly contribute to 
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EMB resistance in the salmon louse.  Also, EMB is a lipophilic drug, hence is slowly 
redistributed and metabolized in the salmon.  Therefore, any changes in metabolism should not 
significantly affect concentration of the drug within the parasite.   
1.5.3.  Environmental and genetic factors affecting parasiticide resistance 
Drug resistance is an evolutionary adaptive process where resistant strains of a parasite 
are favoured through drug selection pressure to become the predominant strain in the population 
(Sangster 1999).  Concurrent disease outbreaks including high sea lice infections can also cause 
depressed appetite (Damsgård, Mortensen & Sommer 1998) in affected fish leading to poor 
uptake of EMB during treatment (Berg & Horsberg 2009).  Such situations increase the rate at 
which resistance to the drug develops, i.e. consequence of sub-therapeutic EMB concentrations 
in the mucus of sick fish.  Also, affected fish can possibly serve as a refuge for drug-selected sea 
lice within the cage and, thus, a source of re-infection for healthy fish, further driving drug 
selection for resistant strains of the parasite.  
The presence of L. salmonis originating from a large wild salmon population in Pacific 
Canada is a likely source of EMB-sensitive sea lice to the salmon farms in the region, which 
should dilute any rise in EMB-resistant sea lice populations (Saksida et al. 2012).  Also, 
threespine stickleback (Gasterosteus aculeatus) has been reported as a host for sea lice in Pacific 
Canada (Jones & Prosperi-Porta 2011).  In contrast, wild salmon populations in the Atlantic have 
declined considerably (Anderson, Whoriskey & Goode 2000) and not a significant source of sea 
lice.  Also, the threespine sticklebacks are not reported to be infected with L. salmonis in this 
region.  These indicate decreasing possibilities of non-farm “wild” sea lice diluting a rising 
EMB-resistant sea lice population in the Atlantic region.  This may explain the higher incidence 
of EMB resistance in salmon farms located in Atlantic Canada compared with the Pacific (Jones 
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et al. 2012).  It is not known whether sea lice have any other wild host species in Atlantic 
Canada.   
Resistance is a consequence of changes in the genetic profile of the parasite population 
resulting in a phenotype of reduced sensitivity to treatment (Eng & Prichard 2005).  Genes 
conferring resistance arise through mutation, but maintain very low frequencies in pest 
populations in the absence of drug exposure (Denholm et al. 2002).  Over time and with 
recurrent treatments, genes conferring resistance are passed from one generation of survivors to 
another (Sangster 1996, Sangster & Gill 1999).  Following each exposure, individuals possessing 
these genes are selectively favoured and increase in frequency within a population.  Early on, the 
number of resistant survivors may be too low to affect treatment outcome, but over time and, 
with continued drug selection, the survivors become the dominant individuals within the 
population causing severe treatment failures (Denholm et al. 2002).  More genetically variable 
organisms possess greater capability of having an allele capable of causing poor treatment 
outcomes.  The evidence for the involvement of a gene in resistance to a drug can be obtained by 
examining the genetic variability of the gene between individuals sensitive and resistant to the 
drug (Blackhall et al. 1998a), where available.  The speed at which resistance develops and its 
extent depends on the virulence of the parasite, type of resistance mechanism, the frequency and 
level/dose of chemical use, and the parasite biology (Denholm et al. 2002).  Variations in 
resistance to sea lice therapeutants could be due to phenotypic or genetic differences and has 
been examined using different approaches (reviewed by Boxaspen 2006).  Provided the 
appropriate genes are investigated, changes in genetic profile are likely to be evident prior to 
widespread resistance-induced treatment failure and such changes in genetic disposition could be 
used to monitor the development of resistance to the parasiticide in use (Eng & Prichard 2005).  
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The application of population genetics promises to be a useful tool in the analysis of drug 
resistance in parasites and other pest species (Blackhall et al. 1998a).  Mutations and/or over-
expression observed in drug resistant parasites, but not in sensitive strains, can be expected not 
only in genes involved in resistance mechanisms, but may also be seen in genes upstream of the 
resistance activation cascade such as the nuclear receptor genes.  Identifying genes associated 
with drug resistance selection will be useful in the development of possible markers for tracking 
reduced drug sensitivity as it develops (Sangster et al. 2002).  Control programs that combine 
genetic, parasitological, and clinical aspects of treatment are usually more effective than any one 
aspect of monitoring (Eng & Prichard 2005).   
1.5.4.  Diagnosis of drug resistance 
Detection of anthelmintic resistance in nematodes of terrestrial livestock is mainly based 
on in vivo (e.g. fecal egg count reduction) and in vitro (e.g. egg hatch/larval development) tests 
(Coles et al. 1992), which have been employed in several studies to monitor ML efficacy (Coles 
et al. 2006, Yazwinski et al. 2009).  Monitoring is important to the rotational use of parasiticides 
so as to detect changes in sensitivity and delay resistance development (Zhao et al. 2006).  
Similar to the key factors discussed in the review by Zhao et al. (2006) on monitoring 
anthelmintic resistance in human onchocerciasis, including host, stage of parasite, and timing of 
monitoring (Churcher & Basanez 2009), proper monitoring of all stages of sea lice is important 
for the strategic timing of treatments of farmed salmon (Brooks 2009).  Depending on 
locality/region, reduced sensitivity and potential resistance to currently available medicines are 
constant threats to the control of sea lice populations on salmon farms.  Hence there is the need 
for on going monitoring of treatment efficacy.  
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Bioassays are commonly used to measure clinical effectiveness and investigate the 
effects of EMB on gene expression in surviving sea lice (Tribble, Burka & Kibenge 2007).  
Although the bioassay protocol shows promise as a method to verify clinical resistance, it lacks 
rapidity and simplicity for use as a routine test (Westcott et al. 2008).  Thus, initial work to 
develop bioassay methods has focused on testing preadult and adult sea lice that have been 
removed from their hosts.  This has several implications.  Firstly, once removed, the sea lice can 
only be used within a limited time frame, usually within 48 h, for meaningful results.  Secondly, 
endpoints can be hard to define, as the parasites can survive in a moribund stage for prolonged 
periods following exposure to most control agents (Denholm et al. 2002).  Hence bioassays are 
best suited for measuring indicators of sensitivity to the parasiticide under study by using a range 
of doses which include those that have been shown to be effective (Westcott et al. 2008).  
Monitoring strategies should be precise and practicable.  They should also be robust, simple and 
repeatable with an unambiguous endpoint as well as having sufficient sensitivity to detect 
changes in efficacy of the parasiticide.  However, no single resistance bioassay is likely to deal 
adequately with all chemicals in use, due to differences in their physico-chemical properties, life-
stage specificity and speed of action (Denholm et al. 2002). 
Assuming a relationship between drug resistance and its biochemical or molecular basis 
can be established, in vitro diagnostics for specific resistance mechanisms offer the prospect of 
more rapid tools for resistance monitoring (Denholm et al. 2002, von Samson-Himmelstjerna & 
Blackhall 2005).  The narrow spectra of available treatment options and the ability of sea lice to 
develop parasiticide resistance underpin the need to understand how these parasites respond to 
therapeutants used for their control (Walsh, Lyndon & Jamieson 2007).  Depending on the 
prevailing resistance mechanism, developing biochemical assays that measure 
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quantitative/qualitative changes in enzymes conferring resistance, or molecular techniques 
(Elard, Cabaret & Humbert 1999, von Samson-Himmelstjerna & Blackhall 2005) that detect 
genetic changes in drug resistant parasites, is a sensible direction to follow as part of the overall 
parasite control strategy (Denholm et al. 2002).  Genetic changes in the structure or expression of 
P-gp (Sangster et al. 1999) and -tubulin (Eng et al. 2006) may provide useful markers for 
monitoring resistance in parasites under prolonged avermectin treatment (Eng & Prichard 2005).  
Selection for -tubulin has been investigated as a marker for IVM and moxidectin resistance in 
nematodes (Prichard & Roulet 2007).  Markers may not be directly involved in the mechanisms 
of resistance to be useful as long as changes in their expression are strongly associated with 
exposure to the specific drug.  Mass use of IVM against O. volvulus in humans caused loss of 
genetic diversity of P-gp-like protein (Ardelli, Guerriero & Prichard 2006), and the ability to 
track this loss may be useful in monitoring IVM resistance (Bourguinat et al. 2008). 
Investigations into differentially expressed genes in sea lice are becoming increasingly 
important and significant.  Reverse transcription quantitative PCR (RT-qPCR) can be used to 
measure how a regulated gene is expressed compared with unregulated reference genes that 
encode proteins involved in routine cellular metabolism.  However, it is important that the 
chosen reference gene is truly unregulated within the biological samples employed (Frost & 
Nilsen 2003).  The study by Frost and Nilsen (2003) using RT-qPCR to identify candidate 
reference genes for transcription profiling throughout the life cycle of L. salmonis showed that 
the structural ribosomal protein S20 (RPS20) and the translation eukaryotic elongation factor 1 
(eEF1) show less than two fold variation in transcript levels and therefore are valid as reference 
genes.  According to the study by Frost and Nilsen (2003), the frequently used reference gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) could be up-regulated by up to six fold.  
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Although 18S RNA was highly expressed, it is not a reliable reference gene for relative 
quantification of most transcripts because of its relative abundance compared with RPS20, 
eEF1 and GAPDH, crossing the cycle threshold after 3 to 4 cycles during an RT-qPCR run 
(Frost & Nilsen 2003).   
As the cost of developing and running molecular assays decreases and their reliability, 
sensitivity, and automation potential increase (Bass et al. 2004), it becomes apparent that 
molecular tools will become an integral and routine part of resistance detection and management 
in the future (Humbert et al. 2001, Sangster 2001, von Samson-Himmelstjerna 2006).  This is 
particularly true for target-site mechanisms such as Rdl, where resistance is caused by point 
mutations in large and complex membrane proteins for which there are no simple biochemical 
assays for assessing target sensitivity (Bass et al. 2004).   
Progress in developing methods and the various approaches employed in genetic studies 
are also very important if host-parasite interactions are to be understood.  Then, new prophylactic 
or therapeutic strategies can be developed to arrest the propagation of sea lice.  
1.6.  Current investigation 
1.6.1.  The problem 
There are reports of sea lice resistance to EMB on fish farms in the Bay of Fundy, NB 
(Westcott et al. 2008).  Nevertheless, some sea lice populations within this region show more 
sensitivity to EMB compared with sea lice populations at other salmon farm locations within the 
Bay (Jones et al. 2012).  This emphasizes the need for continual resistance monitoring so that 
changes in sensitivity can be detected at an early stage.  Sea lice bioassays are commonly used in 
diagnosing clinical resistance, but cannot be routinely performed due to their lack of rapidity and 
simplicity.  Furthermore, results of bioassays can differ widely based on time of year and site of 
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the parasite collection.  Thus, no single bioassay technique will be suitable for all therapeutants 
used for sea lice control due to differences in the characteristics, stage specificity (Westcott et al. 
2008, Heumann et al. 2012) and speed/duration of action of the drugs (Denholm et al. 2002).  
Since the bioassay must be performed shortly after detaching the parasite from the host, to avoid 
biased endpoints from stressed sea lice, endpoints can be unclear especially between weak and 
moribund parasites following exposure in this system (Denholm et al. 2002).  These factors 
create the need for alternative methods of monitoring resistance development in the parasite, for 
example, using molecular tools such as RT-qPCR.  Identification and monitoring expression of 
resistance-associated genes can assist to detect the development of resistance and to modify 
treatment strategies (Eng & Prichard 2005).  Macrocyclic lactones can induce over-expression of 
P-gp in parasites (Lespine et al. 2012) and changes in the expression of this ABC transporter 
could be monitored as a means of detecting the development of EMB resistance in L. salmonis 
on salmon farms. 
There are ongoing efforts towards impeding the rate at which EMB resistance develops in 
sea lice populations through the use of integrated management strategies to control the parasite in 
salmon farms.  This includes the combined use of drugs with differing modes of action, 
chemicals, and non-chemical alternatives such as manipulation of host immunity using vaccines 
and/or immunostimulants (Jenkins et al. 1992, Raynard et al. 1994, Raynard et al. 2002).  
However, the effect of host immunostimulation and subsequent EMB treatment on mRNA levels 
of P-gp is not known.  This is because inducing the innate immune response of the salmon may 
have unintended consequences on other treatment regimens. 
The hypothesis for the present study is that P-gp is involved in resistance development to 
EMB in sea lice. 
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1.6.2.  Specific objectives of the current investigation 
The objectives of the present study were:  
1) Determine possible links between P-gp and EMB by identifying whether EMB interacts with 
the ABC transporter; 
2) Explore the use of RT-qPCR as a tool for monitoring resistance development to EMB in L. 
salmonis; 
3) Identify whether P-gp mRNA expression analysis tracks resistance development in archived 
L. salmonis samples; 
4) Ascertain possible enhancement of EMB efficacy through prior host immunostimulation; 
5) Investigate the effects of the host innate immune response on P-gp mRNA expression in the 
attaching L. salmonis following subsequent EMB treatment;  
6) Identify whether reports of EMB treatment success in Grand Manan, Bay of Fundy, NB, can 
be explained through EMB bioassay and P-gp mRNA expression studies; 
7) Determine if other populations of sea lice, not under EMB selective pressure, display a similar 
or differential response to EMB bioassay assessment, such as the Grand Manan sea lice 
population; and 
8) Investigate whether any differences identified between L. salmonis populations in the Bay of 
Fundy are heritable and result in differences in EMB sensitivity in vivo and in vitro using 
multi-generations and crosses of the parasite. 
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2.1.  Abstract 
Emamectin benzoate (EMB; SLICE®) has been the drug of choice for the control of sea 
lice in salmon aquaculture within the past decade due to its ease of administration as well as 
efficacy on all parasitic stages of sea lice.  This over-reliance has led to increased tolerance to the 
drug and a consequent decline in its use.  ATP-binding cassette (ABC) transporters such as P-
glycoprotein (P-gp) are known to be involved in drug resistance.  The present study investigated 
1) the interaction of EMB with P-gp, 2) the effect of increasing EMB concentrations on P-gp 
mRNA expression in male and female sea lice, Lepeophtheirus salmonis, from Atlantic salmon 
(Salmo salar) farms in the Bay of Fundy, NB, as well as 3) changes in the mRNA expression of 
the transporter in archived adult female L. salmonis.  Analysis of bioassay results indicated a 4 to 
26 fold higher EMB EC50 for samples collected in 2011 compared with a similar study carried 
out between 2002 and 2004 suggesting loss of EMB efficacy in the parasite. An assay for 
ATPase activity as well as a competitive inhibition test showed that EMB interacts with the 
transporter.  Emamectin benzoate had a significant concentration-dependent effect on P-gp 
mRNA expression in the parasite.  There was a temporal increase in levels of P-gp mRNA in sea 
lice samples collected from 2002 to 2011.  Our results indicate that EMB is a substrate for P-gp 





2.2.  Introduction 
Lepeophtheirus salmonis is one of the major species of sea louse that infest both wild and 
farmed Atlantic salmon, Salmo salar, (Burka, Fast & Revie 2012) and is currently the greatest 
challenge to profitable commercial salmon aquaculture in North America and Europe (Costello 
2009).  The adult parasite will normally feed on mucus, but may also ingest blood following 
damage of superficial epidermal capillaries exposed by extensive abrasion of the skin (Bron et al. 
1993).  The attachment and feeding activities of the parasite cause stress to the host (Fast, Ross 
& Johnson 2005) as well as osmoregulatory problems and secondary bacterial infections (Pike & 
Wadsworth 1999).  These will lead to high treatment costs, reduced growth, reduced food 
conversion rate and, consequently, reduced profit margin for the salmon farmer (Costello 2009).  
Drugs used for the control of sea lice are either administered orally in the feed, e.g 
emamectin benzoate (EMB), or topically as a bath treatment, e.g deltamethrin and azamethiphos 
(Burridge et al. 2010).  Emamectin benzoate, a macrocyclic lactone (ML), has been one of the 
most effective drugs (Stone et al. 1999) for combating L. salmonis infection in the past decade. It 
is administered in salmon feed as the chemotherapeutant SLICE® at a dose of 50 g kg-1 fish 
biomass for 7 days (Stone et al. 1999).  When fed to fish, it is absorbed from the gut and 
distributed throughout the fish with the least and highest concentrations in the muscle and 
mucus, respectively (Sevatdal et al. 2005).  Lepeophtheirus salmonis ingests EMB while feeding 
on the host mucus and the drug acts to block nerve transmission leading to flaccid paralysis and 
death of the parasite (Burka, Fast & Revie 2012).  Unlike bath treatments, which are more labor 
intensive and can be stressful to the fish, EMB is easily administered even during unfavourable 
weather conditions (Stone et al. 2000).  It has high efficacy against all parasitic stages of the 
louse, disrupting the life cycle at multiple points (Stone et al. 1999).  Its effectiveness and 
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advantages over other sea lice parasiticides made it the preferred drug for the control of the 
parasite in salmon farms in the Bay of Fundy, NB (Westcott, Hammell & Burka 2004), and 
elsewhere, leading to concerns over resistance development (Westcott et al. 2008). 
Drug resistance is an evolutionary adaptative process whereby susceptible parasites are 
eliminated causing resistant survivors to multiply and become the dominant population.  This has 
been proposed for resistance development by sea lice to anti-parasitic drugs (Denholm et al. 
2002).  The speed at which resistance develops and its extent depend on such factors as the 
nature of parasite-induced damage to the host, the mechanism of resistance, frequency of drug 
use or selection pressure, and the parasite’s biology.  In a study by Bravo, Sevatdal & Horsberg 
(2008), over reliance on EMB was the major cause of the loss of sensitivity to another species of 
sea louse, Caligus rogercresseyi, in Chilean salmon aquaculture.  Several years of use of another 
ML, ivermectin, prior to the introduction of EMB, also favored resistance development towards 
this class of drugs, suggesting lack of selectivity among the MLs.  
P-glycoprotein (P-gp), also known as ABCB1, a member of the ATP-binding cassette 
(ABC) transporter protein superfamily has been linked to ivermectin resistance in nematodes (Xu 
et al. 1998, Eng & Prichard 2005).  These transporters function by causing the efflux of 
chemically diverse substances from within the cell to the outside.  Extrusion of lipophilic 
chemicals from the cell by P-gp is powered by ATP hydrolysis, and this can be employed to 
determine drugs that interact with the transporter using the ATPase activity assay (Schwab et al. 
2003, Lespine et al. 2007).  It is hypothesized that over-expression of P-gp, most-likely in the gut 
epithelium, will impede the absorption of various compounds, including EMB, ingested by the 
salmon louse (Tribble, Burka & Kibenge 2007).  Furthermore, a novel L. salmonis P-gp SL-
PGY1 (GenBank accession no. HQ684737) was recently cloned by Heumann et al. (2012).  
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There have been reports of sea lice tolerance to EMB on fish farms in New Brunswick, 
Canada (Westcott et al. 2010), but whether P-gp is involved in reduced EMB efficacy in the 
parasite is largely unknown.  Early detection of changes in the sensitivity of sea lice towards 
EMB using drug resistance monitoring techniques should be a key component of a successful 
parasiticide resistance management plan (Westcott et al. 2008).  Drug resistance monitoring 
should be precise, easy to perform, simple and repeatable.  Sea lice bioassays are commonly used 
in diagnosing clinical resistance, but cannot be routinely performed due to their lack of rapidity 
and simplicity.  Since the bioassay must be performed shortly after detaching the parasite from 
the host, to avoid biased endpoints from stressed sea lice, endpoints can be unclear especially 
between weak and moribund parasites following exposure in this system (Denholm et al. 2002, 
Westcott et al. 2008).  Results of bioassays can differ widely based on time of year and site of 
the parasite collection.  Also, no single bioassay will be suitable for all therapeutants used for sea 
lice control due to differences in the characteristics, stage specificity and speed/duration of action 
of the drugs (Denholm et al. 2002).  These factors create the need for alternative methods of 
monitoring resistance development in the parasite, for example, using such molecular tools as 
reverse transcription quantitative PCR (RT-qPCR).  Identification and monitoring expression of 
resistance-associated genes can assist to detect the development of resistance and to modify 
treatment strategies (Eng & Prichard 2005).  Macrocyclic lactones can induce over-expression of 
P-gp in parasites (Lespine et al. 2012) and evidence for the involvement of such a gene in 
resistance development to a drug can be obtained by examining differences in expression of the 




The objectives of the present study were 1) to investigate possible links between P-gp 
and EMB by identifying whether EMB interacts with the transporter using an assay for ATPase 
activity and through competitive inhibition of the efflux pump, 2) to explore the use of RT-qPCR 
as a tool for monitoring resistance development to EMB in L. salmonis through temporal and 
dose response analysis of P-gp gene expression, and 3) identify whether P-gp expression analysis 
tracks resistance development in archived L. salmonis samples. 
2.3  Materials and methods 
2.3.1.  Materials 
Emamectin benzoate (PESTANAL®) and chemicals used for this study were of analytical 
grade and purchased from Sigma-Aldrich, St. Louis, MO. Membrane preparation (SB-MDR1-
PREDEASY™-ATPase, SOLVO Biotechnology) from Sf9 (Spodoptera frugiperda) was 
obtained from Xenotech, Lenexa, KS. 
2.3.2.  Parasite collection 
Sample collections for sea lice bioassays were done in March (winter collection) and July 
(summer collection) 2011.  These months were selected to identify seasonal influence on EMB 
efficacy (Lees et al. 2008, Westcott et al. 2008).  Adult male and female L. salmonis were 
carefully detached from host Atlantic salmon from fish farms in the Bay of Fundy, NB, and 
brought back alive to the laboratory in cold seawater collected from the sampling site and 
maintained at 10°C overnight with aeration.  Archived adult female L. salmonis (November 
2002, February 2008, and February 2010) were collected in a similar manner, but were 
immediately flash-frozen on arrival at the laboratory and stored at -80°C prior to further 
processing.  Adult male and female sea lice samples were also collected in December 2011 from 
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fish farms in the Bay of Fundy and F1 generation adult male sea lice grown in the laboratory 
(according to Westcott et al. 2008) for P-gp competitive inhibition tests.  Similarly, the sea lice 
samples were maintained at 10°C overnight with aeration prior to use in the P-gp inhibition 
experiments. 
2.3.3.  Bioassay 
Adult L. salmonis (240 male and 240 female) were selected within 12 h of the 10°C 
overnight storage and randomly distributed into Petri dishes with 10 sea lice per dish; each Petri 
dish contained either male or female L. salmonis.  The sea lice were exposed to EMB at 0, 10, 
100, 300, 1000 and 3000 ppb in 4 replicates per EMB concentration in a 24 h bioassay at 10°C.  
The EMB concentrations were coded and blinded to avoid biased analyses of the bioassay 
endpoint.  Following the overnight incubation, the number of live, weak, moribund and dead lice 
per dish was determined according to Westcott et al. (2008) with slight modifications.  ‘Weak’ 
refers to parasites that displayed poor and irregular swimming and were unable to attach to the 
Petri dish while ‘moribund’ refers to immotile parasites with twitching appendages.  Percentage 
mortality was calculated following the 24 h bioassay and the current half-maximal effective 
concentration (EC50) for EMB was derived from Trimmed Spearman-Kaber analysis (TSK) 
(Hamilton, Russo & Thurston 1977).  Half-maximal effective concentration (EC50) is the 
concentration of EMB that will cause 50% mortality (moribund and dead) of the parasite.  To 
ascertain whether 24 h 10°C incubation had any effect on P-gp mRNA expression, 40 live adult 
female L. salmonis were flash-frozen shortly after collection while another 40 lice were 
incubated (10 lice per dish) for 24 h at 10°C without any treatment; the pre-incubated and post-
incubated samples were compared for changes in P-gp mRNA expression.  All the bioassay 
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survivors (none from the 3000 ppb exposure group) were stored in RNAlater® (Sigma-Aldrich) 
at 4°C for 24 h and then at -80°C prior to RNA extraction. 
2.3.4.  ATPase assay 
Membrane preparations (SB-MDR1-Sf9, SOLVO Biotechnology) were incubated with 
EMB and ivermectin in separate assays, according to the manufacturer’s protocol (Sarkadi et al. 
1992).  Briefly, the test compounds were dissolved in ethanol (2% maximum solvent 
concentration) to achieve 5 mM initial concentration of each test drug followed by a 4-fold serial 
dilution.  The basic and verapamil-activated membrane suspensions as well as the KH2PO4 
controls [0, 4 and 8 nmol inorganic phosphate (Pi) final assay concentration] were dispensed into 
a 96 well plate according to the manufacturer’s setup such that each well contained 4 µg 
membrane (total) protein.  Membrane suspensions were not added to the wells for phosphate 
calibration.  The test drugs were added to the respective duplicate wells to achieve a 
concentration range of 0.01 to 100 µM final assay concentration.  Prior to the initiation of 
ATPase reaction, the plate and MgATP solution were preincubated at 37°C for 10 min, MgATP 
was then added to each well with the exception of the wells for phosphate calibration and 
incubated at 37°C for 10 min.  The ATPase reaction was terminated by addition of 100 µL of the 
supplied developer solution at room temperature.  Two minutes later, 100 µL of the supplied 
blocker solution was added to the wells at room temperature.  The plate was then incubated for 
10 min at 37°C and the optical density read immediately at 620 nm using a BioTek® Synergy HT 
microplate reader (BioTek Instruments, Winooski, VT).  The amount of Pi liberated in the 
presence and absence of 1.5 mM orthovanadate and relative to the KH2PO4 calibration curve 
were determined for both EMB and ivermectin and reported as the vanadate-sensitive ATPase 
activity (nmolPi/mg protein/min).  This is the activation assay and indicates whether the test 
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compounds will stimulate baseline vanadate sensitive ATPase activity.  The inhibition study, 
performed concurrently with the activation assay, was used to determine if the test compounds 
will decrease maximum vanadate-sensitive ATPase activity following stimulation by verapamil, 
a strong activator of P-gp ATPase activity.  P-glycoprotein substrates will stimulate baseline 
vanadate-sensitive ATPase activity while inhibitors of the efflux pump will decrease verapamil-
stimulated maximum vanadate-sensitive ATPase activity. 
2.3.5.  P-glycoprotein inhibition test 
In a preliminary study, adult male and female L. salmonis from host Atlantic salmon from 
fish farms were exposed in duplicate at 10 sea lice per Petri dish to increasing verapamil 
concentrations (0, 10, 30, 100, and 300 µM), and also to increasing verapamil concentrations 
with 100 or 300 ppb EMB concurrently in separate bioassays.  This was done to verify any 
toxicity of the inhibitor on the parasite as well as to ascertain the concentration of EMB at which 
inhibition of the transporter will be evident.  One hundred and 300 ppb EMB concentrations 
were chosen based on results of previous bioassays.  In the subsequent experiment, adult male 
and female L. salmonis from the same sampling location were exposed to increasing verapamil 
concentrations (0, 1, 3, 10, and 30 µM), and also to the same range of increasing verapamil 
concentrations with 100 ppb EMB (adult female L. salmonis) or 300 ppb EMB (adult male L. 
salmonis) in concurrent but separate bioassays at 10 sea lice per Petri dish.  The difference in 
EMB concentration used for the adult male and female sea lice is based on previous experiments 
showing that the male parasite is less sensitive to the drug compared with females.  Also, first 
generation adult male L. salmonis grown in the laboratory (2 -10 per Petri dish in 5 replicates) 
were exposed to 300 ppb EMB with or without 10 µM verapamil; 10 µM of the P-gp inhibitor 
was chosen based on results of initial experiments (Table 2.3).  The bioassays were conducted 
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according to previously described procedure and the criteria for determining the endpoints were 
the same. 
2.3.6.  RNA extraction 
Total RNA was extracted from bioassay survivors and archived samples (stored at -80°C) 
using the RNeasy® Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions 
with minor modifications.  One (female) or two (male) L. salmonis (n = 5) were placed in a 5 mL 
plastic tube containing 1 mL Trizol and homogenized using a hand held electrical tissue 
homogenizer.  The quality of all isolated RNA samples was verified with Experion™ RNA 
StdSens Chips (Bio-Rad Laboratories, Hercules, CA) for high quality (Fig. 2.1).  The cut-off for 
acceptable RNA quality was 8 and above on the RNA integrity scale (1-10).  The RNA 
concentration and the 260/280 nm ratio were confirmed using the Nanodrop 1000 
Spectrophotometer (NanoDrop Products, Wilmington, DE).  The samples were then stored at -
80°C prior to further use.  
2.3.7.  Reverse transcription quantitative PCR 
All the RT-qPCR steps were done according to standard procedures following the 
manufacturer’s protocol.  Briefly, 1 µg RNA of each sample was treated with DNase I 
(Invitrogen, Carlsbad, CA) and then reverse transcribed using SuperScript® III (Invitrogen).  The 
PCR reactions were carried out using SYBR® GreenER™ qPCR SuperMix (Invitrogen) on a 
Rotor-Gene 3000 (Corbett Life Science, Concorde, NSW, AU).  The cycling conditions were as 
follows: 50°C for 2 min (hold), 95°C for 10 min (initial denaturation), 45 cycles of 95°C for 15 
sec (denaturing), 55°C for 15 sec (annealing) and 68°C for 20 sec (extension) steps, and then 
melt step of 72 to 95°C with 5 sec hold at each step.  Primers targeting L. salmonis P-gp 
83 

(forward: TTCTACAGAATTGAAAGATCCGCACGAGTC; reverse: 
TACATAGTACCCGCATAGGCAAAGAAAGG) in the RT-qPCR were designed based on the 
SL-PGY1 sequence (Heumann et al. 2012) using the Primer 3 software.  Expression of P-gp 
mRNA in the different samples were normalized to 4 reference genes (previously validated by 
Frost & Nilsen 2003) - glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 18S rRNA, 
translation eukaryotic elongation factor 1 (eEF1) and structural ribosomal protein S20 
(RPS20) using the geNorm software (Vandesompele et al. 2002).  The geNorm analysis 
excluded 18S rRNA from computation of normalization factor utilized in the 2-Cq analysis as 
the gene has relatively high abundance and instability compared with the other reference genes.  
Primers for the reference genes were: GAPDH (forward: TGATGGACCCTCAGCAAAGAA; 
reverse: CCAGTAGATGCAGGAATAATATTTTGTC), 18S rRNA (forward: 
GCAGCAGGCACGCAAATT; reverse: GATGAGTCCGGCTTCGTTATTTT), eEF1 
(forward: TTAAGGAAAAGGTCGACAGACGTA; reverse: GCCGGCATCACCAGACTT) and 
RPS20 (forward: GCCGGTGTTTAACAATCATCAA; reverse: GGGCTTCGAGTCCTT 
GTATGC).  The efficiency of the qPCR for each primer set was 115%.  P-glycoprotein mRNA 










Figure 2.1.  Virtual gel output for Lepeophtheirus salmonis RNA samples examined for 
integrity/degradation using Experion™ RNA StdSens Chips (Bio-Rad Laboratories, Hercules, 
CA).  Single bands (pointed at by the black arrow) indicate high quality RNA.  L = RNA ladder; 





2.3.8.  Statistical analysis 
Relative P-gp mRNA expression was determined using one way ANOVA with the 
Minitab 15 statistical software (Minitab Inc., State College, PA).  Statistical significance was set 
at p < 0.05.  Graphical representation of the ATPase inhibition and activation assay result for 
EMB and ivermectin were created using the GraFit Version 7 software (Erithacus Software Ltd., 
Horley, UK).  The remaining graphs were plotted using SigmaPlot 10.0 (Systat Software Inc., 
IL).  The ATPase activity EC50 (concentration of test drug that will cause half-maximal 
stimulation of basal vanadate-sensitive ATPase activity) and IC50 (concentration of the test drug 
that will cause half maximal inhibition of maximum vanadate-sensitive ATPase activity) for the 
test compounds were determined using SigmaPlot 10.0 software. 
2.4.  Results 
2.4.1.  Bioassay 
The March 2011 bioassay showed a dose-dependent effect of EMB on the survival of 
both the male and female L. salmonis (Fig. 2.2; Table 2.1).  The female L. salmonis control 
group recorded a higher mean % mortality ± SEM (27.5 ± 6.3%) compared with the male control 
group (0%).  The mean % mortality ± SEM for the male L. salmonis 0, 10, 100 and 300 ppb (2.5 
± 2.5, 5.0 ± 5.0 and 12.5 ± 4.8 % respectively) treatment groups were generally lower than those 
of the female counterparts [12.5 ± 6.3, 17.5 ± 8.5 and 45 ± 16.6% respectively (Fig. 2.2)] except 
for the male 1000 ppb treatment group which had a higher mean % mortality ± SEM (97.5 ± 
2.5%) compared with the female counterpart (92.5 ± 4.8%).  
There was also a dose-dependent EMB effect on the parasite for the July 2011 bioassay 
(Fig. 2.2; Table 2.2).  Unlike the female control group, no mortality was recorded for the male 
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control group.  Again, the mean % mortality ± SEM for the male L. salmonis treatment groups 
were generally lower than those of the female L. salmonis treatment groups with the exception of 
the 1000 ppb treatment groups which were 100% and 95 ± 5% for the male and female parasite 
respectively. 
The March 2011 EMB EC50 values [mean ± SEM (Fig. 2.2)] derived from TSK analysis 
of the bioassay results were 457.20 ± 55.30 and 399.50 ± 93.70 ppb for the adult male and 
female L. salmonis respectively.  These values are 1.4-1.5 fold higher than the July 2011 EC50 
values (mean ± SEM) which were 315.30 ± 56.80 ppb for the adult male sea lice and 279.30 ± 
57.20 ppb for the adult female.  
2.4.2.  ATPase assay 
Emamectin benzoate and ivermectin stimulated baseline vanadate sensitive ATPase 
activity with EC50 of 26.35 µM (Fig. 2.3A) and 0.14 µM (Fig. 2.3B), respectively. Both 
compounds inhibited maximum vanadate-sensitive ATPase activity with IC50 of 7.82 µM for 




Table 2.1.  Mortality analysis of adult male and female Lepeophtheirus salmonis following 




Mortality@ (mean ± SEM) % Mortality 
Male+  Female+  Male Female 
0 0 2.75 ± 0.63 0# 27.5a 
10 0.250 ± 0.250 1.25 ± 0.63 2.5# 12.5a 
100 0.50 ± 0.5 1.75 ± 0.85 5# 17.5a 
300 1.25 ± 0.48 4.50 ± 1.66 12.5# 45a 
1000 9.75 ± 0.25 9.25 ± 0.48 97.5* 92.5b 
+ Samples collected in March 2011 from Atlantic salmon farms in the Bay of Fundy, NB. 
Different superscript (a, b, #, *) denotes significant (P < 0.05) difference between two values 
within each gender group (male or female; n = 5). ppb = parts per billion. % = percentage. @ = 




Table 2.2.  Mortality analysis of adult male and female Lepeophtheirus salmonis following 




Mortality@ (mean ± SEM) % Mortality 
Male+  Female+ Male Female 
0 0 1 ± 0.41 0# 10a 
10 0.25 ± 0.25 0.75 ± 0.48 2.5# 7.5a 
100 0.50 ± 0.50 1.75 ± 0.479 5# 17.5ab 
300 4.50 ± 1.55 5.75 ± 1.11 45* 57.5bc 
1000 10 9.50 ± 0.50 100 95c 
+ Samples collected in July 2011 from Atlantic salmon farms in the Bay of Fundy, NB. 
Different superscript (a, b, c, #, *, ) denotes significant (P < 0.05) difference between two 
values within each gender group (male or female; n = 5). ppb = parts per billion. % = percentage. 








Figure 2.2.  Concentration-mean (± SEM) % mortality relationship for adult male and female 
Lepeophtheirus salmonis (sea lice) exposed to emamectin benzoate in a 24 h bioassay (mean ± 
SEM derived from 4 replicates of 10 sea lice per EMB concentration).  Lepeophtheirus salmonis 






















Figure 2.3.  Activation (A and B) and inhibition (C and D) of ATPase activity [nmolPi/mg 
protein/min (mean ± SEM); n = 4] by emamectin benzoate and ivermectin using Sf9 (Spodoptera 
frugiperda) membranes overexpressing P-glycoprotein (P-gp).  Activation assay indicates 
whether test compounds will stimulate baseline vanadate sensitive ATPase activity; inhibition 
assay determines if test compounds will decrease maximum vanadate-sensitive ATPase activity 
following stimulation by verapamil, a strong activator of P-gp ATPase activity. 
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2.4.3.  P-glycoprotein inhibition test 
In the P-gp inhibition study, the adult male sea lice recorded less than 5% mortality for 
the 0, 1 and 3 µM verapamil (with or without 300 ppb EMB) treatment groups (Table 2.3).  
Exposure of the male parasite to 10 µM verapamil with 300 ppb EMB caused 35% mortality 
while exposure to 300 ppb EMB (without verapamil) resulted in 15% mortality.  Also in the 
male sea lice, concurrent exposure to 30 µM verapamil and 300 ppb EMB caused 100% 
mortality while exposure to the same concentration of the parasiticide without verapamil caused 
5% mortality.  Percentage mortality in the female sea lice following exposure to increasing 
concentration of verapamil was irregular (Table 2.3).  While 10 µM verapamil caused 10% 
mortality, simultaneous exposure to 10 µM verapamil and 100 ppb EMB caused 60% mortality 
for the female parasite.   
For the laboratory-grown adult male sea lice, exposure to 300 ppb EMB without 
verapamil caused 6% mortality while exposure to the same concentration of EMB with 10 µM 
verapamil caused 94% mortality (Fig. 2.4). 
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Table 2.3.  Mortality analysis of adult male and female Lepeophtheirus salmonis (sea lice) 
following exposure to emamectin benzoate (EMB) in a 24 h bioassay with or without increasing 
verapamil concentrations: December 2011 data (pooled sample of 20 sea lice/treatment group). 













Verapamil with 100 
ppb EMB 
0 0 5 20 10 
1 0 0 15 5 
3 0 0 30 25 
10 15 35 10 60 






Treatment with 300 ppb EMB
















Figure 2.4.  Differences in % mortality of F1 generation laboratory-grown adult male 
Lepeophtheirus salmonis (sea lice) exposed to 300 ppb emamectin benzoate (EMB) in a 24 h 







2.4.4.  Reverse transcription quantitative PCR 
For the March 2011 bioassay survivors, EMB induced significantly higher P-gp relative 
mRNA expression in the male and female adult L. salmonis 1000 ppb treatment groups (Fig. 
2.5A and 2.5B) compared with the other treatment groups within each sex category (P < 0.05).  
However, for the male L. salmonis, the relative P-gp mRNA expression of the 1000 ppb 
treatment group did not significantly differ with the 300 ppb group which also did not 
significantly differ from the mRNA expression levels of the transporter in the 0, 10 and 100 ppb 
treatment groups.  For the female L. salmonis, the mRNA expression of the transporter in the 
control, 10, 100 and 300 ppb treatment groups did not significantly differ.  No significant 
differences in P-gp relative mRNA expression were observed for the July 2011 bioassay 
survivors (data not shown).  Overnight incubation had no effect on P-gp mRNA expression in the 
parasite (data not shown). 
Analysis of the relative P-gp mRNA expression for the archived adult female L. salmonis 
(Fig. 2.6) revealed that the 2011 samples had a significantly higher (over 3-fold) levels compared 
with the samples from previous years [November 2002, February 2008 and February 2010; (P < 
0.05)].  Although there was a general upward trend in the expression of P-gp mRNA from 2002 







Figure 2.5.  Relative P-glycoprotein mRNA expression in adult male (A) and adult female (B) 
Lepeophtheirus salmonis emamectin benzoate bioassay (EMB) survivors (mean relative 
expression ± SEM) normalized to 3 reference genes - (glyceraldehyde-3-phosphate 
dehydrogenase, translation eukaryotic elongation factor 1, structural ribosomal protein S20) and 
compared with a calibrator.  Lepeophtheirus salmonis samples collected in March 2011.  A 









Figure 2.6.  Relative P-glycoprotein mRNA expression in adult female Lepeophtheirus salmonis 
collected in November 2002, February 2008, February 2010 and March 2011 from salmon farms 
(mean relative expression ± SEM) normalized to 3 reference genes - (glyceraldehyde-3-
phosphate dehydrogenase, translation eukaryotic elongation factor 1, structural ribosomal 
protein S20) and compared with a calibrator.  A different superscript (a, b) denotes a significant 








2.5.  Discussion 
Macrocyclic lactones have been widely used for the control of human and veterinary 
parasites since 1981 (reviewed by Shoop & Soll 2002), but unfortunately resistance has been 
developing to this family of parasiticides (reviewed by Prichard & Roulet 2007).  Mechanisms of 
resistance include changes in the target sites or decreased concentration of the drug at the 
receptor due to increased metabolism of the drug or decreased uptake/increased excretion in the 
parasite.  It is currently unknown whether EMB undergoes any significant enzymatic breakdown 
within the salmon louse.  However, EMB undergoes only limited metabolism in the host (Kim-
Kang et al. 2004) and, if this can be extrapolated to the parasite, it would suggest that changes in 
metabolism may not significantly contribute to resistance.  Although genetic changes in the 
glutamate-gated chloride channel have been associated with ML resistance (Njue et al. 2004), 
increased expression of the ABC transporter, P-gp, is widely believed to be the primary 
mechanism responsible for loss of parasite sensitivity to MLs (reviewed by Prichard & Roulet, 
2007). 
Kerboeuf and Guégnard (2011) and several other studies demonstrated that nematode P-
gp interacts with EMB as well as other MLs, hence the interest in verifying such involvement in 
the salmon ectoparasite, L. salmonis.  Resistance to parasiticides have been attributed to drug 
selective pressure on parasite populations whereby susceptible strains are eliminated, allowing 
individuals that survive therapeutic concentrations of the drug to multiply and become the 
dominant strain, as proposed for resistance development in sea lice (Denholm et al. 2002).  For 
an anti-infective drug to be clinically useful, resistance needs to be monitored during treatment, 
and concomitant use of closely related drugs should be avoided to prevent selection for drug 
resistance.  This has been reported for L. salmonis in New Brunswick (Westcott et al. 2010) and 
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C. rogercresseyi in Chilean salmon aquaculture where several years of use of ivermectin 
followed by over-reliance on EMB led to the emergence of resistant populations of the parasite 
(Bravo, Sevatdal & Horsberg 2008).  It is therefore important to identify genes and mechanisms 
associated with parasiticide resistance followed by monitoring the expression level of the 
identified genes as well as changes to the efficacy of the parasiticide.  Such a combined 
monitoring approach will help prevent development of drug resistance in parasites such as L. 
salmonis.  Studying parasites at the gene expression level also yields information such as stage 
and sex-related differences in drug sensitivity that could be exploited in parasite control 
strategies. 
Bioassays can be useful in detecting clinical resistance and (Tribble, Burka & Kibenge 
2007) have previously investigated potential effects of EMB on gene expression in sea lice 
following a 24 h bioassay.  For the March 2011 (winter) bioassay in this study, the female L. 
salmonis control group recorded slightly higher % mortality than the male L. salmonis 
counterpart but this trend was less obvious for the July 2011 (summer) bioassay (Fig. 2.2).  Poor 
fitness is generally observed in samples collected during the colder winter period compared with 
the warmer summer months [pers. comm. Dr. J.D. Westcott, Centre for Aquatic Health Sciences 
(CAHS), AVC, Charlottetown, PE], but it is not clear as to why this was more evident in the 
female parasite compared with the male in the present investigation.  Also, it has been reported 
that preadult female L. salmonis are probably more sensitive to EMB than the preadult males 
(Westcott et al. 2008, Whyte et al. 2013); this was confirmed in the current study where the EC50 
values for the female treatment groups were lower than the values for the male treatment groups.  
Although the reason for the sex-based discrepancy in EMB sensitivity in the parasite is yet to be 
elucidated, the reproductive burden imposed on the female L. salmonis could be a predisposing 
98 

factor.  Whether the intrinsically higher expression of P-gp mRNA in the male L. salmonis (Fig. 
2.5A) compared with the female L. salmonis (Fig. 2.5B) is also a contributing factor to the sex-
based differences in EMB sensitivity is unknown.  Bioavailability of MLs in dogs and rats has 
been shown to be higher in females than males and was suggested to be likely due to differences 
in P-gp and/or other MDR transporter activity or expression levels (reviewed by Lespine et al. 
2009).  The 1.4 to 1.5 fold higher EMB EC50 for the March 2011 bioassay compared with the 
July 2011 bioassay could be attributed to differences in water temperature in the Bay of Fundy 
between the two seasons; the mean water temperature in the Bay in March and July 2011 were 
2.6 and 11.2 °C, respectively (pers. comm. Dr. S.K. Whyte, CAHS, AVC, Charlottetown).  
Variations in seasonal temperature have been associated with seasonal variation in EMB 
sensitivity (Westcott et al. 2008), and Lees et al. (2008) have previously shown that seasonal 
temperature could be a risk factor for the outcome of EMB treatment episodes for sea lice.  Since 
the bioassays in the present study were conducted at the same temperature, the differences in 
EMB EC50 between the March and July bioassays could be traced to differing temperature 
preconditioning at the sampling site.  Although the mechanism of such temperature effects on the 
parasiticide is not yet understood, knowledge of such seasonal differences in the efficacy of 
EMB can be useful in the timing of treatment episodes for sea lice on salmon farms. The 
differences in EMB EC50 between the two sampling periods could also be due to variations in 
EMB sensitivity in sea lice populations between different salmon farms in the Bay of Fundy.  
Sea lice samples used in the two bioassays were collected from different sites in the Bay of 
Fundy and Westcott et al. (2010) as well as Whyte et al. (2013) have previously shown that sea 
lice sensitivity to the parasiticide can vary between different salmon farms and Bay management 
areas within the Bay of Fundy.  When compared with the EC50 in the present study, the EC50 
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values derived from a similar study by Westcott et al. (2008) between 2002 and 2004 using 
preadult stages of the parasite were 4 to 26 fold lower and ranged from 50.00 ± 0.00 to 107.80 ± 
3.80 ppb for the male parasite and 15.00 ± 14.50 to 34.50 ± 9.35 ppb for the female parasite 
(mean ± SEM), and is indicative of reduced EMB potency in the bioassays.  The 2002-2004 
bioassays were carried out using preadult stages of the parasite, whereas the present study 
utilized adult stages.  Whether the difference in the stage of L. salmonis used in the bioassays 
accounts for the differences in EMB EC50 values between both studies and the magnitude of such 
differences are yet to be ascertained.  Notwithstanding the foregoing, we suspect that a rightward 
shift in the EC50 of the parasiticide in L. salmonis found on Atlantic salmon in fish farms in the 
Bay of Fundy has occurred.  This normally occurs through drug selective pressure (Lespine et al. 
2012) and has been previously demonstrated for sea lice parasitosis in salmon farms elsewhere 
(Lees et al. 2008, Bravo, Sevatdal & Horsberg 2008). 
Typical of MLs, EMB and ivermectin inhibited basal ATPase activity; Schwab et al., 
(2003) previously showed that ivermectin is an inhibitor of basal P-gp ATPase activity.  In a 
study by Lespine et al. (2007), abamectin, eprinomectin, doramectin, ivermectin, selamectin and 
moxidectin, inhibited the basal P-gp ATPase activity with 50% inhibition at 0.2, 0.3, 0.5, 2, 3 
and 10 µM, respectively.  Slowly transported substrates have been shown to inhibit basal P-gp 
ATPase activity, while substrates that are more readily transported activate the ATPase activity 
(Lespine et al. 2007).  In this study, EMB recorded an EC50 of 26.35 µM (Fig. 2.3A), suggesting 
that it is probably a more readily transported substrate than ivermectin (EC50: 0.14 µM, Fig. 
2.3B) as well as the previously mentioned MLs.  The difference in ivermectin EC50 values 
between the study by Lespine et al. (2007) and our study may be due to the type of membrane 
used in the different experiments.  Whereas Lespine et al. (2007) used membranes derived from 
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DC-3F/ADX cells from Chinese hamster lung fibroblasts overexpressing P-gp, the current study 
utilized SB-MDR1-Sf9 membranes overexpressing the transporter.  It has been shown that 
variations in basal ATPase activity can exist between different membrane preparations 
overexpressing P-gp (Lespine et al. 2007).  More studies to determine the rate of EMB 
transportation by the efflux pump using a cell-based model (Brayden & Griffin 2008) should be 
done to clarify our current observations.  The ATPase activity inhibition study (Fig. 2.3C and 
2.3D) showed that EMB, similar to ivermectin, inhibited maximal vanadate-sensitive ATPase 
activity with IC50 of 7.82 and 4.98 µM, respectively.  Emamectin benzoate and ivermectin are 
lipophilic compounds and are slowly transported in vivo and such compounds have been shown 
to inhibit maximal vanadate-sensitive ATPase activity.  Competitive inhibitors of P-gp could 
also be substrates of the transporter (Garrigos, Mir & Orlowski 1997) and further studies are 
necessary to confirm whether EMB, similar to ivermectin, is a substrate of the efflux pump. 
Ivermectin has previously been shown to be a competitive inhibitor as well as substrate of P-gp, 
hence initial attempts to use the parasiticide as a multidrug-reversing agent in drug resistant 
parasites (Mottier et al. 2006) and cells (Pouliot et al. 1997). 
P-glycoprotein competitive inhibition test using MDR-reversing agents such as verapamil 
(Lespine et al. 2012) is a well established means of determining compounds that are substrates of 
the efflux transporter during drug development and the concept is the basis for the reversal of P-
gp-mediated drug resistance in anthelmintic and anticancer chemotherapy.  Verapamil, a well 
known calcium channel blocker, caused  10% mortality in L. salmonis at 10 and 30 µM (Table 
2.3) and 100% mortality at 100 µM (data not shown), possibly due to blockade of calcium 
channels in the parasite.  However, concurrent exposure of L. salmonis to EMB and verapamil 
caused higher % mortality compared with exposing the parasite to the parasiticide alone (Table 
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2.3, Fig. 2.4).  This data provides further evidence that EMB interacts with P-gp in the parasite 
and also suggests that verapamil may be interacting at the same site on the efflux pump as EMB.  
The increased sensitivity of L. salmonis to EMB following concomitant verapamil exposure is 
most likely a consequence of competitive inhibition of P-gp by the MDR-reversal agent.  
Inhibition of the transporter limits the efflux of the parasiticide, thereby causing an increase in 
the concentration of EMB in the parasite.  Also, the sum of mortalities due to separate exposure 
of the parasite to EMB and verapamil (Table 2.3) is several fold lower than the mortality 
recorded following combined exposure to both drugs at the 10 and 30 µM verapamil 
concentrations.  The sex-based differences in the concentration of verapamil and EMB combined 
exposure that caused over 50% mortality in the parasite further reinforces the idea that the sex-
based differences in EMB sensitivity observed in the parasite could be due to differences in P-gp 
expression between male and female L. salmonis.  Again, the female sea lice treatment groups 
displayed suboptimal fitness compared with the male parasite groups, but that notwithstanding, 
the effect of concomitant verapamil and EMB exposure on % mortality on both parasite sexes is 
evident at the 10 and 30 µM verapamil exposures.  This observation is consistent with previous 
studies on competitive inhibition of P-gp to ivermectin by verapamil in rat (Alvinerie et al. 1999) 
and Haemonchus contortus (Molento & Prichard 1999), and further confirms our hypothesis that 
P-gp could be involved in reduced sensitivity of L. salmonis to EMB.  This implies that 
concurrent administration of MDR-reversing agents (such as verapamil) and EMB could increase 
the sensitivity of sea lice to the parasiticide and bring about significant reduction in EMB-
resistant parasite populations to lower acceptable numbers in salmon farms where reduced EMB 
efficacy has been reported.  More studies are necessary to confirm the possibilty of using MDR-
reversing agents in the control of sea lice in Atlantic salmon farms plagued with EMB-resistant 
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strains of the parasite.  Verapamil was used in this study as a pharmacological tool to ascertain 
the role of P-gp in resistance development in vitro, but would probably not be an ideal agent to 
use therapeutically as it is not likely to accumulate in the skin, limiting availability to the 
parasite.  It would also have the potential of inducing cardiac toxicity to the host salmon due to 
Ca++ channel inhibition.  Other ABC-transporter inhibitors with appropriate pharmacokinetics 
and host and human safety parameters need to be developed.   
Emamectin benzoate induced overexpression of P-gp mRNA in a concentration-
dependent manner for the March 2011, but not July 2011 sampling period.  The approximately 2-
fold P-gp mRNA expression (March 2011 sampling) in the 1000 ppb male treatment group 
compared with the 0, 10 and 100 ppb treatment groups (Fig. 2.5A), as well as the dose-dependent 
upward trend in P-gp mRNA expression (Fig. 2.5A and 2.5B) suggest that there is a positive 
correlation between EMB concentration and P-gp mRNA expression.  Previous studies in 
nematodes have linked ivermectin resistance to over-expression of P-gp and the transporter has 
been reported to be responsible for multidrug resistance to structurally diverse drugs and 
chemicals used in agriculture, medicine and veterinary medicine.  The upward trend in the 
relative P-gp mRNA expression in archived samples (Fig. 2.6) and the fact that P-gp mRNA 
expression for the March 2011 samples was significantly (> 2-fold) higher than the expression 
for 2002, 2008 and 2010 samples suggest that P-gp mRNA expression levels was increasing over 
the years.  Although lipophilic xenobiotics in the sampling site can induce increased expression 
of the transporter gene in the parasite, presence of such contaminants was not confirmed and the 
genetic effect of continuous use of EMB on salmon farms since 2000 could be the prevailing 
factor (Bravo, Sevatdal & Horsberg 2008).  This pattern is similar to what was observed for the 
March 2011 bioassay survivors (Fig. 2.5A and 2.5B) whereby high concentration of EMB (1000 
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ppb) induced significantly higher P-gp mRNA expression and vice versa compared with the 
other treatment groups and control (P < 0.05).  Such pattern of expression was not observed for 
the July 2011 bioassay, suggesting possible correlation between EMB EC50 values and P-gp 
mRNA expression in L. salmonis.  The EC50 value was higher in the March 2011 sampling 
compared with the July 2011 sampling and there were concentration-dependent differences in P-
gp mRNA expression for the earlier sampling period but not for the latter.  Unfortunately, only 
adult female parasites were archived and analysed, otherwise, it would have been interesting to 
investigate the changes in the expression of the transporter in the male parasite over the same 
period.  This is because male L.salmonis are less sensitive to EMB and have a higher level of P-
gp expression (Fig. 2.5A and 2.5B), hence will likely be a better model for tracking development 
of EMB resistance compared with the female parasite.  
2.5.1.  Conclusion  
Results of the present study, especially the P-gp competitive inhibition test results, 
strongly indicate that the efflux transporter is involved in reduced sensitivity of L. salmonis to 
EMB.  This observation may further be confirmed using gene knock-out strategies such as RNA 
interference (RNAi) technique.  Changes in the expression of resistance-associated genes such as 
P-gp can be monitored and used in the diagnosis of early stages of resistance development to 
parasiticides.  Although definitive diagnosis for clinical resistance can only be derived by 
determining changes in EC50, it is important to predict when resistance is likely to occur and plan 
towards forestalling it.  This could be achieved by monitoring markers or genes involved in 
reduced efficacy to the drug using such molecular tools as RT-qPCR (Williamson & 
Wolstenholme 2012) and our studies have demonstrated that this molecular technique can be 
employed in monitoring resistance development to drugs used in aquaculture.  Knowledge of the 
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timing for resistance development will inform necessary changes to treatment options to prevent 
severe treatment failure.  One of the greatest challenges to chemotherapy is that resistance to 
currently available classes of paraciticides already exists and there is an urgent need for the 
discovery of new classes of drugs for the control of parasites including L. salmonis.  Although 
some studies have shown that MLs interact with other ABC transporters, P-gp is believed to be 
the major resistance mechanism for this family of parasiticides (Prichard & Roulet 2007, 
Kerboeuf & Guégnard 2011).  Comparison between EMB sensitive and resistant strains of L. 
salmonis should be carried out to verify whether P-gp is involved in the loss of parasite 
sensitivity to the drug.  
Using the P-gp competitive inhibitor, verapamil, we have demonstrated that the efflux 
transporter could be playing a major role in EMB resistance in L. salmonis.  Also, results 
presented showed that EMB will induce overexpression of the transporter in L. salmonis.  
Further investigation is required to confirm the extent of P-gp involvement in reduced EMB 
efficacy in L. salmonis, and whether this can be targeted for therapy.  The use of RT-qPCR as a 
drug resistance monitoring tool in aquaculture should also be explored further. 
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CHAPTER 3   
IMMUNOSTIMULATION OF SALMO SALAR L., AND ITS EFFECT ON 
LEPEOPHTHEIRUS SALMONIS (KRØYER) P-GLYCOPROTEIN mRNA 
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3.1.  Abstract 
Control of sea lice, Lepeophtheirus salmonis, on farmed Atlantic salmon, Salmo salar, 
relies heavily on chemotherapeutants.  However, reduced efficacy of many treatments and need 
for an integrated sea lice management plan require innovative strategies.  Resistance to 
emamectin benzoate (EMB), a major sea lice parasiticide, has been linked to P-glycoprotein (P-
gp) expression.  We hypothesized that host immunostimulation would complement EMB 
treatment outcome.  L. salmonis infected Atlantic salmon were fed immunostimulatory or control 
feeds.  Sea lice were collected for 24 h EMB bioassays one and two weeks prior to 
commencement of EMB treatment of the fish.  Two weeks after cessation of immunostimulant-
treated feed, EMB was administered at 150 µg/kg fish biomass for 7 days.  The bioassay 
revealed stage, sex and immunstimulant related differences in EMB EC50.  Sea lice attached to 
salmon with a history of immunostimulation exhibited greater survival than those on control 
feeds, despite similar levels of EMB in host tissues.  L. salmonis from salmon with a history of 
immunostimulation also exhibited higher P-gp mRNA expression as well as greater survivability 
compared with controls.  Administration of immunostimulants prior to EMB treatment caused 
increased expression of P-gp mRNA which could have consequently caused decreased efficacy 








3.2.  Introduction 
The sea louse (Lepeophtheirus salmonis), a major ectoparasite of Atlantic salmon (Salmo 
salar), in the North Atlantic (Burka, Fast & Revie 2012), causes significant economic losses to 
commercial salmon producers (Costello 2009).  Attachment and feeding activities of the parasite 
cause health challenges for the salmon arising from electrolyte and ion loss, stress, and 
opportunistic bacterial and/or viral infections (Pike & Wadsworth 1999).  Strategies to control 
sea lice parasitosis in salmon farms include good management practices and administration of 
chemicals or drugs as bath or in-feed treatment, respectively.  Among the several sea lice 
parasiticides available, emamectin benzoate (EMB), a macrocyclic lactone (ML), has been one 
of the most successful.  Emamectin benzoate activates glutamate-gated chloride channels of the 
parasite where it disrupts neurotransmission causing paralysis and, consequently, killing the sea 
louse (Burka, Fast & Revie 2012).  The drug is easily administered and is effective against all 
parasitic stages of sea lice (Stone et al. 1999).  Over-reliance on EMB by salmon farmers 
(Westcott, Hammell & Burka 2004) consequently led to resistance development to the drug by L. 
salmonis in Atlantic Canada and Europe (Hjelmervik et al. 2010, Westcott et al. 2010) and 
Caligus rogercresseyi (Bravo, Sevatdal & Horsberg 2008) in Chile.   
Widespread development of drug resistance in L. salmonis underscores the need for an 
integrated sea lice management approach to the control of sea lice in salmon farms.  This can be 
achieved through the combined use of drugs, chemicals, and non-chemical alternatives including 
manipulation of host immunity using vaccines and/or immunostimulants (Jenkins et al. 1992, 
Raynard et al. 2002).  Stimulating the innate immunity of fish hosts against pathogen and 
parasite invasion (Bricknell & Dalmo 2005) is increasingly adopted as part of disease 
management in aquaculture including sea cage salmon farming (Tacchi et al. 2011).   
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Commonly used immunostimulants in aquaculture, -glucan/yeast extracts (Bridle et al. 
2005, Dalmo & Bøgwald 2008, Guselle et al. 2010) and a known innate stimulating compound, 
cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) ( Jørgensen et al. 2003, 
Carrington & Secombes 2006), were investigated in-feed for their ability to enhance EMB 
efficacy in L. salmonis.  These immunostimulants are highly conserved pathogen-associated 
molecular patterns (PAMPs) found in lower organisms, but absent in Metazoa (Tsoni & Brown 
2008).  Whereas -glucans occur as polysaccharides in fungi, plants and bacteria (Tsoni & 
Brown 2008), CpG ODNs are unmethylated motifs found within bacterial and viral DNA 
(Carrington & Secombes 2006).  Presence of PAMPs within a host are sensed by pattern 
recognition receptors (PRRs) such as Toll-like (TLR) (Bricknell & Dalmo 2005, Cuesta, Esteban 
& Meseguer 2008, Palti et al. 2010) and C-lectin (CLR) receptors (Tsoni & Brown 2008).  On 
recognition of PAMPs, PRRs activate signalling pathways which lead to transcription of genes 
involved in the immune response, including inflammation, antiviral responses and dendritic cell 
maturation (Whyte 2007).  During sea lice parasitosis, a strong inflammatory response by salmon 
is necessary for early and effective rejection of the parasite (Johnson & Albright 1992, Fast et al. 
2003).  Hence administration of immunostimulants to Atlantic salmon to boost the innate 
response to sea lice infection may enable these fish to eliminate the parasite more effectively. 
The basis of this study is that prior host immunostimulation followed by drug treatment 
will lead to greater louse mortality compared with individual use of immunostimulants or drugs.  
It was hypothesized that the innate immune response would likely weaken the parasite, making it 
more sensitive to the action of a parasiticide such as EMB.  The effect of host 
immunostimulation and subsequent EMB treatment on mRNA expression of P-gp, a major EMB 
resistance mechanism in L. salmonis (Chapter 2), is not known.  Some studies have shown that 
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acute and chronic inflammatory responses can increase or decrease P-gp expression, respectively 
(Dumoulin et al. 1997, Ho & Piquette-Miller 2006).  The aims of this study were to a) ascertain 
possible enhancement of EMB efficacy through prior host immunostimulation and b) investigate 
the effects of host innate immune response on P-gp mRNA expression in the attaching L. 
salmonis following subsequent EMB treatment. 
3.3.  Materials and methods 
3.3.1.  Experimental design 
Two recirculation units each consisting of 8 (330 L) tanks with parallel biofilter systems 
were set up and maintained at 11 (± 1) °C water temperature.  Atlantic salmon smolts with a 
were procured from Buckman’s Creek Hatchery Ltd., Pennfield, NB, and transported to the 
Atlantic Veterinary College (AVC) Aquatic Facility.  The fish had a mean weight of 155.1 ± 
82.2 g (mean ± SD) at the beginning of the study and were randomly allocated to tanks at 30 fish 
per tank and allowed to acclimatize to the system (freshwater) for 3 weeks.  The system was then 
changed to recirculation and the salinity gradually raised to ~33 gL-1 with Instant Ocean® 
(Aquarium Systems, Cincinnati, OH) over 7 days.  The fish were allowed to acclimatize again 
for 3 weeks prior to commencement of immunostimulant feed administration (Table 3.1).  The 
fish were fed 1% body weight control diet and maintained on a 14 h light: 10 h dark cycle.  
Concentration of ammonia, nitrite, oxygen and nitrate in the water were closely monitored and 
maintained at optimal levels throughout.  
3.3.2.  Immunostimulant feeds 
Feeds used in this study were produced by Northeast Nutrition Ltd., Truro, NS, as 2.5 
mm pellets.  The tanks containing the salmon were randomly assigned to the three 
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immunostimulants SLX, CpG and Aquate®, in duplicates; control feeds were allocated to 4 
tanks, 2 tanks each for EMB treated and untreated fish.  SLX is a non-commercial proprietary 
immunostimulant feed containing an undisclosed immunostimulant milled directly into the feed 
at 0.6 g/kg of feed, concentration known to induce host inflammatory processes.  CpG 
immunostimulant feed was produced by incorporating unmethylated CpG ODN (Sigma, St. 
Louis, MO) into the base feed at 2 g/kg feed.  The third immunostimulant feed, 0.2 % Aquate® 
(Stirling Products, Charlottetown, PE), contained crude yeast extracts.  
3.3.3.  Infection of S. salar with L. salmonis copepodids 
Copepodids hatched from egg strings of EMB resistant (based on previous EMB bioassay 
results) adult female L. salmonis collected from salmon farms in the Bay of Fundy, NB, were 
used to infect the salmon according to the method of Covello et al. (2011).  Approximately 2100 
copepodids were introduced into each tank with increased aeration for about 6 h (Table 3.1).  
Two days later, an additional 1450 copepodids were added to each tank using the same 
procedure.  Prior to sea lice infection, the recirculation system was turned off and a 100 µm net 
installed across each inflow valve of the different tanks to prevent cross-infection between tanks.  
Water temperature (11 ± 1°C) and O2 level (7-9 mg L-1) were monitored and maintained in each 
tank throughout L. salmonis infection period. 
3.3.4.  Bioassay 
Two and one week(s) prior to commencement of EMB treatment (Table 3.1), fish samples from 
all the control and treatment groups were euthanized with a lethal dose of MS-222 (250 mg L-1; 
Syndel Laboratories Ltd., Qualicum Beach, BC) and sea lice samples were collected.  The sea 
lice were at preadult and adult stages at the first and second sampling, respectively.  Adult sea 
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lice from the second sampling served as EMB untreated control for immunostimulant/EMB 
treament component of this study.  The samples were stored overnight at 10°C in salt water (33-
36 g L-1 salinity) and then used for EMB bioassay within 12 h of collection for both the first.  
The bioassay was carried out according to the described protocol in Chapter 2.  
The EMB concentrations used for the first sampling (preadult stage) were 0, 10, 100, 300 
and 1000 ppb while 0, 100, 200, 400 and 1000 ppb EMB were used for the second sampling 
(adult satge).  The different range of EMB concentrations used was based on the different 
parasite stage used.  At the end of the 24 h EMB bioassay, half-maximal effective concentration 
(EC50) for the parasiticide was derived using US Environmental Protection Agency (USEPA) 
Trimmed Spearman-Kaber (TSK) software version 1.5 (Hamilton, Russo & Thurston 1977) for 
each treatment group.  Survivors of the bioassay were flash-frozen in liquid nitrogen and 
immediately stored at -80°C.  The EMB untreated control sea lice were analysed to verify stage-, 
sex-, and immunostimulant-related differences in relative P-gp mRNA expression. 
3.3.5.  Treatment with immunostimulants and EMB 
Atlantic salmon were placed on the immunostimulant diets for 7 weeks (Table 3.1).  Two 
weeks following cessation of immunostimulant diets, fish were placed on EMB at 150 µg/kg fish 
biomass for 7 days consistent with the current dose used in salmon farms in Atlantic Canada (M. 
Beattie, Department of Agriculture, Aquaculture and Fisheries of New Brunswick, 
http://www.dfo-mpo.gc.ca/science/enviro/aquaculture/rd2011/rdsealice-pou-eng.html) as 
the manufacturer’s recommended 50 µg/kg fish biomass for 7 days is no longer clinically 








Table 3.1.  Timeline in days for infection of Atlantic salmon, Salmo salar, with Lepeophtheirus salmonis copepodids, administration 
of different immunostimulant feeds and emamectin benzoate (EMB), and sampling of L. salmonis.   
























































3.3.6.  Determination of EMB concentration and L. salmonis infection levels  
Four days post-commencement (dpS) of EMB treatment (Table 3.1), 5 fish/tank 
(randomly selected) were euthanized with a lethal dose of MS-222 (250 mg L-1; Syndel 
Laboratories Ltd) to determine the level of sea lice infection, collect sea lice samples for mRNA 
expression analysis, as well as collect salmon muscle and skin samples to measure EMB 
concentration.  The sampling was repeated 5, 15, and 29 days post-cessation (dpSC) of EMB 
treatment (Table 3.1).  Sea lice samples, and salmon muscle and skin were flash-frozen (on dry 
ice) on collection and stored at -80°C for further studies.  Determination of EMB concentration 
in the salmon muscle and skin was conducted according to the method of (van de Riet, J. M. et 
al. 2001) by the Toxicology and Analytical Services Laboratory at the AVC.  Emamectin 
benzoate concentrations in the skin were measured in pooled, rather than individual, samples.   
3.3.7.  RNA extraction 
Total RNA extraction was conducted following standard procedures.  One (female) or 
two (male) L. salmonis per group (4 replicates) were placed in a 5 mL plastic tube containing 0.5 
mL trizol reagent.  The sample was then homogenized using an electric tissue homogenizer 
(VWR, Mississauga, ON).  Following routine standard washes and precipitation, the resultant 
RNA pellet was resuspended in molecular grade water.  Randomly selected subsets of the RNA 
samples were verified for quality using the Experion™ RNA StdSens Chips (Bio-Rad 
Laboratories, Hercules, CA).  Cutoff for good quality RNA was  8 on the RNA integrity 
number rating.  The RNA concentration and 260/280 nm ratio were determined using a 
Nanodrop Spectrophotometer 2000 (Thermo Scientific, Wilmington, DE); the samples were then 
stored at -80°C for further use. 
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3.3.8.  Reverse transcription quantitative PCR (RT-qPCR) 
The RT-qPCR steps were conducted according to standard procedures and have been 
described elsewhere (Chapter 2) with slight modifications.  Briefly, 1 µg RNA from each sample 
was treated for DNA contamination using TURBO DNase-free™ kit (Ambion, Carlsbad, CA) 
and then reverse transcribed using Reverse Transcription System (Promega, Madison, WI), 
according to the manufacturer’s instructions.  DNA elimination was confirmed in qPCR using 
reverse transcriptase-omitted controls.  The qPCR reactions were perfomed using GoTaq® qPCR 
Master mix (Promega) and were run on the Realplex thermocycler (Eppendorf, Mississauga, 
ON).  Expression data normalization was conducted using 4 reference genes employed in the 
preceeding study (Chapter 2) - glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 18S 
rRNA, translation eukaryotic elongation factor 1 (eEF1), and structural ribosomal protein S20 
(RPS20) - using geNorm software (Vandesompele et al. 2002).  The primers for the different 
genes were the same as reported in Chapter 2; the reaction efficiency (%) for each primer set 
were 106 (Table 3.2).  The cycling conditions for P-gp were 95°C for 10 min (initial 
denaturation), 40 cycles of 95°C for 15 sec (denaturing), 55°C for 15 sec (annealing) and 68°C 
for 20 sec (extension) steps, and melt step of 60°C for 15 sec to 95°C for 15 sec to confirm 
amplification single PCR product.  The cycling conditions for the  the 4 reference genes were 
same as P-gp but for the cycling step which was 40 cycles of 95°C for 15 sec, 58°C for 15 sec 
and 72°C for 15 sec.  Relative P-gp mRNA expression was determined using the 2-Cq method 
normalized to the calibrator. 18S rRNA was excluded from geNorm computation of 
normalization factor utilized in the 2-Cq analysis due to its relatively high abundance and level 






Table 3.2.  Primer sets used in qPCR experiments to amplify reference (GAPDH, 18S rRNA, eEF1 and RPS20) and 
target (P-gp) genes in Lepeophtheirus salmonis.  









Present study 101 
GAPDH Forward: TGATGGACCCTCAGCAAAGAA 
Reverse: CCAGTAGATGCAGGAATAATATTTTGTC 
 
(Frost & Nilsen 2003) 100 
18S rRNA Forward: GCAGCAGGCACGCAAATT 
Reverse: GATGAGTCCGGCTTCGTTATTTT 
 
(Frost & Nilsen 2003) 99 
eEF1 Forward: TTAAGGAAAAGGTCGACAGACGTA (Frost & Nilsen 2003) 100 
 Reverse: GCCGGCATCACCAGACTT 
 
  
RPS20 Forward: GCCGGTGTTTAACAATCATCAA 
Reverse: GGGCTTCGAGTCCTT GTATGC 
(Frost & Nilsen 2003) 106 
P-gp = P-glycoprotein; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; eEF1 = translation eukaryotic 





3.3.9.  Statistical analysis 
Relative expression of P-gp mRNA was determined by performing multivariate analysis 
of variance (MANOVA) using the STATISTICA statistical software (StatSoft Inc., Tulsa, OK).  
A Tukey honestly significant difference post-hoc analysis was also conducted using 
STATISTICA to determine significant differences in P-gp mRNA expression among the 
samples.  Statistical significance was set at p<0.05 and 1.5 fold differences.  Graphical 
representations of relative P-gp mRNA expression and salmon muscle concentration of EMB 
were plotted using SigmaPlot 10.0 (Systat Software Inc., Chicago, IL).   
3.4.  Results  
3.4.1.  Bioassay 
Stage, sex, and immunostimulant-related differences in EMB EC50 were revealed 
following TSK analysis of bioassay results (Table 3.3).  While EMB EC50 values for male sea 
lice increased ~2-3 fold from pre-adult to adult stage, female EC50 values were within the same 
range (171to 342ppb) for these life stages.  We were unable to derive confidence intervals (CI) 
for immunostimulant-untreated, SLX and CpG groups.  Also, EMB EC50 values for the male 
Aquate® group was incaculable because only 40% mortality occurred for this group at the 
highest EMB concentration used (1000 ppb) (Table 3.3).  There was  20 % mortality for both 
sexes in the preadult stages and in the female adult sea lice EMB-untreated controls, but no 
mortality in the adult male EMB untreated controls (data not shown). 
3.4.2.  Emamectin benzoate concentration in S. salar muscle and skin 
The concentration of EMB in the salmon muscle significantly differed among the 
different immunostimulant treatment groups on 4 dpS and 5 dpSC (P < 0.05), but not on 15 
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dpSC (Fig. 3.1).  At 4 dpS, muscle EMB concentrations for the control group receiving no 
immunostimulant and the group fed CpG diets, 144.0 ± 21.2 and 142.1 ± 12.7 ppb (mean ± 
SEM), respectively, were significantly lower than the concentration of the parasiticide in the 
SLX- and Aquate®-treated fish, which were 195.6 ± 19.2 and 234.1 ± 39.2 ppb, respectively (P < 
0.05).  Emamectin benzoate was detected in fish from one of the two replicate untreated control 
tanks, just above the detection limit at 4 dpS and 5 dpSC; no sample was assessed for this group 
at15 dpSC (Fig. 3.1).  The highest EMB concentrations were recorded at 4 dpS and 5 dpSC, 
234.1 ± 39.2 and 231.2 ± 21.5 ppb, respectively, for the Aquate® treatment group. 
The EMB concentration in the skin of EMB-treated fish ranged from 225.8 (Aquate®) to 
270.8 (SLX) ppb at 4 dpS with the EMB control and CpG fish having intermediate values of 
250.0 and 231.7 ppb, respectively (data not shown).  Again, the parasiticide was detected in the 
EMB untreated control at 5 and 15 dpSC, 4.8 and 16.5 ppb EMB, respectively; samples were not 
assessed for the control group at 4 dpS and 29 dpSC.  Peak EMB concentrations for the different 
treatment groups were recorded at 5 dpSC.  The highest EMB concentration was recorded for 
Aquate® (539.2 ppb) followed by EMB treated control, CpG and SLX with EMB concentrations 
of 453.3, 383.0 and 318.9 ppb, respectively.  By 29 dpSC, EMB concentration in the skin ranged 
from 90.8 (SLX) to 102.8 (EMB treated control) ppb for the different treatment groups. 
3.4.3.  Lepeophtheirus salmonis infection levels 
The % survival of adult male sea lice was higher than that of females for the different 
control and treatment groups (Table 3.4).  Percentage survival refers to the percentage of time 0 
sea lice numbers that survived to 29 dpSC.  All groups exhibited <60% survival across both 
sexes by the end of the study, with immunostimulant fed groups showing highest % survival 
(Table 3.4).  
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3.4.4.  L. salmonis P-glycoprotein mRNA expression 
There were stage, sex and immunostimulant background related differences in relative P-
gp mRNA expression (Fig. 3.2 A and B) of the EMB untreated control bioassay survivors 
collected prior to commencement of triple dose EMB treatment.  Relative P-gp mRNA 
expression in male sea lice did not significantly differ among all the treatment groups with the 
exception of the adults exposed to salmon fed Aquate® diet (Fig. 3.2A) which was significantly 
higher than SLX (preadult and adult) and CpG (preadult) groups (P < 0.05).  P-glycoprotein 
mRNA expression was significantly higher in pre-adult females compared with adults with the 
exception of adult sea lice with SLX, CpG and Aquate® immunostimulant (Fig. 3.2B, P < 0.05).  
Sea lice from the three latter groups recorded significantly lower P-gp mRNA expression 
compared with pre-adult sea lice associated with the Aquate® feed group (P < 0.05).  
Male L. salmonis showed an increase in the expression of P-gp mRNA at 4dpS and 
5dpSC relative to pre-EMB treatment levels (day 0) for the different treatment groups and 
controls (Fig. 3.3A).  P-gp mRNA expression was low prior to EMB treatment and at 15 and 29 
dpSC compared with 4 dpS and 5 dpSC.  
Again there was an increase in the female P-gp mRNA expression for sea lice from all the 
groups and controls from a low expression prior to EMB treatment to high expression at 15 dpSC 
and then down to an intermediate level by 29 dpSC.  Sea lice from the Aquate® diet group 
recorded a significantly higher P-gp mRNA expression (P < 0.05) at 15 dpSC compared with the 
other sampling periods and to the other treatment groups at all the sampling time points with the 
exception of SLX at 15 dpSC (Fig. 3.3B).   While the peak adult male sea louse P-gp mRNA 
expression was recorded for SLX at 5 dpSC (Fig. 3.3A), the highest expression of the transporter 
for females was recorded for Aquate® treatment group at 15 dpSC (Fig. 3.3B). 
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Table 3.3.  Half-maximal effective concentration (EC50) (95% confindence interval) for preadult 
and adult Lepeophtheirus salmonis exposed to increasing concentrations of emamectin benzoate 
(EMB). 
Stage Sex Treatment % mortality at 
1000 ppb EMB 
EMB EC50 (ppb) (95% CI) 
Pre-adulta  Male No Tx Ctrl 100 308 (214, 443) 
SLX 100 373 (264, 525) 
CpG 100 288 (201, 414) 
Aquate® 100 291 (180, 471) 
Female No Tx Ctrl 100 250 (178, 352) 
SLX 100 319 (211, 484) 
CpG 100 281 (180, 471) 
Aquate® 100 207 (112, 381) 
Adultb  Male No Tx Ctrl 50 1000 
 SLX 50 1000 
 CpG 100 632  
 Aquate® 40 - 
Female No Tx Ctrl 100 171 (118, 248) 
 SLX 100 219 (177, 270) 
 CpG 100 342 (259, 451) 
 Aquate® 100 292 (214, 397) 
Sea lice samples were first generation laboratory reared L. salmonis associated with different 
immunostimulant (SLX, CpG or Aquate®) diets.  No Tx Ctrl = no immunostimulant treatment.  
Half-maximal effective concentration (EC50) is the concentration of EMB that will cause 50% 
mortality (moribund and dead) of sea lice.   
aSea lice exposed to 0, 10, 100, 300 and 1000 ppb EMB.  
bSea lice exposed to 0, 100, 200, 400 and 1000 ppb EMB.  
















Figure 3.1.  Concentration of emamectin benzoate (EMB) in muscle of Atlantic salmon 
following administration of different immunostimulant (SLX, CpG or Aquate®) diets fed for 7 
weeks.  No Tx CTL = no immunostimulant treatment; EMB CTL = EMB treatment only; dpS = 
days post-commencement of EMB treatment; dpSC = days after cessation of EMB treatment.  













Time, sex and ± SEM sea lice numbers per fish (n = 5) % survival 
at 29 dpSC 0 4 dpS 5 dpSC 15 dpSC 29 dpSC 
M F M F M F M F M F M F 
Control 13.3 ± 1.4 14.1 ± 1.5 5.0 ± 0.7 8.4 ± 1.2 2.6 ± 0.7 6.1 ± 1.2 4.1 ± 0.4 1.6 ± 0.6 2.1 ± 0.5 0.8 ± 0.5 15.8 5.7 
EMB Ctl 10.6 ± 1.9 8.8 ± 1.8 4.2 ± 0.7 5.5 ± 1.1 1.8 ± 0.4 3.8 ± 0.9 4.8 ± 0.7 5.0 ± 1.3 2.8 ± 0.6 2.0 ± 0.5 26.4 22.8 
SLX 11.8 ± 2.3 15.6 ± 3.0 7.6 ± 1.3 9.1± 1.6 3.1 ± 0.8 8.4 ± 1.0 6.8 ± 0.8 6.2 ± 0.8 6.8 ± 1.1 4.6 ± 1.1 57.7 29.6 
CpG 8.4 ± 1.4 11.7 ± 1.9 5.5 ± 0.9 7.5 ± 1.7 2.2± 0.7 5.7 ± 1.6 5.3 ± 1.1 5.5± 1.8 4.9 ± 1.2 4.4 ± 1.2 58.1 37.7 
Aquate® 7.6 ± 0.9 6.9 ± 0.9 4.6 ± 0.9 4.3± 1.3 2.1 ± 0.5 4.0 ± 1.0 3.3 ± 0.6 1.7 ± 0.5 4.4 ± 1.2 1.8 ± 0.8 58.7 25.8 
Sea lice samples are first generation laboratory reared L. salmonis associated with different immunostimulant (SLX, CpG or Aquate®) 
diets.  EMB Ctl = EMB treatment only; dpS = days post-commencement of EMB treatment; dpSC = days after cessation of EMB 






Figure 3.2.  Relative P-glycoprotein mRNA expression in pre-adult and adult male (A) and 
female (B) Lepeophtheirus salmonis emamectin benzoate bioassay (EMB) untreated survivors 
(mean relative expression ± SEM) normalized to 3 reference genes - (glyceraldehyde-3-
phosphate dehydrogenase, translation eukaryotic elongation factor 1, structural ribosomal 
protein S20) and compared with a calibrator.  Lepeophtheirus salmonis samples are first 
generation laboratory reared sea lice associated with different immunostimulant (SLX, CpG or 
Aquate®) diets.  No Tx = no immunostimulant treatment; Pre-EMB CTL = prior to EMB 
treatment/also not treated with immunostimulants.  Different superscripts (a, b, c, d) denote 







Figure 3.3.  Relative P-glycoprotein mRNA expression in adult male (A) and female (B) Lepeophtheirus 
salmonis detached from Salmo salar fed first on different immunostimulant infused (SLX, CpG or 
Aquate®) diets for 7 weeks and then on 150 µg emamectin benzoate/kg fish biomass for 7 days (mean 
relative expression ± SEM) normalized to 3 reference genes - (glyceraldehyde-3-phosphate 
dehydrogenase, translation eukaryotic elongation factor 1, structural ribosomal protein S20) and 
compared with a calibrator.  Lepeophtheirus salmonis samples are first generation laboratory reared sea 
lice.  Different superscripts (a, b, c, d, e) denote significant (P < 0.05) differences between two means (n 
= 6).  No Tx = no immunostimulant treatment; Pre-EMB CTL = prior to EMB treatment/also not treated 
with immunostimulants; EMB CTL = EMB treatment only; dpS = days post-commencement of 





3.5.  Discussion 
Boosting host immunity against invading pathogens and parasites through 
immunostimulation has been employed for disease management in aquaculture (reviewed by 
Ringo et al.  2011).  However, the effects of prior host immunostimulation on chemotherapy are 
not well understood and may not always offer protection against a pathogen (Kunttu et al. 2009).  
The present study was aimed at determining the effects of prior host immunostimulation on EMB 
efficacy and mRNA expression of the putative EMB transporter, P-pg, in L. salmonis.  In the 
present study, sea lice with different immunostimulant backgrounds were subjected to a 24 h 
EMB bioassay.  Contrary to our prediction, sea lice associated with immunostimulant-fed salmon 
did not significantly differ with control values within each stage and sex category.  However,  
EMB EC50 values for male sea lice increased >2-fold from preadult to adult stage for treatment 
and control groups while the female EC50 values remained unchanged and ~3 to 6-fold lower 
compared with the males at the adult stage.  This is suggestive of stage and sex differences in 
EMB sensitivity, consistent with earlier studies (Westcott et al. 2008, Whyte et al. 2013).  
Interaction between prior host immunostimulation and EMB efficacy was evident 
especially with sea lice % survival data (Table 3.4).  Although immunostimulation was initially 
beneficial to the host salmon in rejecting infecting sea lice (18-19% of initial infection level) 
(Poley et al. 2013), it had the opposite effect upon subsequent EMB treatment 2 weeks after 
cessation of immunostimulant diet.  Salmon with no immunostimulant treatment (EMB treated 
and untreated groups) had lower sea lice numbers compared with immunostimulant treated fish 
(Table 3.4) despite the fact that the different treatment groups had relatively similar EMB 
concentrations.  Skin from EMB treated salmon had higher concentrations of EMB compared 
with the muscle in agreement with previous studies (Sevatdal et al. 2005, Whyte et al. 2011).  
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This is attributable to the lipophilic nature of EMB and is desirable for drug availability to sea 
lice through the mucus.  While salmon muscle EMB concentration in the Aquate® group was 
relatively unchanged at 4 dpS and 5 dpSC, the concentration of the parasiticide for SLX group 
decreased from 4 dpS to 5 dpSC.  Whether these differences are a result of differences in 
palatability (Whyte et al. 2011) of the different diets or the effects of the constituent 
immunostimulant is not known.  Low levels of EMB, < 9 and < 17 ppb, were detected in the 
muscle and skin of the salmon that were not treated with EMB, a common occurrence with drug 
exposure in a recirculation system (pers. comm. Dr. S.K. Whyte, CAHS).  A similar study that 
used a flow-through system reported low levels of EMB in the skin of untreated controls (Whyte 
et al. 2011).  The results in this study are likely due to inherent inefficiency of the system to 
prevent trace levels of the parasiticide from entering EMB untreated tanks.  Given that there was 
no measureable EMB in the control feeds (sensitivity > 15 µg L-1) and these levels in the muscle 
and skin are so low, they can be considered as background values with no potential effects on 
observations. 
Macrocyclic lactone resistance has been linked to changes in target site (Njue et al. 2004), 
increased metabolism and increased drug efflux (Wolstenholme & Kaplan 2012) but changes in 
structure or increased expression of the ATP-binding cassette (ABC) transporter, P-glycoprotein 
(P-gp), is widely believed to be the primary mechanism for loss of ML sensitivity (reviewed by 
Prichard & Roulet 2007).  We have previously linked differences in EMB sensitivity to sex-
based differences in mRNA expression of P-gp in sea lice (Chapter 2).  Studies have also shown 
that P-gp plays a role in sex-based differences in drug efficacy and toxicity in humans (Sudchada 
et al. 2010), dogs and rats (Lespine et al. 2009), and parasitic nematodes (Prichard & Roulet 
2007).  In this study (Fig. 3.2 A and B), female sea lice had higher P-gp mRNA expression as 
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preadults compared with adults, male expression of the transporter was not significantly different 
at both preadult and adult stages, except for male sea lice from fish fed the Aquate® diet.  Also, 
increases in the expression of P-gp occurred earlier in male compared with female sea lice.  
Timing of P-gp mRNA expression appears to be related to survival of the parasite during EMB 
treatment and may be the reason why male parasites had greater survival compared with females.  
Whether louse sex-based differences in EMB sensitivity are due to timing (present study), rather 
than level (Chapter 2) of P-gp mRNA expression, is unknown.  While the study in Chapter 2 was 
performed using sea lice samples exposed to EMB in vitro in a 24 h bioassay, the current study 
employed sea lice samples previously exposed to the parasiticide while feeding on treated fish 
and over a longer period.  These differences could explain why, in the earlier study, male sea lice 
expressed higher P-gp mRNA levels compared with female sea lice.  A study to track timing of 
increasing P-gp expression in L. salmonis following on-host EMB treatment is in progress in our 
laboratory.   
Differences in sea lice numbers observed among different treatment groups and controls 
(Table 3.4) can be linked to differences in P-gp expression especially for the female sea lice 
groups (Fig. 3.3B).  Immunostimulant treatment groups that displayed >1.5 fold increase in P-gp 
mRNA expression recorded relatively higher % parasite survival.  This was contrary to our 
hypothesis that prior host immunostimulation would cause higher sea lice mortality following 
subsequent EMB treatment compared with the administration of immunostimulants or EMB 
alone.  Twenty-nine (29) dpSC was the most logical time point to use in assessing treatment 
outcome (% survival) but its choice could have influenced our conclusion.  This is because the 
rate at which the sea lice numbers decreased over time was not linear, and in fact in some cases, 
sea lice numbers increased during the treatment thereby influencing final assessment of treatment 
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effects at 29 dpSC.  For example, while % survival of male EMB treatment group at 5 dpSC was 
17 % compared with 26.4 % at 29 dpSC; the values for the no EMB controls were 19.5 and 15.8 
% at 5 and 29 dpSC, respectively. 
The Aquate® diet contains yeast extracts, including -glucans, potent PAMPs that boost 
the innate immune response through pro-inflammatory processes (Ringo et al. 2011).  -glucan 
decreased susceptibility of rainbow trout [Oncorhynchus mykiss Walbaum] to white spot 
disease [Ichthyophthirius multifiliis (Xueqin, Kania & Buchmann 2012)] through increased 
expression of major histocompatibility complex class II, C3 complement factor and lysozyme 
activity (De Baulny et al. 1996).  However, some studies have associated -glucan with 
exacerbation of infection intensity in Artemia franciscana (Kellogg), infected with Vibrio 
campbelli (Soltanian et al. 2007) and in juvenile rainbow trout (O. mykiss) treated for 
Flavobacterium columnare infection (Kunttu et al. 2009).  In fact in the study by Kunttu et al. 
(2009), more mortalities were recorded for the F. columnare infected fish that received -glucan 
than in infected immunostimulant untreated controls.  In our study, the higher % survival in 
immuostimulant fed groups compared with controls following EMB treatment could be due to 
host tolerance to innate stimulation, immunosuppression and/or stress induced by prolonged (7 
weeks) immunostimulant administration (Bricknell & Dalmo 2005).  It has also been shown that 
increased plasma cortisol expression seen during stress from sea lice infection can lead to 
depressed immune responses (Johnson & Albright 1992).  Although Roy et al. (2000) report no 
adverse effects of EMB administration up to 3.5 times the recommended dose (50 µg/kg fish 
biomass per day for 7 days), the 3 times dosage used in the field and in the current study may 
have immunosuppressive effects as well, as has been observed in ivermectin treatments in rabbits 
(Sajid et al. 2009).  Immunosuppression of the hosts due to EMB may allow for greater survival 
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of sea lice in all EMB treatment groups when compared with untreated controls.  Further 
research into interactions between EMB administration and host immunocompetence are 
required to answer these questions. 
While SLX adult male sea lice had the same EMB EC50 values as the adult male EMB-
untreated group, EMB EC50 values for the CpG male sea lice was ~1.6 fold lower compared with 
the two former (Table 3.3).  Why sea lice from the adult male CpG group recorded lower EMB 
EC50 values compared with the rest of the adult male groups, including the no-immunostimulant 
background group, is unknown, but suggestive of an immunostimulant effect possibly on P-gp 
expression.  Studies also indicate that P-gp expression can be affected by inflammatory 
responses whereby acute inflammation will cause increased expression of the transporter 
(reviewed by Ho & Piquette-Miller 2006), while the reverse is the case for chronic inflammatory 
responses (Llorente et al. 2000).  The study by Llorente et al. (2000) linked P-gp over-activity in 
patients with rheumatic autoimmune disease to increased expression of TNF.  
The SLX, CpG, and Aquate® treated salmon had the highest number of sea lice and these 
same sea lice expressed higher levels of P-gp mRNA compared with the sea lice attached to 
salmon with no immunostimulant treatment.  This suggests that administration of the 
immunostimulant feed for 7 weeks to the respective treatment groups could have induced 
chronic immune responses including inflammation and release of other immune factors and 
molecules within the sea louse.  Since the occurrence of chronic inflammation was not 
investigated in the sea lice sampled, it could also be that chronic inflammation/wound healing in 
the host, as seen in previous studies of salmon infected with L. salmonis (Skugor et al. 2008) 
may have direct effects on sea lice P-gp mRNA expression.  Recent work, however, has also 
shown that CpGs and yeast extracts administered through the feed can induce inflammation both 
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systemically and at the attachment site in Atlantic salmon infected with L. salmonis (Covello et 
al. 2011, Poley et al. 2013).  As P-gp has been shown to mediate platelet activation factors and 
cytokine transport in human mesangial and T-cell populations, respectively (Drach et al. 1996, 
Ernest & Bello-Reuss 1999), it may serve the salmon louse in an immunomodulatory capacity 
into immunostimulated hosts.   
Inflammatory processes and release of reactive oxygen/nitrogen species can induce 
oxidative/nitrosative stress, which may affect L. salmonis tissues in contact with the 
reaction/feeding site or within the salmon louse gut.  The corollary to this would be cellular 
necrosis within L. salmonis foregut and potential depletion of ATP at the mitochondrial level.  
Enhanced production of P-gp within these affected sea louse tissues, in particular the gut, could 
provide enhanced protection to the parasite against stimulated host responses.  Studies have 
shown that crustaceans possess -glucan binding receptors and other PRRs responsive to 
different immunostimulants (Smith, Brown & Hauton 2003).  The innate crustacean immune 
response has been exploited in disease control in kuruma shrimp, Penaeus japonicus (Bate) 
(Itami et al. 1998), and black tiger prawn, P. monodon (Fabricius) (Sritunyalucksana et al. 1999).  
Given the relationship between chronic innate immune response and P-gp expression (Llorente et 
al. 2000), it is possible that by-products of SLX, CpG, and Aquate® diet inflammatory induction 
interacted with the louse to induce over-expression of P-gp and consequently reduced EMB 
efficacy in the parasite.  Perhaps less likely, the possibility remains that immunostimulants taken 
up by the host are only partially processed in the gut and/or systemically; and that some 
transportation of these molecules to the skin/mucosal membrane occurs, directly stimulating the 
parasite itself.  Further investigation into the half-life and fate of these compounds within the 
host organism is needed to be able to verify these propositions more accurately.  
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Our study demonstrates that prior host Atlantic salmon immunostimulation may result in 
decreased EMB efficacy in sea lice, possibly due to over-expression of P-gp and/or induction of 
non-specific protective mechanisms within the parasite.  This reinforces the importance and need 
for monitoring the effects of treatments, especially to avoid unintended consequences.  Further 
studies are needed to elucidate the mechanisms by which host immunostimulation affects 
expression of ABC transporters and/or other mechanisms of resistance to parasiticides in L. 
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4.1.  Abstract 
Parasitic sea lice, including Lepeophtheirus salmonis and Caligus elongatus, are a major 
challenge currently facing commercial salmon production.  Attempts over several decades to 
control the parasite using drugs and chemicals have led to emergence of widespread drug 
resistant strains of the organisms.  There are recent reports of reduced efficacy to emamectin 
benzoate (EMB), the major sea lice therapeutant within the last decade.  However, there are fish 
farm locations in the Bay of Fundy, NB, Canada, where EMB-sensitive sea lice still exist.  
Previous studies have linked EMB resistance in sea lice to over-expression of the ATP-binding 
cassette (ABC) transporter, P-glycoprotein (P-gp) in the parasite.  We investigated 1) whether 
reports of EMB treatment success in Grand Manan, Bay of Fundy, NB, can be explained through 
EMB bioassay and P-gp mRNA expression studies, 2) if other populations of sea lice not under 
EMB selective pressure possess similar EMB sensitivity as Grand Manan sea lice populations, 
and 3) the heritability of EMB sensitivity/resistance in L. salmonis populations.  The EMB 
bioassay results indicated population, species, sex-based, and temporal differences in EMB EC50 
values.  L. salmonis collected from Grand Manan showed >2 fold lower EMB EC50 values 
compared with two reference populations, confirming the presence of relatively EMB-sensitive 
sea lice in Grand Manan.  Sea lice reared in the laboratory maintained their EMB sensitivity 
status for up to three filial generations.  C. elongatus, collected from Grand Manan also showed 
>2 fold lower EMB EC50 values compared with L. salmonis collected from the same site, 
suggesting species differences in EMB sensitivity in sea lice.  Also addition of verapamil, a 
competitive inhibitor of P-gp, yielded no increase in C. elongatus EMB sensitivity.  Taken 
together, these findings emphasize the need to understand and monitor for EMB resistance even 
in sea lice populations perceived to be EMB insensitive.   
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4.2.  Introduction 
Sea cage production of Atlantic salmon, Salmo salar, one of the most intensively farmed 
marine fish (Naylor & Burke 2005), is currently hampered by sea lice, ectoparasites of salmonids 
commonly found in marine environments.  Lepeophtheirus salmonis and Caligus elongatus are 
the major species of sea lice that infect salmon in Atlantic Canada (Burka, Fast & Revie 2012).  
Strategies that have been used or are under development for sea lice control in salmon farms 
include biological predators (Deady, Varian & Fives 1995, Treasurer 2002), vaccines (Ross et al. 
2006, Frost, Nilsen & Hamre 2007, Carpio et al. 2011), immunostimulation (Covello et al. 2012, 
Purcell et al. 2012), drugs and chemicals, as well as good management practices.  The most 
effective intervention strategy has been chemicals or drugs administered either topically or in-
feed.  The macrocyclic lactones (MLs), which could be administered in-feed, to avoid the 
disadvantages (i.e. labor intensive, stress to fish, inability to simultaneously treat all cages on 
site, etc.) associated with bath applications, held promise as an efficacious treatment against all 
parasitic stages of sea lice (Smith & Clarke 1988, Roy et al. 2000).  Ivermectin was the initial 
ML to be used in sea lice control (Smith & Clarke 1988) but the low therapeutic index 
discouraged its continued use (Johnson & Margolis 1993, Davies & Rodger 2000), hence, the 
development of another ML, emamectin benzoate (EMB; SLICE®), which had a better 
therapeutic index (Roy et al. 2000).  Emamectin benzoate was initially effective for sea lice 
control at a dose of 50 g kg-1 fish biomass for 7 days (Ramstad et al. 2002), but currently 
double and triple doses are used in some salmon farms in Atlantic Canada (M. Beattie, 
Department of Agriculture, Aquaculture and Fisheries of New Brunswick (NB), 
http://www.dfo-mpo.gc.ca/science/enviro/aquaculture/rd2011/rdsealice-pou-eng.html), as 
the manufacturer’s recommended 50 µg kg-1 fish biomass for 7 days is no longer clinically 
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effective.  Macrocyclic lactones interrupt neurotransmission in nematodes through the activation 
of glutamate-gated chloride channels, resulting in starvation, paralysis and, consequently, death 
of the parasite (Arena et al. 1995, Wolstenholme & Rogers 2005).  Emamectin benzoate has high 
efficacy against all parasitic stages of sea lice, disrupting the life cycle at several points (Stone et 
al. 1999).  Lipophilicity of EMB creates sustained effective tissue concentrations leading to 
protection for prolonged periods (Horsberg 2012).  These attributes quickly made EMB the drug 
of choice for sea lice control on fish farms in the Bay of Fundy, NB (Westcott, Hammell & 
Burka 2004).  However, use of EMB has declined due to resistance development, a consequence 
of over-reliance on the drug for over a decade.  Resistance to EMB by L. salmonis has been 
reported in Atlantic Canada and Europe (Hjelmervik et al. 2010, Westcott et al. 2010) and in C. 
rogercresseyi in Chile (Bravo, Sevatdal & Horsberg 2008). 
While resistance to EMB by multiple species of sea lice is indisputable, some refuges for 
the parasite remain as not all sea lice populations within a given area are resistant to the drug 
(Westcott et al. 2010).  There are reports that sea lice populations on Atlantic salmon farms in 
Grand Manan, an island in the Bay of Fundy, approximately 30 km from the mainland, are more 
EMB-sensitive compared with sea lice populations at locations close to the mainland (Jones et al. 
2012).  Also, within a given L. salmonis population, males have been shown to be more EMB-
resistant compared with females (Chapter 2, Westcott et al. 2008, Heumann et al. 2012, Whyte et 
al. 2013), but sex differences in EMB sensitivity have not been explained.  Such knowledge 
could be exploited in tracking EMB resistance development in salmon farms more efficiently.   
The narrow spectra of treatment options and ability of sea lice to develop drug resistance 
underpin the need to understand how these parasites respond to drugs used for their control.  
Macrocyclic lactone resistance in arthropods and nematodes has been linked to changes in target 
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site (Njue et al. 2004), but changes in structure or increased expression of the ATP-binding 
cassette (ABC) transporter, P-glycoprotein (P-gp), is widely believed to be the primary 
mechanism for loss of ML sensitivity in nematodes (reviewed by Prichard & Roulet 2007).  
Results of Chapter 2 demonstrated a temporal increase in P-gp mRNA expression in L. salmonis 
samples collected from the Bay of Fundy from 2002 to 2011.  Also, studies by Heumann et al. 
(2012) and findings from Chapter 2 showed that sub-acute EMB exposure induces over-
expression of P-gp mRNA in L. salmonis.  Competitive inhibition of P-gp in L. salmonis using 
verapamil caused increased EMB sensitivity in the parasite, suggesting that P-gp plays a role in 
sea lice resistance to the drug (Chapter 2). 
The objectives of this study were 1) to identify whether reports of EMB treatment success 
in Atlantic salmon farms in Grand Manan can be explained through EMB bioassay and P-gp 
mRNA expression studies, 2) to determine if other populations of sea lice not under EMB 
selective pressure display a similar or differential response to EMB bioassay assessment as sea 
lice samples collected from Grand Manan, and 3) whether any differences identified between L. 
salmonis populations are heritable and result in differences in EMB sensitivities following drug 
exposure on or off the host. 
4.3.  Materials and methods 
4.3.1.  Chemicals 
Emamectin benzoate (PESTANAL®) and chemicals used for this study were of analytical 
grade and purchased from Sigma-Aldrich, St. Louis, MO, except where stated otherwise.  
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4.3.2.  Salmo salar population 
All Atlantic salmon used for this study were procured from Buckman’s Creek Hatchery 
Ltd., Pennfield, NB, and transported to the Atlantic Veterinary College (AVC) Aquatic Facility.  
The fish were weighed (97 ± 8.3 g) and randomly allocated to tanks at 20 fish per tank (330 L) 
and allowed to acclimatize to the flow-through system for 3 weeks.  The system was then 
changed to recirculation and the salinity gradually raised to 31-33 g L-1 with Instant Ocean® 
(Aquarium Systems, Cincinnati, OH) over 7 days and allowed to acclimatize again for 3 weeks.  
The fish were fed 1% body weight base feed (Northeast Nutrition Ltd., Truro, NS), as 2.5 mm3 
pellets and maintained on a 14-h light/10-h dark cycle.  Water temperature (11 ± 1°C), 
concentration of ammonia, nitrite, oxygen and nitrate in the water were closely monitored and 
maintained at optimal levels. 
4.3.3.  Lepeophtheirus salmonis and Caligus elongatus populations 
According to Chang et al. (2007), Atlantic salmon farms in southwestern New Brunswick 
are grouped into six Bay Management Areas [BMAs; (Fig. 4.1)].  BMA 1 is made up of 
Passamaquoddy Bay, Deer Island, and a large part of Campobello Island; BMA 2 consists of 2a 
(Back Bay, Bliss Harbour, and Lime Kiln Bay) and 2b (eastern Grand Manan Island and White 
Head Island); BMA 3 also consists of 3a (Beaver Harbour to Haleys Cove) and 3b (southern 
Grand Manan); BMA 4 (Harbour de Loutre, Campobello Island); BMA 5 (Dark Harbour, Grand 
Manan Island) and BMA 6 (Letete Passage).  The present study was carried out using sea lice 
samples collected from BMAs 1, 2a and 2b.  While sea lice population from BMAs 1 and 2a are 
believed to be EMB resistant, BMA 2b sea lice samples are suspected to be EMB sensitive 
(Jones et al. 2012).   
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Adult male and female L. salmonis were carefully removed from host Atlantic salmon 
from fish farms in BMA 1 and BMA 2a, Bay of Fundy, NB.  The samples were brought back 
alive to the laboratory in cold (10°C) sampling site seawater and stored in a cold incubator at 
10°C overnight with aeration.  The samples were collected from EMB-resistant populations of L. 
salmonis based on treatment efficacy in the area [(Jones et al. 2012) and confirmed through 
previous EMB bioassays] and will be referred to as R0-1 (collected in October 2011) and R0-2a 
(collected in March 2012) in this study, for BMA 1 and BMA 2a, respectively.  Adult male and 
female L. salmonis samples were previously collected in November 2011 from another location 
within BMA 2a and will be referred to as R0a-2a.  Approximately 14 to 18 wks after the October 
2011 sea lice collection, 2 batches (4 weeks apart) of adult male and female C. elongatus were 
collected from BMA 1 (the same salmon farm location as R0-1) and brought back to the 
laboratory in a similar manner.  Samples of L. salmonis were collected alongside the first C. 
elongatus sampling for comparison purposes.  Adult male and female L. salmonis were also 
collected (April 2012) in the same manner as above from Grand Manan (BMA 2b).  The Grand 
Manan L. salmonis population has been reported to be more EMB sensitive compared with L. 
salmonis from other sites within the Bay of Fundy (Jones et al. 2012) and will be referred to as 
S0-2b.  Finally, archived adult female L. salmonis collected from Grand Manan (BMA 2b) in 
2005 and stored at -80°C were used to verify changes in the expression of P-gp mRNA over time 







Figure 4.1.  Map of Southern New Brunswick showing distribution of Atlantic salmon farms 
(black spots) within the different Bay Management Areas (1, 2a, 2b, 3a, 3b, 5 and 6).  Courtesy 
of Dr. Blythe Chang, Department of Fisheries and Oceans Canada, St. Andrews Biological 
Station, St. Andrews, NB, Canada.  Arrows point at zones/areas of sea lice collection. 
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4.3.4.  Responses to EMB exposure across sea lice populations 
4.3.4.1.  EMB bioassay 
A total of 5 EMB bioassays were carried out in this study to compare EMB sensitivity of 
sea lice populations collected from 3 different BMAs (1, 2a and 2b), as well as their laboratory 
reared progeny.  All the bioassays were carried out at 10°C for 24 h using adult stages of both 
sexes according to methods and criteria described in Chapter 2.  Brief descriptions of the 
bioassays are as follows:   
Bioassay I: EMB EC50 values determined for in-house reared F1 generation (R1-1) of L. 
salmonis collected from BMA 1 (R0-1) using 0, 10, 100, 300 and 1000 ppb EMB concentrations. 
Bioassay IIa: EMB EC50 values determined for L. salmonis collected from BMA 2a (R0a-2a) at 
0, 100, 200, 400 and 1000 ppb EMB concentrations.  
Bioassay IIb: EMB EC50 values determined for in-house reared F1 generation (R1-2a) of L. 
salmonis collected from BMA 2a (R0-2a) and F0 L. salmonis collected from BMA 2b (S0-2b) 
using 0, 0.1, 25, 300 and 1000 ppb EMB concentrations.  The choice of F1 and F0 generations of 
R1-2a and S0-2b, respectively, were a combination of logistical (i.e. R1-2a were already one 
generation ahead of S0-2b) and experimental reasons (i.e. to ascertain how different R1-2a are 
from S01-2b in EMB susceptibility given the generational differences). 
Bioassay III: EMB EC50 values determined for C. elongatus collected from BMA 1 using 0, 30, 
100, 300 and 1000 ppb EMB concentrations.   
Bioassay IV: EMB EC50 values determined for in-house reared F2 generation of L. salmonis 
collected from BMA 2a (R2-2a) and in-house reared F1 generation of L. salmonis collected from 
BMA 2b (S1-2b) using 0, 0.1, 25, 300 and 1000 ppb EMB concentrations. 
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The differences in concentration of EMB among the bioassays are based on suspected 
variations in the parasiticide sensitivity of the test sea lice populations. 
4.3.4.2.  RNA extraction 
Total RNA was extracted from Bioassay IIb survivors and the archived samples 
following standard procedures as described in Chapter 3.  Bioassay IIb survivors were chosen 
based on suspected population-based differences in EMB sensitivity between R1-2a and S0-2b 
samples. 
Briefly, one (female) or two (male) [to obtain optimal RNA yield for males as the females 
are twice bigger than the males] L. salmonis were homogenized in a 5 mL plastic tube containing 
0.8 mL trizol reagent using an electric tissue homogenizer (VWR, Mississauga, ON).  The RNA 
pellets derived following standard washes and precipitation were re-suspended in molecular 
grade water.  A subset of RNA samples was verified for quality using Experion™ RNA StdSens 
Chips (Bio-Rad Laboratories, Hercules, CA).  Cutoff for good quality RNA was  8 on the RNA 
integrity scale.  RNA concentration and 260/280 nm ratio were determined using a Nanodrop 
Spectrophotometer 2000 (Thermo Scientific, Wilmington, DE).  The samples were then stored at 
-80°C prior to further use. 
4.3.4.3.  Reverse transcription quantitative PCR 
RT-qPCR steps were conducted according to standard procedures and have been 
described in Chapter 3.  Briefly, DNA contamination was eliminated from the RNA samples 
(Bioassay IIb survivors) using TURBO DNase-free™ kit (Ambion, Carlsbad, CA).  One 
microgram of each DNA-free RNA sample was reverse transcribed using Reverse Transcription 
System (Promega, Madison, WI), according to manufacturer’s instructions.  Successful 
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elimination of DNA contamination was confirmed by performing qPCR using No Reverse 
Transcriptase-treated RNA control samples.  The qPCR reactions were done using GoTaq® 
qPCR Master mix (Promega) on a Realplex thermocycler (Eppendorf, Mississauga, ON) and the 
cycling conditions were as reported previously (Chapter 3).  Relative P-gp mRNA levels were 
normalized using 4 reference genes employed in a previous study (Chapter 2) -glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), 18S rRNA, translation eukaryotic elongation factor 1 
(eEF1), and structural ribosomal protein S20 (RPS20) - using geNorm software (Vandesompele 
et al. 2002).  Due to its relatively high abundance and instability 18S rRNA was excluded from 
generation of the normalization factor during geNorm analyses.  The primers for the different 
genes were the same as reported in Chapter 2.  Reaction efficiency (%) of the primer sets were 
103 (P-gp), 98 (eEF1), 91 (18S rRNA), 100 (RPS20) 99 (GAPDH).  Relative fold differences in 
P-gp mRNA level were determined using the 2-Cq method normalized to the calibrator.  
4.3.4.4.  P-glycoprotein inhibition test 
P-glycoprotein inhibition test was conducted according to the method described in 
Chapter 2 using adult female C. elongatus collected from BMA 1.  Briefly, sea lice samples were 
subjected to EMB bioassay at 10°C for 24 h using 0, 30, 100, 300 and 1000 ppb with or without 
10 µM verapamil, a P-gp inhibitor.  The choice of 10 µM verapamil was based on results of 
previous studies (Chapter 2). 
4.3.4.5.  On-host comparison of L. salmonis populations following triple dose EMB 
treatment: series I 
Having confirmed susceptibility of L. salmonis from BMAs 2a and 2b (Bioassay IIb), we 
determined whether EMB resistance phenotype would be passed on to the next generation of L. 
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salmonis grown in-house (Table 4.1).  F1 generation of L. salmonis from BMA-2b (S1-2b) was 
reared, at the same time on Atlantic salmon (243.5 ± 10.3 g) in different 330 L tanks, as a 
confirmed F2 resistant population (R2-2a) from BMA 2a.  Upon reaching the preadult stage, 
male and female L. salmonis from both groups were again tested for EMB sensitivity (Bioassay 
IV; sub-section 4.3.4.1).  These two L. salmonis populations were exposed to EMB on-host 
whereby, following removal of sea lice for EMB Bioassay IV, two tanks of fish infected with 
R2-2a and S1-2b were placed on 7 day triple-dose EMB treatment (150 g kg-1 fish biomass; 
actual EMB concentration in feed was 120 mg L-1 based on the methods described in Chapter 2).   
Briefly, L. salmonis egg strings harvested from BMA 2a were hatched in-house, yielding 
F1 generation (R1-2a) nauplii, and allowed to develop to the copepodid life stage in static 
seawater incubators prior to exposure to naïve Atlantic salmon (Chapter 3, Covello et al. 2012).  
Lepeoptheirus salmonis were reared to adult stage on their hosts and allowed to in-breed to 
produce egg strings for a second filial generation: R2-2a.  S0-2b egg strings were also hatched in 
the lab and the resultant copepodids [S1-2b (120 copepodids/fish)], as well as R2-2a (50 
copepodids/fish), were used to infect salmon separately.  Due to time constraints on egg 
extrusion, S1-2b copepodids were used to infect Atlantic salmon (1 tank) 8 days prior to 2 tanks 
of a separate group of salmon in a different system being infected with R2-2a copepodids.  
Again, the choice of F1 and F2 generations of S1-2b and R2-2a, respectively, were a 
combination of logistical (i.e. R2-2a were already one generation ahead of S1-2b) and 
experimental reasons (i.e. ascertain how different R2-2a will be from S1-2b in EMB 
susceptibility despite generational differences).  Prior to infections, one-way water flow valves 
were installed in the recirculation system to prevent backpressure of water and exposure of L. 
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salmonis to the biofilter.  To ensure maintenance of single cultures in each system, 100 µm 
meshes were also placed over inflow valves to prevent cross-infection of sea lice. 
Upon >90% of the L. salmonis reaching preadult life stages, six fish per tank were 
euthanized using 250 mg L-1 MS-222 (Syndel Laboratories Ltd) and the sea lice enumerated and 
collected.  One day later, the 7 day triple-dose EMB treatment began for two tanks (S1-2b and 
R2-2a), while the third tank (R2-2a) was maintained on non-medicated feed (i.e. no EMB 
treatment).  Sea lice were then collected at two time points as follows:  One day post-
commencement (1 dpS) of the 7 day EMB treatment, fish (n=5) were euthanized for each 
treatment group and L. salmonis samples collected, staged, and enumerated.  This was repeated 
13 days post-cessation (dpSC) of the 7 day EMB treatment, with the exception that 10 fish per 
group were sampled on this day from each of the treatment tanks; 20 fish were also sampled 
from the untreated tank.  All L. salmonis samples collected were flash-frozen on dry ice within 2 
min of removal from the tank and stored at -80°C for future genetic analysis.  
4.3.5.  Responses to EMB exposure of L. salmonis from susceptible and resistant crosses 
4.3.5.1.  Crossbreeding of EMB-sensitive and -resistant L. salmonis 
To assess whether EMB sensitivity/resistance was heritable and affected by different 
parental backgrounds, we performed several crosses using EMB-resistant and -sensitive L. 
salmonis samples collected from the same areas described above:  BMA 2a and BMA 2b, 
respectively (Table 4.2).  R2-2a males were mated with S1-2b females at 1:11 (male to female 
ratio) on single fish per tank as follows:  Four (4) fish with S1-2b preadult/adult male and 
preadult female L. salmonis were anesthetized [250 mg L-1 MS-222 (Syndel Laboratories Ltd)] 
individually.  While the males had begun to exhibit mate guarding, the pairs were pre-copulatory 
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and, as such, all females were virgins at this stage.  All male L. salmonis were removed leaving 
only preadult females on the fish.  Then, as the fish recovered in individual recovery baths, 
single adult male R2-2a were added to each recovery bath and inspected to ensure parasite 
attachment to the host.  If the male R2-2a failed to attach within 10 sec, it was replaced with a 
new male R2-2a.  On full recovery, each fish was returned to a 200 L housing tank alone and 
maintained for the remainder of the mating experiment. 
Three weeks post initiation of mating the fish were inspected to ensure sea lice remained 
attached on the fish.  The inspection was repeated 6 weeks post initiation of mating during which 
males from the three successful mating groups were removed and flash-frozen for future genetic 
analysis.  One of the 4 fish lost all the female L. salmonis leaving only the male parasite; hence, 
this fish was removed from further study.  The first batch of egg strings (~44) collected from the 
successful crosses had <10% develop to the copepodid stage.  Twelve days later, ~40 egg strings 
were collected (i.e. 2nd batch of egg strings) and successfully hatched and developed to 
copepodids [i.e. cross-1 (RX1S F1) ~350 copepodids from 9 egg strings; cross-2 (RX2S F1) 
~1000 copepodids from 16 egg strings; cross-3 (RX3S F1) ~400 copepodids from 14 egg strings; 







Table 4.1.  Summary of experimental outline for on-host (Atlantic salmon) comparison of Lepeophtheirus salmonis populations 
following triple dose (150 µg/kg fish biomass) emamectin benzoate (EMB) treatment. 
BMA = Bay Management Area, Bay of Fundy, NB, Canada; R1-2a = F1 generation laboratory reared L. salmonis hatched from F0 sea 
lice egg strings collected from BMA 2a; S0-2b and S1-2b = F0 (field) and F1 (laboratory reared), respectively, generation L. salmonis 
collected from BMA 2b; dpS = days post-commencement of EMB treatment; dpSC = days after cessation of EMB treatment. 
 
Table 4.2.  Summary of experimental outline for on-host (Atlantic salmon) comparison of Lepeophtheirus salmonis crosses following 
triple dose (150 µg/kg fish biomass) emamectin benzoate (EMB) treatment. 
R2-2a = F2 generation laboratory reared L. salmonis derived from F0 sea lice egg strings collected from Bay Management Area 
(BMA) 2a, Bay of Fundy, NB, Canada; S1-2b = F1 generation laboratory reared L. salmonis hatched from F0 sea lice egg strings 
collected from BMA 2b; dpS = days post-commencement of EMB treatment; R = EMB resistant; S = EMB sensitive.
Steps 1 2 3 4 5 (1 dpS) 6 (13 dpSC) 
Activity Egg strings 
collected from  
BMA 2a hatched 
to yield R1-2a 
R1-2a in-bred in 
the laborartory 
yielding R2-2a;  
egg strings 
collected from 
BMA 2b (S0-2b) 








R1-2a and S1-2b 
infected fish 
placed on 7 days 
EMB treatment  
at 150 µg/kg fish 
biomass 
Fish sampled for 
sea lice infection 
level and staging 
Fish sampled for 
sea lice infection 
level and staging 
Steps 1 2 3 4 5 6 (treatment day 0) 7 (7 dpS) 





















8 weeks post initiation 
of mating, egg strings 
hatched to 
copepodids: RX1S F1, 
RX2S F1 and RX3S 
F1.  RX1S F1 and 
RX3S F1 combined 




F1,  RX1-3S 
F1 and R3-2a  
At preadult stage, 
infected groups of fish 
(RX2S F1,  RX1-3S 
F1 and R3-2a) were 
sampled for sea lice 
infection level and  
placed on 7 days EMB 
treatment  at 150 
µg/kg fish biomass 
Fish sampled 






4.3.5.2.  Single dose EMB bioassay 
A single bioassay was conducted in this sub-study, as described above with slight 
modifications; single dose of EMB (200 ppb) was used (Westcott et al. 2010).  A brief overview 
of the bioassay is as follows: 
Bioassay V: EMB sensitivity was determined for preadult male and female RX2S F1, RX3S F1, 
and R3-2a (i.e. progeny from R2-2a; see sub-section 4.3.5.3 below) collected prior to 
commencement of the second EMB on-host triple dose treatment. 
4.3.5.3.  On-host comparison of L. salmonis populations following triple dose EMB 
treatment: series II 
As in the first on-host EMB exposure, the copepodid life stages were cultivated in static 
seawater incubators prior to exposure to naïve (n=15/tank) Atlantic salmon (Chapter 3, Covello 
et al., 2012).  RX2S F1 copepodids (n~1000) were used to infect one tank of salmon (~70 sea 
lice/salmon); RX1S F1 and RX3S F1 copepodids were combined (will be referred to as RX1-3S 
F1; n~750) and used to infect a second individual tank of salmon (~50 sea lice/salmon); and F3 
generation of L. salmonis collected from BMA 2a [(R3-2a) (~2350 copepodids)] generated at the 
same time were used to infect two tanks of salmon (~70 sea lice/salmon).  Despite synchronized 
hatching of egg strings, RX1S F1, RX2S F1 and RX3S F1 all developed to copepodids slower 
and, as such, were used to infect salmon 2 days later than fish infected with R3-2a copepodids.  
Again, upon >90% of the sea lice reaching preadult life stages, three fish per tank were 
euthanized and the parasites enumerated and collected from each tank.  A triple dose EMB 
treatment (150 g kg-1 fish biomass) was administered to 3 tanks (RX2S F1, RX1-3S F1, R3-2a), 
with another tank (R3-2a) on control feed as described previously.  Fish were euthanized and the 
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sea lice counted and collected from the tanks 7 days post cessation of EMB treatment.  As with 
the first on-host EMB exposure, all L. salmonis samples collected were frozen on dry ice within 
2 min of removal from the tank and stored at -80°C for future genetic studies.   
4.3.6.  Statistical analysis 
The half-maximal effective concentration (EC50) for EMB was derived using US 
Environmental Protection Agency Trimmed Spearman-Kaber (TSK) software version 1.5 
(Hamilton, Russo & Thurston 1977).  Differences in relative P-gp mRNA expression were 
determined by performing multivariate analysis of variance (MANOVA) using STATISTICA 
statistical software (StatSoft Inc., Tulsa, OK).  Least significant difference post-hoc analysis was 
also conducted using STATISTICA to determine significant differences in P-gp mRNA 
expression among the different samples.  Statistical significance was set at p < 0.05 and/or  1.5 
fold changes in relative expression.  Graphs of relative P-gp mRNA expression were plotted 
using SigmaPlot 10.0 (Systat Software Inc., Chicago, IL).   
4.4.  Results 
4.4.1.  Responses to EMB exposure across sea lice populations  
In-house reared F1 generation adult L. salmonis from BMA 1 (R1-1) showed no 
significant difference in EC50 values in both sexes of the parasite (Table 4.3, Bioassay I).  
Similar  EC50 values were also observed in BMA 2a field and F1 generation (R0a-2a and R1-2a, 
respectively) adult male L. salmonis while the females exhibited lower EC50 values (Table 4.3; 
Bioassay IIa and IIb).  S0-2b, collected from Grand Manan Island (Fig. 4.1) and suspected of 
greater susceptibility to EMB, recorded EMB EC50 values lower in both sexes with 63 ppb for 
the adult male and 75 ppb for the adult female compared with in-house reared F1 generation of 
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L. salmonis collected from BMA 2a [R1-2a (Table 4.3; Bioassay IIb)].  Another comparison was 
made using a different species of sea lice, C. elongatus.  Adult female C. elongatus and L. 
salmonis were collected simultaneously from BMA 1, the same source as the L. salmonis used 
for Bioassay I (Table 4.3).  Although the number of L. salmonis collected was insufficient to 
determine EMB EC50 values, all the L. salmonis survived EMB exposure at  100 ppb, in 
agreement with the R1-1 bioassay result.  Caligus elongatus, however, exhibited lower EC50 
values (Bioassay III) compared with R1-1 EC50 values, i.e. in the same range as the suspected 
susceptible population of L. salmonis from Grand Manan (Bioassay IIb; Table 4.3). 
4.4.2.  Reverse transcription quantitative PCR 
To determine if P-gp was involved in differential resistance to EMB across sea lice 
populations, RT-qPCR was used to analyze P-gp mRNA expression in archived L. salmonis from 
BMA 2b, as well as, Bioassay IIb survivors.  There were no significant differences in P-gp 
mRNA expression in adult female L. salmonis collected from BMA 2b in 2005 and 2012 (Fig. 
4.2).  It would have been ideal to verify temporal differences in relative P-gp mRNA expression 
for the male L. salmonis, but, unfortunately, only female samples were archived. 
P-glycoprotein mRNA expression, however, differed between BMAs 2a and 2b L. 
salmonis (R1-2a and S0-2b, respectively) within Bioassay IIb survivors.  Relative P-gp mRNA 
expression for the EMB-untreated male R1-2a (0 ppb) group was significantly higher than male 
and female S0-2b groups as well as the female R1-2a no treatment groups (Fig. 4.3, P < 0.05).  
The transporter was induced more readily in resistant male L. salmonis (R1-2a) compared 
with the females and the relatively less EMB sensitive (S0-2b) male populations.  Increasing 
concentrations of EMB caused significant differences in relative P-gp mRNA expression 
between male R1-2a and S0-2b sea lice samples, but not in their female counterparts.  Male R1-
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2a 300 and 1000 ppb EMB treatment groups displayed significantly higher relative P-gp mRNA 
expression compared with the other treatment groups (P < 0.05).   
4.4.3.  P-glycoprotein inhibition test 
As there was no sequence information for C. elongatus P-gp at the time of this study, we 
were unable to directly assess P-gp mRNA expression pattern in BMA 1 C. elongatus.  However, 
we tested the susceptibility of adult female C. elongatus to EMB in the presence of a P-gp 
inhibitor, verapamil.  Exposure of adult female C. elongatus to increasing concentrations of 
EMB with or without 10 µM verapamil yielded EMB EC50 values (confidence limits) of 160 
(140, 182) and 72 (55, 95) ppb, respectively.   
4.4.4.  On-host exposure of L. salmonis populations to triple dose EMB 
The first on-host exposure of R2-2a and S1-2b to EMB revealed higher % survival of R2-
2a compared with S1-2b (Table 4.4).  A single tank of fish infected with R2-2a maintained 
without EMB treatment showed similar mortality over the course of the experiment as EMB on-
host treated R2-2a [22.8 ± 1.2 (mean ± SEM) sea lice per fish at day 0, and 9.4 ± 1.0 sea lice per 
fish at 13 dpSC].  Unfortunately due to low sea lice numbers, we were unable to maintain an 
untreated S1-2b infection group.  Also, standard error of mean for S1-2b at day 0 was not 
obtainable as only total lice were counted over the six fish and not per individual fish. 
A second on-host EMB exposure was conducted to compare the sensitivity of progeny 
from crosses-1 and -3 (RX1-3S F1), cross-2 (RX2S F1) and R3-2a, an in-bred progeny of R2-2a.  
The crosses recorded proportionately higher sea lice reductions from day 0 to 7 compared with 
the EMB-treated and untreated R3-2a groups (Table 4.5). 
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Despite infection within 2 days of each other the crosses were significantly delayed in 
terms of stages by the end of the trial.  RX1-3S F1 comprised of 75% adult male and 25% 
preadult females while RX2S F1 was 33% adult male and 67% preadult female.  The two R3-2a 
tanks were 60% adult males, 37% adult females and 3% preadult females. 
4.4.5.  Response of L. salmonis from susceptible and resistant crosses to single dose EMB 
exposure 
While male and female R3-2a survived exposure to 200 ppb EMB (Bioassay V; Table 
4.3), lower % survival was observed in sea lice, especially females, from the two crosses (RX1-


































Results [(EC50- ppb; 95% confidence 
interval) or (% Survival)] 
I BMA 1 
(R1-1) 
 
0, 10, 100, 300, 1000 EC50:  
Male- 329 (275, 394)  
*Female- 304 (241, 383) 
IIa BMA 2a 
(R0a-2a) 
0, 100, 200, 400, 1000 
 
EC50: 
Male- 840 (614, 1047) 
Female- 254 (218, 296) 




0, 0.1, 25, 300, 1000 EC50: 
R1-2a: Male- 403 (230, 706) 
            Female- 170 (56, 519) 
S0-2b: Male- 63 (11, 352) 
            Female- 75 (13, 432) 
III BMA 1  
C. elongatus 
0, 30, 100, 300, 1000 EC50: 
Male- 105 (33, 334) 
Female- 55 (43, 69) 




0, 0.1, 25, 300, 1000 EC50: 
R2-2a: Male- 403 (230,706) 
            Female- 218 (87, 548) 
S1-2b: Male- 421 (258, 686) 
            Female- 274 (146, 516) 





200  % Survival: 
*R3-2a : Male- 100; Female- 100 
*RX1-3S F1: Male- 94; Female- 70 
*RX2S F1: Male- 100; Female- 67 
All sea lice samples are Lepeophtheirus salmonis except where stated otherwise and were 
collected from the Bay of Fundy, NB, Canada.  The differences in concentration of EMB are 
based on suspected variations in sensitivity of the test sea lice populations to the parasiticide.  All 
sea lice samples are adult stage except where indicated otherwise: *, preadult stage.  % control 






































Figure 4.2.  Relative P-glycoprotein mRNA expression (mean relative expression ± SEM; n = 5) 
in adult female Lepeophtheirus salmonis (sea lice) collected in 2005 (March and May) and April 



















Figure 4.3.  Relative P-glycoprotein mRNA expression (mean relative expression ± SEM) in 
adult male and female Lepeophtheirus salmonis emamectin benzoate bioassay (EMB) survivors.  
Lepeophtheirus salmonis samples were collected in 2012 from Atlantic salmon farm locations at 
2 different Bay Management Areas (R1-2a = EMB resistant laboratory-reared F1 sea lice from 
BMA 2a; S0-2b = EMB sensitive field sea lice from BMA 2b) in the Bay of Fundy, NB, Canada.  
Different superscripts (a, b, c, d, e, f, g) denote significant (p<0.05 and/or 1.5 fold) difference 






Table 4.4.  Sensitivity of adult male and female Lepeophtheirus salmonis populations following 
on-host exposure to triple dose emamectin benzoate (EMB; SLICE®).  
L. salmonis 
population 
Number of sea lice (male and female)   
[Mean ± SEM] 
% Survival Average % mortality 
Male Female 
 Day 0 1 dpS 13 dpSC 1 dpS 13 dpSC   
S1-2b 40. 7 (n = 6) 34.6 ± 2.1 
(n = 5) 
27.6 ± 2.0 
(n = 8) 
85.1 67.8 53.8 24.4 
R2-2a 23.6 (n = 6) 26.6 ± 1.6 
(n = 5) 
12.2 ± 1.7 
(n = 10) 
112.7 51.7 36.6 20.8 
dpS = days post-commencement of emamectin benzoate treatment; dpSC = days after cessation 





Table 4.5.  Emamectin benzoate (EMB; SLICE®) sensitivity of adult male (EMB resistant) and 
female (EMB sensitive) Lepeophtheirus salmonis crosses following on-host exposure to a triple 
dose EMB treatment (n = 5).  
Days post commencement 
of SLICE treatment (dpS) 





RX2S F1 RX1-3S F1 
0 17.0 ± 2.6 26.7 ± 7.7 15.7 ± 2.8 11.0 ± 4.1 
7 10.0 ± 1.7 17.2 ± 1.9 1.2 ± 0.5 2.6 ± 0.8 
dpS = post-commencement of emamectin benzoate treatment; R3-2a = F3 generation EMB 






4.5.  Discussion 
We investigated locations of sea lice populations across different Atlantic salmon farming 
regions in the New Brunswick side of the Bay of Fundy and sex differences as factors 
contributing to EMB resistance in sea lice following off-host (i.e. bioassays and P-gp mRNA 
analyses) and on-host (i.e. sea lice survival on EMB-treated Atlantic salmon) drug exposure.  
The EMB bioassay results indicate population, species, sex and temporal differences in EMB 
EC50 values.  An earlier study by Westcott et al. (2008) reported EMB EC50 values of 37 and 12 
ppb for preadult male and female F1 laboratory reared L. salmonis respectively, derived from 
farms (in 2005) prior to confirmed resistance development.  Results of Bioassay I (present study) 
carried out using adult male and preadult female F1 in-house reared L. salmonis derived from 
farms with EMB-resistant sea lice (BMA 1), indicated EC50 values of 329 and 304 ppb, 
respectively.  Notwithstanding the differences in EC50 values, both studies demonstrated that F1 
in-house reared L. salmonis were similar in EMB sensitivity as the field F0 generation from 
which they were derived (Jones et al. 2012) and further confirmed the reduced sensitivity to 
EMB in recent field and lab-isolated populations of the parasite.  Also, EMB EC50 values [25 to 
118 (CI = 17 - 292) ppb; from 2002 to 2005] reported by Westcott et al. (2008) for preadult sea 
lice collected from the Bay of Fundy are several fold lower than the current EMB EC50 values 
for BMAs 1 (adult male and preadult female) and 2a (adult male and female) [Table 4.3], 
evidence for reduced EMB efficacy in some locations within the Bay.  It has been observed that 
differences in sea lice EMB sensitivity can exist within a given region (Westcott et al. 2010, 
Whyte et al. 2013).  Consistent with the BMA 1 EMB EC50 values, as well as the EMB EC50 
values reported in Chapter 2, the 2012 EMB EC50 values from Bioassays IIa and IIb (R0a-2a and 
R1-2a) were significantly higher (> 2-fold) for the adult males compared with adult females 
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(Table 4.3).  Bioassay IIb results also revealed that S0-2b was more sensitive to EMB compared 
with R1-2a despite one generation difference between both populations of L. salmonis.  The 
higher EMB EC50 value of BMA 2a sourced L. salmonis (R1-2a) is most likely a consequence of 
drug selective pressure whereby sensitive strains of the parasite are gradually replaced with more 
resistant strains that were originally in the minority prior to introduction of the sea lice 
medication.  We did not have access to farm treatment records to ascertain whether there were 
any differences in the number of EMB treatments and/or efficacy between the salmon farms 
sourced for sea lice in BMAs 2a and 2b.  However, Jones et al. (2012) reported that although 
there was increasing number of sea lice from 2004 to 2008 in the Bay of Fundy, sea lice numbers 
were lowest in Grand Manan (BMAs 2b and 3b).  Jones et al. (2012) also reported that there 
were fewer EMB treatments and greater efficacy in Grand Manan compared with other salmon 
farm locations within the Bay.  In the follow-up Bioassay IV (present study), the S0-2b progeny 
(S1-2b) displayed a resistant phenotype.  This may have occurred due to: 1) the low EMB 
sensitivity in L. salmonis collected from BMA 2b Atlantic salmon farms not being heritable to 
the first generation in-house developed parasite or 2) as a result of a relatively lower contribution 
of EMB susceptible progeny following re-infection and development compared with more EMB 
resistant strains within the population, consequence of EMB treatment and selection just prior to 
sea lice collection.  Avermectin resistance can develop very quickly compared with other classes 
of anthelmintics, e.g. F1 progeny from reciprocal crosses between avermectin-sensitive and -
resistant parent Haemonchus contortus displayed the same level of resistance as the resistant 
parent (Dobson, Le Jambre & Gill 1996).  Also, reciprocal crosses of thiabendazole-resistant and 
-sensitive parent H. contortus yielded F1 and F2 progenies that were nearly as thiabendazole-
resistant as their resistant parents (Le Jambre, Southcott & Dash 1976).  However, F1 and F2 
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progenies from reciprocal crosses of cambendazole-resistant and -susceptible strains of H. 
contortus were as sensitive to the parasiticide as the sensitive parent (Herlich, Rew & Colglazier 
1981).  The foregoing suggests that although Grand Manan sea lice currently respond to EMB 
treatment relative to the other BMAs (Jones et al. 2012), resistance to the parasiticide may be 
developing.   
On the other hand, the EMB resistant/sensitive L. salmonis crosses recorded lower % 
survival compared with F3 generation EMB resistant L. salmonis samples (R3-2a) especially for 
the female treatment groups (Table 4.3).  This is in agreement with the second on-host EMB 
treatment whereby the crosses had greater sea lice reduction between 0 and 7 dpS compared with 
the in-bred R3-2a L. salmonis samples.  Hence, our results suggest that sea lice reared in the 
laboratory will maintain their EMB sensitivity status for up to three filial generations (Bioassay 
V).  The existence of biological costs to maintaining resistance phenotype in L. salmonis, 
especially for the female parasite, is not known.  Also, the number of generations it may take for 
a resistant population of sea lice to lose its resistance status in the absence of drug exposure is 
not known.  Passage of cambendazole resistant strain of H. contortus up to 24 generations did 
not result in reduced resistance phenotype (Herlich, Rew & Colglazier 1981).  
Female L. salmonis expressed lower levels of P-gp in both the resistant and sensitive 
populations (see Fig. 4.3 and discussion further below).  How the choice of resistant and 
sensitive sex (i.e. crossing resistant males with sensitive females or vice versa) for the 
crossbreeding experiment affects EMB sensitivity of the progeny is not known.  We chose to 
cross sensitive females with resistant males because males have been shown to be the more 
EMB-resistant sex within both EMB-resistant (Chapter 2, Westcott et al. 2008, Heumann et al. 
2012) and -sensitive sea lice populations (present study).  Although the pattern of EMB 
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resistance inheritance in sea lice is not known, avermectin resistance inheritance in the 
nematode, H. contortus, is believed to be completely dominant and under the control of a single 
gene (Le Jambre et al. 2000).  It is unknown whether one or more EMB resistant traits in sea lice 
are dominant, recessive or sex-linked.  Endosulfan resistance was associated with sex-linked 
alleles in Helicoverpa armigera (Daly & Fisk 1998).  Inheritance of thiabendazole resistance in 
H. contortus and Trichostrongylus colubriformis is semi- and incompletely recessive, 
respectively (Le Jambre, Royal & Martin 1979, Martin, McKenzie & Stone 1988, Sangster, 
Redwin & Bjorn 1998).  Although maternal influence (sex-link) was reported for thiabendazole 
resistance inheritance in T. colubriformis, the maternal aspects of inheritance of resistance to the 
parasiticide in H. contortus was described as matroclinous.  In T. colubriformis, when resistance 
was inherited through the female parent, the trait was incompletely recessive while when through 
the male parent, it was completely recessive (Martin, McKenzie & Stone 1988).  Inheritance of 
the levamisole resistance trait in H. contortus was described as incomplete recessive with no 
maternal influence or sex linkage (Sangster, Redwin & Bjorn 1998).  On the contrary, 
inheritance of the levamisole resistance trait in T. colubriformis is completely recessive and sex-
linked (Martin & McKenzie 1990).  Studies by Herlich, Rew & Colglazier (1981) suggest that 
inheritance of cambendazole resistance in H. contortus is not sex-linked, and that it could be 
associated with a heterozygous recessive allele.  Understanding how anthelmintic resistance 
phenotypes are passed from one generation of parasite to the next could be useful in effective 
drug rotations to control parasite infections (Dobson et al. 1987, Gill & Lacey 1998).  The 
limited range of treatment options and control strategies for several years has contributed to 
resistance development in sea lice (Denholm et al. 2002).  Although the need for chemical 
diversity and the avoidance of over-dependence on a single chemotherapeutant cannot be over-
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emphasized (Sangster 2003, Wolstenholme et al. 2004), the tendency to rely on single products 
for salmon lice control still exists.  This may be traced to the difficulty in developing and 
licensing new drugs (Denholm et al. 2002) and the insistence of farmers to use “the” drug that 
works.  Emamectin benzoate was initially approved for use in Canadian salmon aquaculture in 
1999 by Health Canada Veterinary Drugs Directorate under the Emergency Drug Release 
program, but did not receive full drug approval until 2009. 
At day 0 of the first on-host EMB exposure, the infection level of S1-2b was nearly 2-
fold higher than the infection of R2-2a sea lice.  This may have caused a relatively higher stress 
for the respective host (i.e. S1-2b infected group), which may consequently lead to lower EMB 
exposure of S1-2b compared with R2-2a populations.  Although the amount of EMB in the feed 
was confirmed to be 120 mg L-1, concentration of the drug available to and ingested by the 
parasite, while feeding on the host, is unknown.  Some studies reported increased stress in 
Atlantic salmon in response to a higher (~100 per fish) sea lice burden (Bowers et al. 2000, 
Mustafa et al. 2000) and was attributed to development from copepodid to late chalimus and 
preadult stages.  Contrariwise, 10 sea lice per fish for up to 10 days caused increased Na+/K+-
ATPase activity and plasma chloride ion concentrations compared with 3 and 6 sea lice/fish 
groups (Nolan, Reilly & Wendelaar Bonga 1999) suggesting that as the number of sea lice on 
fish increases, and for prolonged periods, level of stress increases which may cause poor feeding 
and sub-therapeutic EMB concentration in the host. 
Caligus elongatus from a suspected EMB-resistant site (BMA 1) displayed >2 fold lower 
EMB EC50 values compared with L. salmonis collected previously from the same BMA and from 
another location known to contain an EMB-resistant sea lice populations (BMA 2a).  There are 
unconfirmed reports that populations of C. elongatus at various locations in the Bay of Fundy 
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fluctuate, but the exact pattern of the fluctuations has not been described.  Whether sea lice 
treatments influence the rise and fall of C. elongatus numbers is not known.  Outbreaks of C. 
elongatus most likely pre-date those of L. salmonis in sea cage culture of salmonids in the Bay of 
Fundy (Hogans & Trudeau 1989, Hogans 1995).  Therefore the fact that C. elongatus is 
relatively EMB-sensitive compared with L. salmonis could be linked to the transient presence of 
C. elongatus on salmon in sea cages.  This has probably resulted in a reduced exposure history to 
EMB due to greater opportunity for refuge in wild fish populations for C. elongatus compared 
with L. salmonis as has been reported for the latter in Pacific Canada (Jones & Prosperi-Porta 
2011, Saksida et al. 2012); consequently causing reduced selection pressure for the development 
of EMB resistance in C. elongatus.  Caligus elongatus may also lack the ability to develop EMB 
resistance as rapidly as L. salmonis.  EMB-resistant C. rogercresseyi was reported in Chile 
several years post-introduction of the parasiticide in Chilean salmon aquaculture (Bravo, 
Sevatdal & Horsberg 2008) and the emergence of resistant strains of this sea lice species may 
have been hastened by prior use of ivermectin for controlling the parasite.  It is known that drugs 
of the same class will select for the same resistance mechanism, but whether P-gp plays a role in 
EMB resistance in Caligus spp. is yet to be investigated.  Given the proposed involvement of P-
gp in EMB resistant L. salmonis (Chapter 2), as well as its role in ivermectin resistance in 
nematodes (Prichard & Roulet 2007), it is quite possible that the ABC transporter will be 
involved in EMB resistance in Caligus spp. 
It is not clear why concomitant exposure of C. elongatus to EMB and 10 µM verapamil 
caused higher EMB EC50 compared with EMB exposure alone.  The drug resistance reversal 
agent caused an increase in anthelmintic efficacy against ivermectin and moxidectin-selected 
strains of H. contortus (Molento & Prichard 1999).  There was increased mortality in L. salmonis 
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concomitantly exposed to verapamil (at the same concentration used in this study) and EMB 
compared with EMB exposure alone, previously (Chapter 2).  Whether the discrepancy between 
the effects of verapamil in the present study and earlier report in Chapter 2 is due to species’ 
and/or EMB sensitivity differences is not known.  While the study in Chapter 2 employed 
resistant population of L. salmonis (BMA 2a), the present study used a relatively EMB-sensitive 
population of C. elongatus.  A previous study demonstrated that benzimidazole resistance 
reversal effect of verapamil in H. contortus is more pronounced in the anthelmintic-resistant 
strain than in the sensitive strain (Beugnet, Kerboeuf & Gauthey 1997).  Verapamil at similar or 
higher concentrations has been shown to induce P-gp expression in human carcinoma cells [~10 
µM verapamil] (Herzog et al. 1993) and LS180 human colonic cell [50 µM verapamil] (Collett, 
Tanianis-Hughes & Warhurst 2004).  The P-gp reversal agent may have caused a decrease, 
instead of increase, in mortality of C. elongatus in the present study, potentially due to different 
sensitivities to the Ca++ channel blocker (Nygren & Larsson 1990) and/or through induction of 
the ABC transporter, consequently decreasing the efficacy of EMB.   
Quantitative PCR analyses revealed no significant differences in P-gp mRNA expression 
between adult female L. salmonis samples collected in 2005 and 2012 from BMA 2b, unlike 
results from other areas unresponsive to the drug (Chapter 2).  These findings, combined with the 
bioassay results for BMA 2b sea lice and treatment efficacy of EMB described by Jones et al. 
(2012) and Whyte et al. (2013), indicate that Atlantic salmon farms in Grand Manan still contain 
EMB-sensitive strains of L. salmonis.  Also, based on the relatively lower EMB EC50 reported by 
Westcott et al. (2008), our findings suggest that resistance is already developing in Grand 
Manan.  However, given that female L. salmonis may be a poor indicator of developing EMB 
resistance within a given sea lice population (Chapter 2), it is difficult to conclusively determine 
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the relationship with P-gp in this area.  Previous studies have shown that EMB can induce P-gp 
mRNA expression in a dose-dependent manner (Chapter 2).  Our results suggest the need to 
consider sex-based differences in the expression of P-gp while monitoring for EMB resistance 
development in sea lice.  The spatial differences between the BMA 2a and 2b (Fig. 4.1) L. 
salmonis populations may account for the differences in relative P-gp mRNA expression 
between both populations consequently leading to differences in their relative EMB sensitivities 
as well as in their progenies.  The spatial differences may be linked to differences in tidal 
excursions (Chang et al. 2007) and/or access to refuge (Saksida et al. 2012).  The study by 
Saksida et al. (2012) associated the relatively low EMB EC50 values recorded by L. salmonis 
found in British Columbia to influx of sea lice from the wild salmon population refuge which 
serve to dilute the effects of EMB selective pressure on salmon farm sourced sea lice.  Also, 
although not confirmed, it is possible that the closer proximity of BMA 2a to the mainland 
compared with BMA 2b, may have caused exposure of BMA 2a sea lice to environmental 
contaminants (such as industrial wastes and pesticide runoffs from nearby farms) resulting to a 
higher expression of P-gp mRNA. 
Although males are more tolerant to EMB, express P-gp at higher levels, and are more 
readily induced compared with female L. salmonis, the evolutionary link associated with the sex-
based differences is unclear.  Apart from the reproductive burden imposed on the female towards 
egg production, the sexual behavior of the parasite is such that the males change sexual partners 
more readily than the females and are likely to change host more frequently (Stephenson 2012).  
Hence it may make more biological sense for the male parasite to be more EMB-resistant 
compared with the female.  Although polyandry exists in copepods, females only require a single 
copulatory event to produce offspring for the remainder of their lives, in combination with 
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greater movement between hosts by males (Stephenson 2012), probably provide males with 
greater opportunity to spread their gametic contribution to future generations over a larger spatial 
scale.  This may allow for resistance development to be driven by the males, rather than the 
female.   
The present study has shown that within an area suspected to contain parasiticide-
resistant sea lice, there could be micro-populations of the parasite relatively sensitive to the same 
drug.  This is the first assessment of the EMB sensitivity of C. elongatus found in the Bay of 
Fundy.  It is interesting and noteworthy, but not unexpected, that EMB-sensitive C. elongatus 
and -resistant L. salmonis were located in the same site (BMA 1; Fig. 4.1).  More investigations 
on the nature of the species’ differences in EMB sensitivity in sea lice, as well as the heredity of 
EMB resistance mechanisms, is necessary for a better understanding of how this economically 
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5.1.  General discussion 
Resistance to sea lice therapeutants has developed rapidly with increased farmed salmon 
production.  As with land-based animal production, prevalence of infection increases with 
increase in fish density.  This makes it easier for a parasite such as sea lice to locate its host, feed 
and keep multiplying.  Drug selection due to prolonged dependence on a specific chemical or 
drug, in this case emamectin benzoate (EMB), further exacerbates the situation.  This is because 
if a particular drug is continually employed for sea lice control, surviving parasites are favoured 
to continue propagating, and will eventually become the dominant strain of parasite in the 
population.  Other classes of drugs, such as organophosphates and pyrethroids, which have been 
used for sea lice control, over time have also become ineffective in some salmon farms 
(Denholm et al. 2002).  This was linked to the emergence of sea lice strains resistant to the 
respective drugs.  The fact that EMB resistance in sea lice, similar to other parasiticides, occurs 
over time underscores the need to understand the mechanisms of loss of efficacy and investigate 
sensitive tools to monitor resistance development.  
The effectiveness of EMB and its advantages over other sea lice medicines made it the 
drug of choice with almost exclusive use for sea lice control in salmon farms in the Bay of 
Fundy, NB (Westcott, Hammell & Burka 2004) and elsewhere.  Consequently, the use of EMB 
has declined considerably due to resistance development.   
Numerous studies have linked P-glycoprotein (P-gp) with resistance to the closely related 
ivermectin in nematodes and arthropods (reviewed by Prichard & Roulet 2007).  It was 
hypothesized that over-expression of P-gp in the gastrointestinal epithelium would impede the 
absorption of EMB, ingested by the salmon louse (Tribble, Burka & Kibenge 2007).  P-
glycoprotein, a member of ATP-binding cassette (ABC) transporters, causes the efflux of diverse 
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range of molecules from within cells to the exterior (Fojo et al. 1985, Raviv et al. 1990).  
Although genetic changes in the EMB target GluCl channels have been associated with ML 
resistance (Njue et al. 2004), increased expression of P-gp is thought to be the primary 
mechanism responsible for loss of sensitivity to MLs in nematodes (reviewed by Prichard & 
Roulet 2007).  Also, P-gp appears to play a major role in the protection of aquatic invertebrates 
from xenobiotics (Smital & Kurelec 1998, Fulton et al. 1999, Lyons-Alcantara et al. 2002).  
Macrocylic lactones are substrates for P-gp and have high binding affinity for the transporter 
(Lespine et al. 2007).  The present study investigated the role of P-gp in EMB resistance in sea 
lice using multiple methods such as P-gp gene expression, competitive inhibition test, and an 
assay for ATPase activity.  The latter two tests indicated that P-gp interacts with EMB in vitro 
(Chapter 2).  Increased expression of P-gp was linked to ML resistance in C. elegans and H. 
contortus (Blackhall et al. 1998a, Xu et al. 1998, Sangster et al. 1999, James & Davey 2009).  
Using in situ hybridization technique, P-gp mRNA was localized in the digestive tract and 
pharynx of H. contortus (Smith & Prichard 2002).  Unfortunately, we were unable to detect P-gp 
at the mRNA and protein levels using in situ hybridization, immunohistochemistry, Western 
blotting and ELISA techniques (Appendix 1).  This is likely due to low expression (mRNA and 
protein) and/or sub-optimal antigenic specificity (protein) of the C219 anti-mouse P-gp antibody 
used.  Trypsin was detected in epithelial cells of L. salmonis digestive tract following similar 
tissue handling and processing employed for P-gp (Kvamme et al. 2004), and was successfully 
used as a positive control in the present study.  
The P-gp competitive inhibition test using MDR-reversing agents, such as verapamil, is a 
well-established means of determining compounds that are substrates of the efflux transporter.  
The strategy has been employed for the reversal of P-gp-mediated drug resistance in 
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anthelmintic therapy (reviewed by Lespine et al. 2012).  Concurrent exposure of L. salmonis to 
EMB and verapamil caused higher sea lice mortality compared with exposing the parasite to the 
parasiticide or verapamil alone, indicating that EMB interacts with P-gp in the parasite (Chapter 
2).  This also suggests that verapamil may be interacting at the same site on the efflux pump as 
EMB.  Hence, the increased sensitivity of L. salmonis to EMB following concomitant verapamil 
exposure is most likely a consequence of competitive inhibition of P-gp by the MDR-reversal 
agent, causing an increase in the concentration of EMB in the parasite.  However, relatively 
EMB sensitive C. elongatus responded differently to concurrent verapamil/EMB exposure 
whereby the group that were treated with both drugs recorded higher EMB EC50 values 
compared with the EMB-treatment group.  This suggests that the effect of verapamil may be 
most prominent when used on a resistant population, although potential species differences 
should be considered as well.  Reversal of ivermectin resistance in nematodes using verapamil 
has been previously reported (Molento & Prichard 2001).  Although this is a potential means of 
enhancing ML efficacy (Bartley et al. 2009), differences in kinetics of different MLs and existing 
reversal agents and potential toxicity of the latter may hamper realistic use of this strategy in the 
field (Lespine et al. 2008).  Although results indicate that concurrent administration of MDR-
reversing agents (such as verapamil) and EMB could increase the sensitivity of sea lice to the 
parasiticide, more studies are necessary to confirm the possibility of using MDR-reversing 
agents in the control of sea lice in salmon farms.  In the present study, verapamil, a well known 
calcium channel blocker, caused 10% mortality in L. salmonis at 10 and 30 µM and 100% 
mortality at 100 µM, possibly due to blockade of calcium channels in the parasite.  Verapamil 
was used in this study as a pharmacological tool to ascertain the role of P-gp in EMB resistance 
in vitro, but would probably not be ideal for field application, as it is not likely to accumulate in 
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the host skin, limiting availability to the parasite.  It may also induce cardiac toxicity to the host 
salmon due to Ca++ channel inhibition.  Other ABC-transporter inhibitors with appropriate 
pharmacokinetics and host and human safety parameters need to be developed.   
Resistance is a consequence of changes in the genetic profile of the parasite population 
and/or selection for resistant strains of parasite that will subsequently lead to a phenotype of 
reduced sensitivity to treatment (Eng & Prichard 2005).  Genes conferring resistance arise 
through mutation, but maintain very low frequencies in pest populations in the absence of drug 
exposure (Denholm et al. 2002).  Over time and with subsequent treatments, genes conferring 
resistance are passed from one generation of survivors to another (Sangster 1996, Sangster & 
Gill 1999).  Following each treatment, individuals possessing these genes survive and multiply.  
Early on, the number of resistant survivors may be low to affect treatment outcome, but over 
time and, if resistance is unchallenged, the survivors will become the dominant individuals 
within the population, causing treatment failures (Denholm et al. 2002).  More genetically 
variable organisms possess greater capability of having an allele capable of causing poor 
treatment outcomes.  The evidence for the involvement of a gene in resistance to a drug can be 
obtained by examining the genetic variability of the gene between individuals sensitive and 
resistant to the drug (Blackhall et al. 1998b), where available.  Variations in resistance to sea lice 
therapeutants could be due to phenotypic or genetic differences and has been examined using 
different approaches (Boxaspen 2006).  Provided the appropriate genes are investigated, changes 
in genetic profile are likely to be evident prior to widespread resistance-induced treatment failure 
and such changes in genetic disposition could be used to monitor the development of resistance 
to the parasiticide in use (Eng & Prichard 2005).  The application of population genetics 
promises to be a useful tool in the analysis of drug resistance in parasites and other pest species 
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(Blackhall et al. 1998b).  Identifying genes associated with drug resistance selection will be 
useful in the development of possible markers for tracking reduced drug sensitivity as it develops 
(Sangster et al. 2002).  Monitoring is important for the rotational use of parasiticides so as to 
delay resistance development (Zhao et al. 2006).  Similar to the key factors discussed in the 
review on monitoring anthelmintic resistance in human onchocerciasis, including host, stage of 
parasite, and timing of monitoring (Churcher & Basanez 2009), proper monitoring of all stages 
of sea lice is important for the strategic timing of treatments of farmed salmon (Brooks 2009).  
Depending on locality/region, reduced sensitivity and potential resistance to currently available 
medicines are constant threats to the control of sea lice populations on salmon farms.  Hence 
there is the need for ongoing monitoring of treatment efficacy and effects on performance. 
Monitoring strategies should be precise and practical. They should also be robust, simple and 
repeatable with an unambiguous endpoint as well as have sufficient sensitivity to detect changes 
in efficacy of the parasiticide.  Bioassays are commonly used to measure clinical effectiveness 
and have been used to investigate the effects of EMB on gene expression in surviving sea lice 
(Tribble, Burka & Kibenge 2007).  Although the bioassay protocol shows promise as a method 
to verify clinical resistance, it lacks rapidity and simplicity for use as a routine test (Westcott et 
al. 2008).  Thus, initial work to develop bioassay methods has focused on testing preadult and 
adult sea lice that have been removed from their hosts.  This has several implications. Firstly, 
once removed, the sea lice can only be used within a limited time frame, usually within 48 h (to 
avoid stressed samples), for meaningful results.  Secondly, endpoints can be hard to define, as 
the parasites can survive in a moribund stage for prolonged periods following exposure to most 
control agents (Denholm et al. 2002).  Hence the bioassay is best used to establish indicators of 
sensitivity to the parasiticide under study that is by using concentrations that have been shown to 
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be effective (Westcott et al. 2008).  Since the bioassay must be performed shortly after detaching 
the parasite from the host, to avoid flawed results due to stressed sea lice, endpoints can be 
unclear especially between weak and moribund parasites following exposure in this system 
(Denholm et al. 2002).  These shortcomings create the need for alternative methods of 
monitoring resistance development in the parasite, for example, using molecular tools such as 
RT-qPCR. 
Depending on the prevailing resistance mechanism, developing biochemical assays that 
measure quantitative/qualitative changes in enzymes conferring resistance, or molecular 
techniques (Elard, Cabaret & Humbert 1999, von Samson-Himmelstjerna & Blackhall 2005) that 
detect genetic changes in drug resistant parasites, is a sensible direction to follow as part of the 
overall parasite control strategy (Denholm et al. 2002).  Genetic changes in the structure or 
expression of P-gp (Sangster et al. 1999) may provide useful markers for monitoring resistance 
in parasites under prolonged avermectin treatment (Eng & Prichard 2005).  Macrocyclic lactones 
can induce over-expression of P-gp in parasites and changes in the expression of this ABC 
transporter could be monitored as a means of detecting EMB resistance in L. salmonis on salmon 
farms.  In the present study, EMB induced over-expression of L. salmonis P-gp mRNA in a 
concentration-dependent manner (Chapters 2 and 4).  The upward trend in the relative P-gp 
mRNA expression in archived L. salmonis and the fact that P-gp mRNA expression for the 
March 2011 samples was significantly (> 2-fold) higher than the expression for 2002, 2008 and 
2010 samples suggest that P-gp mRNA expression level was increasing over the years.  
Unfortunately, only adult female parasites were archived and analyzed; otherwise, it would have 
been interesting to investigate the changes in the expression of the transporter in the male 
parasite over the same period.  This is because L. salmonis males are less sensitive to EMB and 
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have a higher level of P-gp expression, hence would likely be a better model for tracking 
development of EMB resistance compared with the female parasites (Chapter 2).  All the same, 
results indicate that RT-qPCR could be employed to monitor EMB resistance development in L. 
salmonis and should be an integral and routine part of resistance detection and management, 
similar to what has been done with parasitic nematodes (Humbert et al. 2001, Sangster 2001, von 
Samson-Himmelstjerna 2006). 
A putative L. salmonis P-gp was initially cloned (Tribble et al. 2008); however, with the 
cloning and addition of more P-gp sequences to the GenBank database, the putative ABC 
transporter reported by Tribble et al. (2008) was discovered to be ABCB8 (Heumann et al. 
2012).  ABCB8 is a mitochondrial half-transporter speculated to be involved in intracellular 
transport of iron and sulphur (Burke & Ardehali 2007).  ABCB8 has been shown to be involved 
in melanoma resistance to doxorubicin (Elliott & Al-Hajj 2009).  As a follow-up on initial 
reports of EMB induced concentration-dependent differential expression of ABCB8 in L. 
salmonis (Tribble, Burka & Kibenge 2007), the effect of EMB on cellular respiration of L. 
salmonis using isolated mitochondria was investigated (data not shown).  Unfortunately, 
transitioning from state 3 to state 4 respiration was not achieved; hence we were unable to 
determine possible effects of the parasiticide on cellular respiration in the parasite.   
Widespread parasiticide resistance in L. salmonis underscores the need for an integrated 
sea lice management strategy achievable through combined use of drugs, chemicals, and non-
chemical alternatives including manipulation of host immunity using vaccines and/or 
immunostimulants (Raynard et al. 2002).  Innate immunity provides protection against pathogen 
invasion in fish (Magnadóttir 2006, Whyte 2007) and its manipulation is currently being 
explored as a sea lice control strategy.  Inflammation, cellular infiltration and hyperplasia are the 
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3 main hallmarks of effective innate responses to sea lice infection.  Chinook (Oncorhynchus 
tshawytscha) and coho (O. kisutch) salmon mount inflammatory and hyperplastic responses at 
the sites of sea lice attachment and are able to reject the parasite shortly after infection (Johnson 
& Albright 1992, Braden et al. 2012).  However, Atlantic salmon lack such effective responses 
(Fast et al. 2003) despite induction of innate immune response genes (Skugor et al. 2008, Tadiso 
et al. 2011), generating interest in inducing innate immune responses of Atlantic salmon as a 
possible control strategy against sea lice infection.  Boosting host immunity against invading 
pathogens and parasites through immunostimulation has been employed for management of 
numerous infections in several commercially produced aquatic species, including the salmonids 
(Ringo et al. 2011).  However, the effects of prior host immunostimulation on chemotherapy are 
not well understood and may not always offer protection against a pathogen (Kunttu et al. 2009).  
In the present study, sea lice with different immunostimulant backgrounds were subjected to a 24 
h EMB bioassay.  Contrary to our prediction, the parasites associated with immunostimulant-fed 
salmon did not significantly differ with control values within each stage and sex category and 
had higher levels of P-gp.  Some studies have shown that acute and chronic inflammatory 
responses can increase or decrease P-gp expression, respectively (Dumoulin et al. 1997, Ho & 
Piquette-Miller 2006).  Although inducing inflammation promotes the rejection of sea lice, 
especially in Pacific salmonids (Johnson & Albright 1992, Jones, Kim & Bennett 2008, Wagner 
2008), concurrent administration of EMB and immunostimulants to Atlantic salmon may, in fact, 
favour resistance development to the drug, which may thus limit the use of immunostimulants in 
combination with certain therapeutants.  This also indicates species differences in response to 
therapy among the salmonids. 
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Within a given L. salmonis population, males were observed to be more EMB resistant 
compared with females (Westcott et al. 2008, Heumann et al. 2012), but this sex-based 
difference in the parasite’s EMB sensitivity is not well described.  Such knowledge could be 
exploited in tracking EMB resistance development in salmon farms more efficiently.  For 
example, findings from the present study (Chapter 3) suggest that laboratory-reared L. salmonis 
will maintain EMB resistance phenotype for up to 3 filial generations and that inheritance of 
resistance to the parasiticide may be through the male parasite.   
Although there are reports of sea lice tolerance to EMB on fish farms in the Bay of Fundy 
(Westcott et al. 2008), some sea lice populations within this region are still relatively EMB-
sensitive compared with sea lice populations at other salmon farm locations within the region 
(Jones et al. 2012).  We investigated locations of sea lice populations across different salmon 
farming areas in the Bay of Fundy and sex-based differences as factors contributing to EMB 
resistance in sea lice (Chapter 4).  Results indicate population, species, sex-based and temporal 
differences in EMB EC50 values confirming presence of micro-populations of the parasite 
relatively sensitive to the drug.  Also, EMB-sensitive C. elongatus and -resistant L. salmonis 
were located in the same site, confirming species differences in EMB sensitivity and could 
indicate existing differences in refuge sea lice populations between both parasite species.  In 
contrast, there is a lack of resistance of sea lice to EMB on Pacific Canadian salmon farms, likely 
due to the presence of L. salmonis originating from a large wild salmon population in Pacific 
Canada, diluting any rise in EMB-resistant sea lice populations (Saksida et al. 2012).  Also, 
threespine sticklebacks (Gasterosteus aculeatus) have been reported to be a refuge for sea lice in 
Pacific Canada (Jones & Prosperi-Porta 2011).  The wild salmon population in the Atlantic has 
declined considerably (Anderson, Whoriskey & Goode 2000) and threespine sticklebacks are not 
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known to be infected with L. salmonis in this region, decreasing the possibility of EMB-sensitive 
non-farm sea lice from diluting any rise in EMB-resistant sea lice population in the Atlantic. It is 
not known whether sea lice have any other refuge in Atlantic Canada. 
5.2.  Conclusion and future directions 
It is evident that drug rotations together with non-chemical alternatives are necessary for 
effective sea lice management.  This will entail a sensitive means of early detection of drug 
resistance and making necessary changes to the treatment used, thereby disrupting the rise of 
parasiticide-resistant sea lice populations.  Drug resistance management in sea lice control 
requires effective implementation of multi-faceted integrated pest management strategies 
(Sangster 2001).  However, given our findings on possible effects of prior host 
immunostimulation on EMB efficacy, possibly via upregulation of P-gp, caution has to be 
exercised in the implementation of integrated sea lice management strategies.  The salmon 
aquaculture industry should avoid over-reliance on single therapeutants.  Regulatory bodies 
should be prudent in approving new compounds such that there are several alternative sea lice 
therapeutants with different modes of action available at any given in time.  Also, drug 
companies should be keen on developing products with different mechanisms of action 
(Denholm et al. 2002). 
Finally, although some studies have shown that MLs interact with other ABC 
transporters, P-gp is believed to be the major resistance mechanism for this family of 
parasiticides (Prichard & Roulet 2007, Kerboeuf & Guégnard 2011).  Results of the present 
study, especially the P-gp competitive inhibition test results, strongly indicate that the efflux 
transporter is involved in reduced sensitivity of L. salmonis to EMB.  However, there is a need to 
characterize P-gp mRNA and protein in situ using more sensitive tools specifically developed for 
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L. salmonis.  Changes in the expression of resistance-associated genes, such as those for P-gp, 
can be monitored and used in the diagnosis of resistance development to parasiticides.  The 
present study has demonstrated that RT-qPCR can be employed in monitoring resistance 
development to EMB.  Knowledge of the timing for resistance development will inform 
necessary changes to treatment options to prevent treatment failure.  Further comparisons 
between EMB-sensitive and -resistant strains of L. salmonis may be necessary to verify the 
degree to which P-gp is responsible for the loss of parasite sensitivity to the drug.  More 
investigations on the nature of the species differences in EMB sensitivity in sea lice, as well as 
the heredity of EMB resistance mechanisms, is necessary for a better understanding of how this 
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6.1.  Summary 
This section describes work done to detect L. salmonis at the mRNA and protein levels 
and to quantify the protein expression.  This is important because knowledge of where P-gp is 
expressed in the parasite could assist in understanding the role of the transporter in sea lice 
resistance to EMB.  The ability to determine P-gp levels in different sea lice populations and 
sexes will be helpful in tracking EMB resistance development in the parasite. 
6.2.  Introduction 
Resistance development to the macrocyclic lactone (ML), emamectin benzoate (EMB; 
the major sea lice medicine for about a decade), has been a major concern for L. salmonis control 
due to over-reliance on the parasiticide by salmon farmers (Westcott, Hammell & Burka 2004).  
Consequently resistance development to the drug by L. salmonis has been reported in Atlantic 
Canada and Europe (Hjelmervik et al. 2010, Westcott et al. 2010) and in Caligus rogercresseyi 
in Chile (Bravo, Sevatdal & Horsberg 2008, Horsberg 2012).  P-glycoprotein, a member of ABC 
transporters that belong to integral plasma membrane proteins, cause the efflux of a diverse 
range of molecules from within cells to the exterior (Fojo et al. 1985, Raviv et al. 1990).  
Although genetic changes in GluCl channels have been associated with ML resistance (Njue et 
al. 2004), increased expression of P-gp is widely believed to be the primary mechanism 
responsible for loss of parasite sensitivity to MLs (reviewed by Prichard & Roulet, 2007).  P-
glycoprotein plays a major role in the protection of aquatic invertebrates from xenobiotics 
(Smital & Kurelec 1998, Fulton et al. 1999, Lyons-Alcantara et al. 2002).  Macrocylic lactones 
have been shown to be substrates for P-gp (Lespine et al. 2007) and increased expression of P-gp 
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was linked to ML resistance in Caenorhabditis elegans and Haemonchus contortus (Blackhall et 
al. 1998, Xu et al. 1998, Sangster et al. 1999, James & Davey 2009).   
Several studies have associated P-gp with resistance to the closely related ivermectin in 
invertebrates.  P-glycoprotein mRNA was localized in the digestive tract and pharynx of H. 
contortus (Smith & Prichard 2002).  It is hypothesized that up-regulation or over-expression of 
P-gp in epithelial cells of L. salmonis digestive tract would serve to limit the absorption of EMB, 
ingested by the salmon louse (Tribble, Burka & Kibenge 2007).  This study investigates the 
abundance and expression pattern of P-gp mRNA and protein in L. salmonis using in situ 
hybridization, immunolocalization, ELISA and Western blot techniques.  We hypothesize that 
EMB resistance in L. salmonis is due to increased P-gp expression in epithelial cells of the 
parasite digestive tract.  Experiments to localize P-gp in epithelial cells of the parasite digestive 
tract at the protein and mRNA levels were carried out using immunohistochemistry and in situ 
hybridization techniques, respectively.  Differential levels of P-gp in archived sea lice 
populations were investigated using ELISA and Western blot techniques to determine temporal 
increase in the expression of the transporter. 
6.3.  Materials and methods 
6.3.1  Chemicals 
The chemicals used for this study were of analytical grade and purchased from Sigma-
Aldrich, St. Louis, MO, unless stated otherwise.   
6.3.2.  Immunolocalization  
Immunolocalization of P-gp in L. salmonis was conducted according to the method 
described in Tribble et al. (2008).  Briefly, adult male and female L. salmonis collected from 
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Atlantic salmon farms in the Bay of Fundy in July 2009 were transported back alive to the 
laboratory in cold (10°C) seawater, and were fixed in 10% buffered neutral formalin for 24 h at 
room temperature (RT).  The samples were then dehydrated with increasing concentrations of 
ethanol (70%, 95% and 100%), cleared in xylene, and then embedded in paraffin.  The 
embedded samples were cut into 5 µm-thick sections, mounted on positively charged slides, 
allowed to air-dry at RT, and then stored at RT until further use.   
Prior to rehydration for immunolocalization, the sections were deparaffinized in xylene 
and then incubated in 0.3% hydrogen peroxide in 100% methanol with shaking. The sections 
were then rehydrated using decreasing ethanol concentrations (100% for 30 min, and 95%, 70%, 
50% and distilled water for 2 min each).  The samples were rinsed with phosphate-buffered 
saline (PBS) and incubated with 10% normal horse serum (Vector Laboratories, Burlingame, 
CA) in PBS for 20 min to block for non-specific binding of the secondary antibody.  Primary 
mouse monoclonal (C219) antibody (Abcam, Cambridge, MA) specific for mammalian P-gp 
was then applied to the slides empirically at 1:20 and 1:40 dilutions in PBS, and incubated for 12 
h at 4°C.  Following the overnight incubation, the slides were first rinsed and then washed with 
PBS for 10 min with shaking.  Secondary antibody was applied to the slides and incubated for 1 
h at RT.  The PBS rinse and wash were repeated and a solution made up of DAB, NiCl2 and 
H2O2 applied on the slides.  The slides were rinsed and washed with tap water and then 
dehydrated in increasing ethanol concentrations (50%, 70%, 95% and 100%) and xylene.  




6.3.3.  SDS-PAGE with Western blotting 
Archived adult female sea lice samples (collected in 2002, 2004, 2005, 2008 and 2010 
and stored at -80°C) were tested for differential P-gp expression.  Briefly, 3 or 4 adult female L. 
salmonis were randomly selected from each group (year of collection) and placed in a plastic 5 
mL tube containing 1.5 mL ice-cold 0.1 M PBS and homogenized.  The homogenate was 
centrifuged at 300 x g for 20 min at 4°C.  The supernatant were collected and centrifuged at 
20,000 x g at 4°C for 30 min.  The resultant pellet was dissolved in PBS and the protein 
concentration was determined using the Bio-Rad protein assay (Bio-Rad, Mississauga, ON).  
Fifty to 100 µg of protein were separated on a 8% SDS-polyacrylamide gel at 100 V for ~45 
min.  The separated protein was then transferred to nitrocellulose membrane at 100 V for 1 h.  
Afterwards, the nitrocellulose was placed face-up in a plastic container and the protein blocked 
with excess 5% skim milk in 0.2% Tris-PBS (T-PBS) for 1 h at RT with rocking.  This was 
followed by PBS wash.  C219 and JSB1 primary antibodies [(Abcam) specific for mammalian P-
gp], reconstituted (1:500) in T-PBS (separately) were applied to the nitrocellulose membrane and 
incubated for 1 h at RT with rocking.  The nitrocellulose was washed again with 0.1 M PBS.  
Secondary antibody conjugated with Horseradish peroxidase (HRP), reconstituted in T-PBS, was 
applied to the nitrocellulose and then incubated for 1 h at RT with slow agitation.  Excess 
secondary antibody-HRP was rinsed off the nitrocellulose membrane using 0.1 M PBS.  
Chemiluminescent detection of HRP was performed using an ECL Western blotting detection kit 
(Amersham, Little Chalfont, Buckinghamshire, UK) according to the manufacturer’s protocol.  
MDR1 MDCK II (Madin-Darby canine kidney) cell line (over-expressing P-gp), salmon liver 
and upper intestine, and lobster mid-intestine served as positive controls.  The MDCK II cell 
lines (MDR1 and parental) were kindly donated by Dr. Alfred Schinkel (Division of Molecular 
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Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands).  All the tissue samples 
were collected fresh from the donor animals, were immediately frozen and then stored at -80°C 
prior to further use.  Sample preparations for Western blotting were done at 0°C to minimize 
tissue degradation. 
6.3.4.  ELISA 
A total of 12 snap-frozen adult female L. salmonis (collected from Atlantic salmon farms 
in the Bay of Fundy in February 2010) weighing ~0.3 g were placed in 2 mL of ice-cold 0.1 M 
PBS and homogenized.  In separate tubes, pooled sea lice gut and whole sea lice without the gut 
were homogenized in 2 mL of ice-cold 0.1 M PBS.  Freshly collected mouse liver was processed 
similarly and served as a positive control.  All the tissues were processed on ice.  The 
homogenate was centrifuged at 300 x g for 20 min.  The resultant supernatant was collected and 
centrifuged at 20, 000 x g for 30 min.  Both centrifugation steps were carried out at 4°C.  The 
pellet formed was re-suspended in PBS.  Protein concentration was determined for each sample 
using the Bio-Rad protein assay.  The samples were made up to four different 100 µL volumes 
by the addition of 0, 25, 50 and 75 µL 0.1 M PBS.  Detection of P-gp was carried out using a P-
gp ELISA kit (USCN Life Science Inc., Wuhan, China) according to the manufacturer’s 
instructions.  Briefly, a 2-fold P-gp concentration standard ranging from 0.156 to 10.0 ng mL -1 
was prepared using the supplied stock solution.  One hundred microlitres of the standard, 
standard diluent and samples were added to respective wells pre-coated with biotin-conjugated 
polyclonal antibody specific to mouse P-gp, in duplicate.  The wells containing standard diluent 
served as the blank.  Plate sealer was applied and the plate was then incubated for 2 h at 37°C.  
After this initial incubation, the liquid in each well was carefully removed and 100 µL of the 
supplied detection reagent A containing biotin-conjugated polyclonal antibody specific to mouse 
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P-gp was added to each well.  The plate was sealed and incubated at 37°C for 1 h.  After 
removing the detection reagent A, each well was washed 3 x with 400 µL of the supplied wash 
solution.  The wells were drained of the wash fluid by inverting the plate on absorbent paper.  
Hundred microlitre of supplied detection reagent B containing Avidin- conjugated HRP was then 
added to each well.  The plate was then sealed and incubated for 30 min at 37°C.  Reagent B was 
then removed from each well and the wells washed with the wash solution supplied.  Ninety 
microlitre of the substrate solution was added to each well.  The plate was then sealed and 
incubated for 25 min in the dark.  The enzyme-substrate reaction was terminated by the addition 
of 50 µL of stop solution containing 3,3',5,5'-Tetramethylbenzidine (TMB) to each well and the 
plate was immediately read (to determine colorimetric change) at 450 nm on a BioTek® ultra 
microplate reader (BioTek Instruments, Winooski, VT).  Only the wells containing P-gp and 
biotin-conjugated polyclonal antibody specific to P-gp will show a change in color.  
Concentration of P-gp in each sample was determined by comparing optical density of the 
samples to the standard curve.   
6.3.5.  In situ hybridization 
6.3.5.1.  Production of RNA probe 
6.3.5.1.1.  Generation of PCR product 
RNA was extracted (separately) from adult male and female L. salmonis (collected live 
from Atlantic salmon farms in the Bay of Fundy in May 2011) using the RNeasy® Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s instructions, and then reverse 
transcribed following standard procedure.  Briefly, one (female) or two (male) L. salmonis were 
placed in a 5 mL plastic tube containing 1 mL Trizol and homogenized using a hand-held 
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electrical tissue homogenizer.  The quality of isolated RNA samples was verified with 
Experion™ RNA StdSens Chips (Bio-Rad Laboratories).  The RNA concentration and the 
260/280 nm ratio were confirmed using the Nanodrop 1000 Spectrophotometer (NanoDrop 
Products, Wilmington, DE).  The samples were then stored at -80°C prior to further use.  
Subsequently, 1 µg RNA of each sample was treated with DNase I (Invitrogen, Carlsbad, CA) 
and then reverse transcribed using SuperScript® III (Invitrogen) to generate cDNA.  PCR 
reactions were then carried out using Taq 2 x Master Mix (New England BioLabs Inc., Ipswich, 
MA).  Briefly, 1 µg DNA template was added to 25 µL of the Master Mix; 1 µL each of forward 
and reverse primers [designed based on the SL-PGY1 sequence (Heumann et al. 2012) using the 
Primer 3 software on the NCBI website: http://www.ncbi.nlm.nih.gov/tools/primer-blast/], 
and the reaction volume was brought up to 50 µL total volume.  The PCR was done at the 
following cycling conditions: initial denaturation at 95°C for 2 min, 40 cycles of 95°C for 30 s, 
55°C for 30 s and 70°C for 30 s, with a final extension at 72°C for 10 min.  The reaction was 
then terminated at 4°C.  The size of the PCR product was confirmed using gel electrophoresis. 
6.3.5.1.2.  Cloning of PCR product 
The PCR product was cloned into a PCR®4-TOPO® vector (Invitrogen) following 
manufacturer’s instruction as follows.  To 2 µL of the PCR product, 1 µL salt solution, 2 µL 
molecular grade water and 1 µL of the vector were added.  The mixture was shaken briefly and 
incubated at 22°C for 5 min and placed on ice prior to transformation.   
6.3.5.1.3.  Transformation of plasmids into TOP10 Escherichia coli cells 
Escherichia coli cells were incubated with 2 µL cloning reaction for 20 min.  Then the 
reaction was heat-shocked at 42°C for 30 s and transferred to ice.  Two hundred and fifty 
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microlitre of supplied S.O.C. medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was added to the reaction.  The tube 
containing the reaction was then capped, and incubated with horizontal shaking (200 rpm) at 
37°C for 1 h.  Thereafter, the mixture was spread on pre-warmed (37°C) lysogeny broth (LB) 
agar plate containing 100 µg mL-1 Ampicillin and 50 µg mL-1 Kanamycin.  While the control LB 
agar plate was spread with 50 µL S.O.C. medium only, 2 agar plates were spread with 30 µL 
diluted (10 µL cells + 20 µL S.O.C.) and 50 µL undiluted mixture of the transformed cells.  The 
three plates were then incubated overnight (~12 h) at 37°C. 
6.3.5.1.4.  Selection and analysis of colonies by PCR 
Distinct colonies were carefully marked, picked, and added to the PCR master mix, as 
described in sub-section 5.3.5.1.1., and the PCR reactions carried out under the same conditions 
described therein.  Positive transformants were confirmed using gel electrophoeresis and 5 
distinct colonies were inoculated into separate tubes containing LB medium.  The tubes were 
incubated overnight (~12 h) at 37°C with shaking. 
6.3.5.1.5.  Isolation of plasmid DNA 
All the steps for isolation of the plasma DNA were carried out at RT.  Following the 
overnight incubation, 1.5 mL of cell suspension was collected from the LB broth and centrifuged 
at 12,000 x g for 3 min to form a pellet.  The remaining LB broths were stored in 40% fresh 
glycerol at -80°C for future use.  The entire medium was removed from the isolated pellet and 
the isolated DNA was purified using the PureLinkTM Quick Plasmid Miniprep Kit (Invitrogen) 
according to the manufacturer’s instructions.  Briefly, the isolated pellet was resuspended using 
250 µL of the supplied Resuspension Buffer (R3) with RNase A, ensuring that no clumps were 
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formed.  Two hundred and fifty microlitre of the supplied Lysis Buffer (L7) was added to the 
mixture; the tube was capped and gently mixed by inverting it 5 x.  The tube was then incubated 
for 5 min at RT, after which 350 µL of supplied Precipitation Buffer (N4) was added and the 
contents mixed by inverting or shaking (for large pellets) to form a homogenous suspension.  
The suspension was then centrifuged at 12,000 x g for 10 min to remove lysis fragments from the 
lysate.  The isolated supernatant was then put into the supplied Spin Column and spun at 12,000 
x g for 1 min and the resultant solution was discarded.  Seven hundred microlitre of supplied 
Wash Buffer (W9; ~70% ethanol) was added to the tube and centrifuged at 12,000 x g for 1 min.  
Again, the supernatant was discarded; residual Wash Buffer was eliminated from the column by 
repeating the last centrifugation and the resultant supernatant discarded.  DNA within the column 
was eluted by adding 75 µL preheated (70°C) supplied TE Buffer to the column, incubating for 1 
min and centrifuging at 12,000 x g for 2 min.  The concentration and the 260/280 nm ratio of 
DNA in the resultant solution were done using Nanodrop 1000 Spectrophotometer (NanoDrop 
Products).  Fifteen microlitre of the mixture containing DNA was sequenced to confirm the 
orientation of the DNA insert within the plasmid DNA.  The remaining DNA samples were 
stored at -80°C for DIG (digoxigenin) labeling.  
6.3.5.1.6.  Linearization of plasmid DNA 
Positive clones selected from the sequencing result were linearized using NOTI and Pst1 
enzymes (Thermo Fisher Scientific, Inc. Waltham, MA) targeting the T3 and T7 promoters on 
the plasmid DNA, yielding DNA templates for making the antisense and sense RNA probes, 
respectively.  Briefly, 10 µg DNA sample was combined with 10 µL of the enzyme (T3 and T7, 
separately), gently mixed and briefly spun to bring contents to the bottom of the tube.  Samples 
were then incubated at 37°C for 35 min (NOT1) or 10 min (Pst1).  NOT1 digestion was 
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terminated by heating the tube at 80°C for 5 min prior to purification of the product while for the 
Pst1 reaction heat inactivation of the enzyme was omitted.  
6.3.5.1.7.  Purification of linearized plasmid DNA 
Following linearization of the plasma DNA, the DNA samples were column-purified 
using the QIAquick® PCR Purification Kit (Qiagen Sciences, Germantown, MD) according to 
the manufacturer’s instructions.  All the centrifugation steps were conducted at 17,900 x g for 1 
min at RT.  Briefly, 5 volumes of the supplied Buffer PB were added to 1 volume of the PCR 
reaction and then mixed; yellow colour indicated optimal pH (7.5) of the solution.  The mixture 
was transferred to the supplied column and centrifuged.  Thereafter, 750 µL of supplied Buffer 
PE (~71% ethanol) was added to the column and centrifuged.  The resultant solution was 
discarded and excess buffer was eliminated from the column by repeating the last centrifugation.  
The column was placed in a clean 1.5 mL tube, and 30 µL of supplied Elution Buffer was added 
to the column, incubated for 1 min at RT, and then centrifuged.  The concentration and 260/280 
nm ratio of DNA in the resultant solution were done using Nanodrop 1000 Spectrophotometer 
(NanoDrop Products).   
6.3.5.1.8.  DIG labeling 
RNA probe specific to L. salmonis P-gp mRNA was generated using the DIG RNA 
Labeling Kit (Roche Diagnostics, Laval, QC) according to the manufacturer’s instructions.  To 1 
µg of purified DNA template, 2 µL 10x NTP labeling mix, 2 µL 10x Transcription Buffer, 1 µL 
Protector RNase inhibitor and RNA Polymerase (T3 and T7, separately) were added and the 
reaction was brought up to 20 µL final volume with water.  The solution was gently mixed and 
incubated for 2 h at 37°C.  Two microlitre of supplied DNase I was then added to the reaction 
207 

and incubated for 15 min at 37°C to eliminate any contaminating DNA.  The DNase treatment 
was terminated by addition of 2 µL 0.2 M EDTA (pH 8.0) to the reaction.  One microlitre of the 
reaction was removed for RNA gel analysis.  Two microlitre of 8 M LiCl and 75 µL 95% ethanol 
were added to the remaining reaction, mixed and stored overnight (~12 h) at -80°C.   
6.3.5.1.9.  Hydrolysis of RNA probe 
To reduce the RNA probe from 561 bp to an optimal length of 250 bp, hydrolysis 
reaction was performed based on the following equation: 
 t = 
L0 - Lf 
K x L0 x Lf 
 t = incubation time in minutes 
L0 = initial length of transcript (in kb) 
Lf = desired probe length (in kb) 
K = constant (0.11 kb/min at 60°C) 
t = 
0.561 - 0.250 
0.11 x 0.561 x 0.250 
 
= 0.311 =  20.16 min 
0.0154275  
 
The RNA probe was removed from the overnight -80°C storage and centrifuged at 
13,000 x g for 30 min at 4°C.  The supernatant was decanted off and the probe was washed with 
70% ethanol using centrifugation at 13,000 x g for 10 min at 4°C.  Ethanol supernatant was 
poured off and RNA probe was air-dried.  One hundred and eighty microlitre of DEPC treated-
water was added to the tube and kept on ice.  Fifteen minutes later, 20 µL of hydrolysis buffer 
(40 mM NaHCO2, 60 mM Na2HCO3) was added to the tube, incubated at 60°C for ~20 min and 
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then placed on ice.  Hydrolysis neutralization buffer was then added to the RNA probes, mixed 
and stored at -80°C for at least 30 min.  Following the cold storage, the tube was centrifuged at 
13,000 x g for 30 min at 4°C and then washed with 100 µL 70% ethanol at 13,000 x g for 10 min 
at 4°C.  The ethanol was discarded, resultant pellet was air-dried for 15 min and resuspended in 
100 µL hybridization buffer [50% formamide, 1 x Denhardt’s solution, 5 x SSC (saline-sodium 
citrate), 100 µg mL-1 Heparin, 0.1% Tween 20, 0.1% CHAPS (3-{(3-cholamidopropyl) 
dimethylammonio}-1-propanesulfonate), 1 mg mL-1 Torula RNA)] and stored at -80°C until 
further use.   
6.3.5.2.  Fixation and processing of L. salmonis tissue 
Adult male and female L. salmonis collected from Atlantic salmon farms in the Bay of 
Fundy in May 2011, were fixed in 10% neutral buffered formalin (4% formaldehyde) in 1x fish 
saline (175 mM NaCl, 2.7 mM KCl, 0.64 mM MgCl2.6H2O, 2.74 mM CaCl2.2H2O, 2.22 mM D-
glucose 6-phosphate, 3.0 mM Tris HCl) (Valerio, Kao & Fletcher 1992) for ~18 h at 4°C with 
gentle rocking.  Sea lice samples were then dehydrated with increasing concentration of ethanol 
(70%, 95% and 100%), xylene and then embedded in paraffin.  The embedded samples were cut 
into 7 µm sections, mounted on positively charged slides, baked at 60°C for 1 h and then stored 
at RT in the dark until further use.   
From this point on, all equipment, including glassware and jars used for tissue handling, 
was decontaminated for RNase either by autoclaving (>230°C) or cleaning with DR NAse 
FREETM (Argos Technologies, Elgin, IL).   
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6.3.5.3.  RNA probe hybridization 
The tissue sections chosen for probe hybridization were deparaffinized in xylene twice, 
10 min each at RT.  The sections were then rehydrated through decreasing concentration of 
ethanol (100%, 95%, 70%, and 50%) and 1x fish saline, 2 min each at RT.  Predigestion of the 
tissue sections was conducted using 2.5 µg mL-1 Proteinase K (Roche Diagnostics) in 1x fish 
saline for 30 min at 37°C to render the samples permeable to RNA probe.  The samples were 
then incubated in 2 mg mL-1 glycine in 1x fish saline for 2 min at RT to terminate the action of 
Proteinase K.  Treatment with 0.1 M triethanolamine pH 7.5 was then done for 5 min at RT.  
This was repeated (with addition of 0.25% acetic anhydride to the buffer) for 10 min at RT.  The 
sections were then rinsed in 2x SSC and dehydrated using increasing ethanol concentration 
(50%, 95%, and 100%) for 2 min each at RT.  The tissue sections were air dried for 2 h at RT.  
50 µL of diluted RNA probe [(5 µL RNA probe and 45 µL hybridization buffer) sense and 
antisense] were added on the sections, cover slips were placed over the sections, and then 
incubated in a humid chamber (soaked with 50% formamide in 2x SSC) overnight (~12 h) at 
45°C in a water bath. 
6.3.5.4.  Detection of hybridization reaction 
To dislodge the cover slips, tissue sections were immersed in 2x SSC for 5 min at RT 
followed by incubation in 50% formamide in 2x SSC for 1 h at 45°C.  The slides were rinsed in 
10 mM Tris-HCl (pH 8) with 500 mM NaCl, made up to 50 mL total volume using molecular 
grade water for 2 min at RT.  This was repeated but with the addition of 0.002 µg µL-1 RNase A 
and 0.01 U µL-1 RNase T1 for 30 min at 37°C.  The slides were washed in decreasing salt 
concentration- 2x, 0.5x and 0.1x SSC, each for 30 min at 45°C.  Following the stringent washes, 
the slides were rinsed in 0.1 M Tris-HCl (pH 7.5) with 150 mM NaCl for 2 min at RT.  This was 
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repeated with the addition of 1% BSA (bovine serum albumin) and 10% lamb serum for 30 min 
at RT to block non-specific binding sites in the tissue.  To detect DIG, 500 µL sheep anti-DIG-
alkaline-phosphatase (1:100 of blocking buffer) was applied on each slide and incubated for 30 
min at RT.  The slides were washed with blocking buffer containing 0.1% Tween 20 and 1% 
BSA for 30 min, with gentle rocking, and then rinsed in chromogenic buffer [4 mL 1M Tris-HCl 
(pH 9.5), 1 mL 1M MgCl2, 0.8 mL 5M NaCl, 40 µL Tween 20, 9.68 mg levamisol; brought to 40 
mL total volume] for 15 min at RT.  Detection of the antibody was done by incubating the slides 
in chromogenic buffer containing 1.6% Nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl-
phosphate [(NBT/BCIP); Roche] for 30 min at RT.  NBT/BCIP reaction was eliminated by 
immersing the slides in tap water for 2 min at RT and the sections were counterstained with 
Nuclear Fast Red (Vector Laboratories) for 3 min at RT.  Following a 2 min wash in tap water at 
RT, the tissue sections were rapidly dehydrated using increasing concentrations of ethanol (50%, 
95%, and 100%) and twice in xylene, all at RT.  Cover slip was placed on each slide and then 
viewed under the microscope.   
6.4.  Results 
6.4.1.  Immunolocalization 
Immunoreactions were not observed for all the tissues examined except salmon liver bile 
canaliculi (Figs 5.1-5.2). 
6.4.2.  SDS-PAGE with Western blotting 
P-glycoprotein was detected by Western blot in salmon liver and MDR1 MDCK II cell 
lines but not in sea lice (Fig. 5.3).   
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6.4.3.  ELISA 
Concentration of P-gp detected from whole sea lice, pooled sea lice gut, sea lice without 
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Figure 6.1.  P-glycoprotein antibody (C219)-treated and -untreated Lepeophtheirus salmonis and 
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Figure 6.2.  P-glycoprotein antibody (C219)-treated and -untreated Salmo salar tissues.  
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       Salmon                                                Lobster mid-intestine 
Figure 6.3.  Immunoblotting for P-glycoprotein in different populations of Lepeophtheirus 
salmonis, MDCK II cell lines, Salmo salar liver and upper intestine, and Homarus americanus 
mid-gut. C219 used except where stated otherwise.  Protein ladder in KDa. 
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Figure 6.4.  Detection of P-glycoprotein mRNA in Lepeophtheirus salmonis using in situ 
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Figure 6.5.  Detection of trypsin mRNA in Lepeophtheirus salmonis gut using in situ 




6.4.4.  In situ hybridization 
No reaction to P-gp RNA probes (sense and antisense) was detected for L. salmonis gut 
(Fig. 5.4); some reactions were observed at the cuticular matrix for the antisense probe.  Reaction 
was detected in the gut of the parasite for the antisense trypsin positive control (Fig. 5.5). 
6.5.  Discussion 
Immunodetection is commonly used to describe the abundance and distribution of 
proteins and mRNA of interest in a biological entity.  The technique utilizes the ability of labeled 
antibodies or RNA probes to bind specific regions of a protein or mRNA, respectively, and has 
been employed for P-gp analyses in different tissues (van der Heyden et al. 1995).  
Unfortunately, we were neither able to detect P-gp mRNA and protein using in situ hybridization 
and immunolocalization, respectively, nor quantify the transporter using ELISA and Western 
blot techniques. 
Our hypothesis was that P-gp mRNA is expressed in epithelial cells along the digestive 
tract of the parasite where the transporter causes the efflux of xenobiotics and lipophilic drugs 
including EMB (Tribble, Burka & Kibenge 2007).  Several RNA probes targeting different 
regions of L. salmonis P-gp mRNA were used, but to no avail.  This may be due to P-gp mRNA 
expression below minimum detection levels.  Trypsin was detected in epithelial cells of L. 
salmonis digestive tract following the same tissue handling and processing employed for P-gp 
(Kvamme et al. 2004), and was successfully used as the positive control in the present study.  
Using an ELISA kit, P-gp was detected in mouse liver but poorly detected in sea lice, even when 
up to 500 µg total protein was used.  The detection range of the ELISA kit for P-gp was 0.156-
10.0 ng mL-1.  Based on the hypothesis that the transporter is expressed higher in the digestive 
tract of the parasite, pooled sea lice gut investigated for P-gp expression revealed levels below 
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the P-gp detection range of the kit.  However, this does not conclusively imply low P-gp level in 
the pooled sea lice gut tissue examined.  In addition, the ELISA kit was designed for detection of 
mouse P-gp, which may have resulted in less than optimal detection of L. salmonis P-gp.  Thus, 
low expression and suboptimal antigenic specificity may have been the major reasons why 
detection of the transporter using Western blot and immunhistochemistry were unsuccessful.  
Studies have shown that even a single amino acid substitution in the epitope of a protein can lead 
to loss of antibody recognition (Georges et al. 1990).  To overcome the putative obstacles to 
detecting and/or quantifying the transporter in L. salmonis, antibodies specific to the parasite P-
gp need to be developed.  In addition to that, techniques such as cryosectioning, which would 
minimize damage to P-gp epitope during tissue processing, have to be explored (Cordon-Cardo 
et al. 1990, Smith & Prichard 2002).  It has been noted that formalin and paraffin treatment can 
potentially compromise the integrity of P-gp epitopes (Cordon-Cardo et al. 1990).  Based on the 
positive controls utilized in this study, we believe that the unsuccessful detection of L. salmonis 
P-gp at the mRNA and protein levels was not as a result of poor methodology, tissue processing 
and handling.  Also, whether there is more than one P-gp gene or isoform in L. salmonis is not 
known.  Two different P-gp antibodies, C219 and JSB1, targeting different isoforms of the 
transporter were used in the present study, but yielded negative results for L. salmonis.  A 
previous study identified different isoforms (classes I, II and III) of P-gp in hamster using C32, 
C219 and C494 monoclonal antibodies which target different P-gp epitopes (Georges et al. 
1990).  Nematodes have numerous P-gp genes compared with mammals (Sangster 1994, Broeks 
et al. 1995, Sangster 1999) with C. elegans possessing up to 15 (Prichard & Roulet 2007).  In 
situ hybridization component of the present study was based on L. salmonis P-gp SL-PGY1 
(GenBank accession number HQ684737) cloned by Heumann et al. (2012).  More studies are 
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needed to develop L. salmonis P-gp antibody as it will be helpful in elucidating the expression 
pattern of the transporter at the protein.  Also, more studies are necessary to determine whether 




6.6.  References 
Blackhall, W.J., Liu, H.Y., Xu, M., Prichard, R.K. & Beech, R.N. 1998, Selection at a P-
glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus. 
Molecular and Biochemical Parasitology, 95, 193-201.  
Bravo, S., Sevatdal, S. & Horsberg, T.E. 2008, Sensitivity assessment of Caligus rogercresseyi 
to emamectin benzoate in Chile Aquaculture, 282, 7-12.  
Broeks, A., Janssen, H.W., Calafat, J. & Plasterk, R.H. 1995, A P-glycoprotein protects 
Caenorhabditis elegans against natural toxins. EMBO Journal, 14, 1858-1866.  
Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R. & Melamed, M.R. 1990, 
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and 
tumor tissues. Journal of Histochemistry and Cytochemistry, 38, 1277-1287.  
Fojo, A., Akiyama, S-I., Gottesman, M.M. & Pastan, I. 1985, Reduced drug accumulation in 
multiply drug-resistant human KB carcinoma cell lines. Cancer Research, 45, 3002-3007.  
Fulton, M.H., Moore, D.W., Wirth, E.F., Chandler, G.T., Key, P.B., Daugomah, J.W., Strozier, 
E.D., Devane, J., Clark, J.R., Lewis, M.A., Finley, D.B., Ellenberg, W., Karnaky Jr, K.J. & 
Scott, G.I. 1999, Assessment of risk reduction strategies for the management of agricultural 
nonpoint source pesticide runoff in estuarine ecosystems. Toxicology & Industrial Health, 
15, 200-213.  
Georges, E., Bradley, G., Gariepy, J. & Ling, V. 1990, Detection of P-glycoprotein isoforms by 
gene-specific monoclonal antibodies. Proceedings of the National Academy of Sciences of 
the United States of America, 87, 152-156.  
Heumann, J., Carmichael, S., Bron, J.E., Tildesley, A. & Sturm, A. 2012, Molecular cloning and 
characterisation of a novel P-glycoprotein in the salmon louse Lepeophtheirus salmonis. 
Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 155, 198-
205.  
Hjelmervik, T.O., Sevatdal, S., P G Espedal, P. G., H Kongshaug, H., Glover, K., Nilsen, F. & 
Horsberg, T.E. 2010, Sequencing of target genes in salmon lice resistant to emamectin 
benzoate, pyrethroids or both. The 8th International Sea Lice Conference, pp. 36.  
Horsberg, T.E. 2012, Avermectin use in aquaculture. Current Pharmaceutical Biotechnology, 
13, 1095-1102.  
James, C.E. & Davey, M.W. 2009, Increased expression of ABC transport proteins is associated 
with ivermectin resistance in the model nematode Caenorhabditis elegans. International 
Journal for Parasitology, 39, 213-220.  
221 

Kvamme, B.O., Skern, R., Frost, P. & Nilsen, F. 2004, Molecular characterisation of five 
trypsin-like peptidase transcripts from the salmon louse (Lepeophtheirus salmonis) intestine. 
International Journal for Parasitology, 34, 823-832.  
Lespine, A., Martin, S., Dupuy, J., Roulet, A., Pineau, T., Orlowski, S. & Alvinerie, M. 2007, 
Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. 
European Journal of Pharmaceutical Sciences, 30, 84-94.  
Lyons-Alcantara, M., Lambkin, H.A., Nordmo, R., Lyng, F. & Mothersill, C. 2002, Cross-
reactivity of some antibodies to human epitopes with shrimp Pandalus borealis proteins: a 
possible aid in validation and characterization of crustacean cells in vitro. Cell Biochemistry 
and Function, 20, 247-256.  
Njue, A.I., Hayashi, J., Kinne, L., Feng, X. & Prichard, R.K. 2004, Mutations in the extracellular 
domains of glutamate-gated chloride channel 3 and  subunits from ivermectin-resistant 
Cooperia oncophora affect agonist sensitivity. Journal of Neurochemistry, 89, 1137-1147.  
Prichard, R.K. & Roulet, A., 2007, ABC transporters and -tubulin in macrocyclic lactone 
resistance: prospects for marker development. Parasitology, 134, 1123-1132.  
Raviv, Y., Pollard, H.B., Bruggeman, E.P., Pastan, I. & Gottesman, M.M. 1990, Photosensitized 
labeling of a functional multidrug transporter in living drug-resistant tumor cells. Journal of 
Biological Chemistry, 265, 3975-3980.  
Sangster, N.C. 1994, P-glycoproteins in nematodes. Parasitology Today, 10, 319-322. 
Sangster, N.C. 1999, Anthelmintic resistance: past, present and future. International Journal for 
Parasitology, 29, 115-124. 
Sangster, N.C., Bannan, S.C., Weiss, A.S., Nulf, S.C., Klein, R.D. & Geary, T.G. 1999, 
Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-
glycoproteins. Experimental Parasitology, 91, 250-257.  
Smital, T. & Kurelec, B. 1998, The chemosensitizers of multixenobiotic resistance mechanism in 
aquatic invertebrates: a new class of pollutants. Mutation Research/Fundamental and 
Molecular Mechanisms of Mutagenesis, 399, 43-53.  
Smith, J.M. & Prichard, R.K. 2002, Localization of P-glycoprotein mRNA in the tissues of 
Haemonchus contortus adult worms and its relative abundance in drug-selected and 
susceptible strains. The Journal of Parasitology, 88, 612-620.  
Tribble, N.D., Burka, J.F. & Kibenge, F.S.B. 2007, Evidence for changes in the transcription 
levels of two putative P-glycoprotein genes in sea lice (Lepeophtheirus salmonis) in 




Tribble, N.D., Burka, J.F., Kibenge, F.S.B. & Wright, G.M. 2008, Identification and localization 
of a putative ATP-binding cassette transporter in sea lice (Lepeophtheirus salmonis) and 
host Atlantic salmon (Salmo salar). Parasitology, 135, 243-255. 
Valerio, P.F., Kao, M.H. & Fletcher, G.L. 1992, Fish skin: An effective barrier to ice crystal 
propagation. Journal of Experimental Biology, 164, 135-151.  
van der Heyden, S., Gheuens, E., DeBruijn, E., Van Oosterom, A. & Maes, R. 1995, P-
glycoprotein: clinical significance and methods of analysis. Critical Reviews in Clinical 
Laboratory Sciences, 32, 221-264.  
Westcott, J.D., Hammell, K.L. & Burka, J.F. 2004, Sea lice treatments, management practices 
and sea lice sampling methods on Atlantic salmon farms in the Bay of Fundy, New 
Brunswick, Canada. Aquaculture Research, 35, 784-792.  
Westcott, J.D., Revie, C.W., Giffin, B.L. & Hammell, K.L. 2010, Evidence of sea lice 
Lepeophtheirus salmonis tolerance to emamectin benzoate in New Brunswick, Canada. The 
8th International Sea Lice Conference, pp. 85.  
Xu, M., Molento, M., Blackhall, W., Ribeiro, P., Beech, R. & Prichard, R. 1998, Ivermectin 
resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Molecular 
and Biochemical Parasitology, 91, 327-335.  
 
 
 
 
 
